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With an aging population, neurodegenerative diseases are getting a severe problem. A big 
disadvantage by that is, that medications are poorly discovered. Common in many 
neurodegenerative diseases is the death of neurons. Neurotrophins, like nerve growth factor 
(NGF) and brain-derived neurotrophic factor (BDNF), are involved in the central and peripheral 
nervous system in regulation of survival and regeneration of neurons. These factors have been 
the focus of much research attention as potential therapies for severe neurodegenerative disease. 
However, the problem in using neurotrophins is their high molecular weight which prevents 
them from passing through the blood-brain barrier (BBB). To circumvent these limitations, 
much effort is currently focused on searching for small molecules, small enough to pass the 
BBB and that exhibit either intrinsic neurotrophic activity or stimulatory effects on neurotrophic 
factors. Several secondary metabolites from species of the medicinal mushroom genus 
Hericium have already been purified and were found to have a neurotrophic effect. In this thesis 
different substances isolated from Hericium sp. were characterized regarding their neurotrophin 
stimulating ability. Corallocins, unknown structures isolated from the fruiting body of H. 
coralloides were able to stimulate NGF and BDNF. The same was shown for erinacines 
(metabolites from mycelia cultures of H. erinaceus). One important member of the erinacines 
is erinacine C. Using a small library of transcriptional activation reporters, different activation, 
and inactivation of signaling cascades were analyzed. Treatment of astrocytoma cells with 
erinacine C causes a profound change in their transcriptional activity. Transcriptional activation 
was seen for E26 transformation specific (ETS), glioma -associated oncogene (Gli1), signal 
transducer and activator of transcript (STAT3), ETS like protein (Elk1) and Polyomavirus 
enhancer activator (Pea3B) transcription factor. Since several times, the conserved sequence of 
ETS is highly activated upon erinacine C treatment (in ETS, Elk1, Pea3B), the ETS-mediated 
signaling cascades were analyzed. It was demonstrated that the activation of ETS acted in 
parallel and independent of neurotrophin induction. Another approach was the analysis of 
erinacine C dependent activation of a putative Tetraodon enhancer region of the ngf gene. It 
was proven, that this 2.1kb large enhancer region was activated in the presence of erinacine C 
as well as with the activation and repression of ETS signaling. Erinacine C is a molecule having 
a smaller molecular weight, suggesting, that it can cross the BBB. In this thesis the ability to 
cross the BBB was shown by using an in vitro approach of mimicking the BBB as well as by 
using an in vivo vertebrate model system, the zebrafish. To analyze the effect of these 
compounds in vivo it was clarified in this thesis where ngf or its receptor trkA are expressed. It 
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is also essential to show their effect in vivo using zebrafish as model organism. Therefore, a 
reporter line was established, expressing mClover in trkA expressing cells, which are the 
trigeminal neurons and motor neurons, but also in sensory neurons of the central nervous 
system. Using this transgenic line different regeneration models were established. This finding 
provides access to explain the functions of Hericium derived cyathane diterpenoids, like 
erinacine C. These studies offer first genetic ability to the function of cyathane diterpenoids, 
secondary metabolites isolated from Hericium sp., in astrocytic cells and improves the 
mechanistically understanding of the action of cyathanes in glial cells. On the other hand, 
different model system for analyzing the neurotrophin stimulating effects in vivo were 
established. This study allows to characterized other signaling cascades being activated by 






Mit einer alternden Bevölkerung werden neurodegenerative Erkrankungen zu einem ernsten 
Problem. Ein großer Nachteil dabei ist, dass mit Medikamenten meist nur die Symptome 
behandelt werden. Bei vielen neurodegenerativen Erkrankungen ist der Tod von Neuronen 
charakterisierend. Neurotrophine sind, wie der Nervenwachstumsfaktor (NGF) und der brain-
derived-neurotrophic-factor (BDNF), im zentralen und peripheren Nervensystem an der 
Regulation des Überlebens und der Regeneration von Neuronen beteiligt. Diese Faktoren 
stehen im Mittelpunkt vieler Forschungsarbeiten als potenzielle Therapien für schwere 
neurodegenerative Erkrankungen. Das Problem bei der Verwendung von Neurotrophinen ist 
jedoch ihr hohes Molekulargewicht, das verhindert, dass sie die Blut-Hirn-Schranke (BBB) 
passieren. Um diese Einschränkungen zu umgehen, werden derzeit große Anstrengungen 
unternommen, um nach kleinen Molekülen zu suchen, die klein genug sind, um die BHS zu 
passieren, und die entweder eine intrinsische neurotrophe Aktivität oder stimulierende 
Wirkungen auf neurotrophe Faktoren aufweisen. Viele Sekundärmetaboliten wurden bereits 
aus Heilpilzgattungen wie Hericium aufgereinigt und es wurde gezeigt, dass sie eine 
neurotrophe Wirkung zeigen. In dieser Arbeit wurden verschiedene aus Hericium sp. isolierte 
Metabolite hinsichtlich ihrer Neurotrophin-stimulierenden Fähigkeit charakterisiert. 
Corallocine, unbekannte Strukturen, die aus dem Fruchtkörper von H. coralloides isoliert 
wurden, sind in der Lage NGF und auch BDNF stimulieren. Gleiches wurde für Erinacine 
(Metaboliten aus Myzel Kulturen von H. erinaceus) gezeigt. Ein wichtiges Mitglied der 
Erinacine ist Erinacin C. Unter Verwendung einer kleinen Bibliothek von 
Transkriptionsaktivierungsreportern wurden verschiedene Aktivierungen und Inaktivierungen 
von Signalkaskaden analysiert. Die Behandlung von Astrozytom-Zellen mit Erinacin C führt 
zu einer tiefgreifenden Veränderung ihrer Transkriptionsaktivität. Die 
Transkriptionsaktivierung wurde für den E26-transformationsspezifischen (ETS), Gliom-
assoziierten Onkogen (Gli1), transducer and activator of transcript (STAT3), ETS-ähnliches 
Protein (Elk1) und den Transkriptionsfaktor des Polyomavirus-Enhancer-Aktivators (Pea3B) 
beobachtet. Da die konservierte Sequenz von ETS bei Behandlung mit Erinacin C (in ETS, 
Elk1, Pea3B) mehrmals stark aktiviert wurde, wurden im Weiteren die ETS-vermittelten 
Signalkaskaden analysiert. Es wurde gezeigt, dass die Aktivierung von ETS parallel und 
unabhängig von der Neurotrophin-Induktion erfolgt. Ein anderer Ansatz war die Analyse der 
Erinacin C-abhängigen Aktivierung einer mutmaßlichen Tetraodon-Enhancer-Region des ngf-
Gens. Es wurde nachgewiesen, dass diese 2,1 kb große Enhancer-Region in Gegenwart von 
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Erinacin C sowie bei Aktivierung und Unterdrückung der ETS-Signalübertragung aktiviert 
wurde. Erinacin C ist ein Molekül mit einem geringeren Molekulargewicht, was darauf 
hindeutet, dass es die BHS überqueren kann. In dieser Arbeit wurde die Fähigkeit zur 
Überwindung der BHS unter Verwendung eines In-vitro-Ansatzes zur Nachahmung der BHS 
sowie unter Verwendung eines In-vivo-Wirbeltiermodellsystems, des Zebrafisches, gezeigt. 
Um die Wirkung dieser Verbindungen in vivo zu analysieren, wurde in dieser Arbeit geklärt, 
wo ngf oder sein Rezeptor trkA exprimiert werden. Es ist auch wichtig, ihre Wirkung in vivo 
unter Verwendung von Zebrafischen als Modellorganismus zu zeigen. Daher wurde eine 
Reporterlinie hergestellt, die mClover in trkA-exprimierenden Zellen markiert. Diese zeigt 
Expression in Trigeminus- und Motorneuronen, aber auch in sensorischen Neuronen des 
Zentralnervensystems. Unter Verwendung dieser transgenen Linie wurden verschiedene 
Regenerationsmodelle etabliert. Dieser Befund bietet Zugang zur Erklärung der Funktionen von 
aus Hericium stammenden Cyathan diterpenoiden wie Erinacin C. Diese Studien bieten erste 
genetische Möglichkeiten zur Analyse der Funktion von Cyathan diterpenoiden, aus Hericium 
sp. isolierten Sekundärmetaboliten, in Astrozytenzellen und verbessern das mechanistische 
Verständnis der Wirkung von Cyathanen in Gliazellen. Andererseits wurden verschiedene 
Modellsysteme zur Analyse der Neurotrophin-stimulierenden Wirkungen in vivo etabliert. 
Diese Studie ermöglicht es, andere Signalkaskaden zu charakterisieren, die von Cyathanen 







Caused by an aging population, neurodegeneration in the brain during lifetime could lead to 
severe problems. Unfortunately, no medication is found until now to heal neurodegenerative 
diseases. It is only possible to treat their symptoms. In this aspect, small secreted polypeptides 
called neurotrophins, could serve for possible medications (Hefti, 1994). Neurotrophins can 
influence the degeneration, maturation, maintenance and regeneration of neurons, which are 
mostly affected during the development of neurodegenerative diseases (Xiao and Le, 2016). 
However, neurotrophins have relatively high molecular weights, which prevent them to cross 
the blood-brain barrier (BBB) (Pardridge, 2002b). Instead, small molecular weight metabolites 
that can cross the BBB are suspected to influence the expression of neurotrophins (Pardridge, 
2002a). It is unknown until now, how such small metabolites work and influence the 
neurotrophin expression. This thesis focuses on pure compounds that are isolated from an edible 
fungus and characterizes its suspected effect to stimulate neurotrophin expression.  
1.1 With an aging population, neurodegenerative diseases lead to severe problems. 
 
Neurodegenerative disease is a collective term for several diseases that affect neurons in the 
nervous system. Neurons are differentiated cells that do not divide (Yang et al., 2014) and are 
important components of the nervous system. Damaged or dead neurons, caused by traumata 
or neurodegenerative disease, cannot be replaced. The most prominent neurodegenerative 
diseases are Parkinson's, Alzheimer's and Huntington's disease. These diseases are not curable. 
The progressive death of neuronal cells results in problems with mental abilities (dementia) or 
leads to impaired abilities in the movement coordination (ataxia). Here, neurotrophins could 
serve as possible medications. 
1.2 Neurotrophins can serve as possible medication. 
 
The term “neurotrophin” was introduced by Viktor Hamburger and Rita Levi-Montalcini 
earning the Nobel prize for that discovery (Levi-Montalcini and Cohen, Nobel prize 1986). 
Neurotrophins are the body's own signaling substances that guide targeted connections between 
neuronal cells (Loughlin and Fallon, 1993) and ensure the maintenance of neuronal 
connections. Neurotrophins are small proteins with a molecular mass of approximately 13 kDa. 
These molecules are secreted proteins, produced by a target tissue in small quantities. It is 
assumed that immature neurons compete for limited trophic factors. Only those neurons that 
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successfully establish synaptic connections get enough trophic factors to survive (Huang and 
Reichardt, 2001). Neurons that do not receive enough trophic factors are removed by apoptosis 
(Dekkers et al., 2013). If neurotrophins are present, they bind to cell surface receptors of the 
Trk family (tropomyosin receptor kinase) (Huang and Reichardt, 2001). Then, a cascade of 
kinases become triggered and target proteins can suppress apoptosis (Lu and Xu, 2006; Pearson 
et al., 2001). 
Different neurotrophins have been identified up to now: nerve growth factor (NGF; Franck et 
al., 1983, Weis, 1972), brain-derived neurotrophic factor (BDNF; Leibrock et al., 1989) and 
five more neurotrophins, called NT3 (neurotrophin 3; Maisonpierre et al., 1990), NT4 
(neurotrophin 4; Hallbrook et al., 1991), NT5 (neurotrophin 5; Berkemeier et al., 1992, 
Berkemeier et al., 1991), NT6 (neurotrophin 6; Götz et al., 1994) and NT7 (neurotrophin 7; 
Nilsson et al., 1998). It was shown before, that neurotrophins can work as chemotactic and as 
chemorepulsive factors (Paves and Saarma, 1997), but they can also act as survival factors. 
Neurotrophins are a group of proteins, which are encoded by genes that show a similar structure 
(Figure 1). The coding gene has one larger exon of approximately 1kb (Berkemeier et al., 1992; 
Ebendal et al., 1986; Ip et al., 1992; Leingartner and Lindholm, 1994), which codes the 
neurotrophin precursor. A smaller exon is located upstream of the large exon which codes for 
the neurotrophin precursor (Edwards et al., 1986; Salin et al., 1997; Sekimoto et al., 1998). The 
neurotrophin precursor element contains the signal sequence, the pro-peptide and the mature 
neurotrophin (Francke et al., 1983; Meier et al., 1986). Six cysteine residues form disulfide 
bridges that generate a specific tertiary structure called cysteine knots (Server et al., 1976). 
Therefore, these cysteines are important for the folding and the maintenance of a stable tertiary 




Figure 1: Exon/ intron organization of selected neurotrophin genes. Exons are represented by boxes and lines represent 
introns and alternative splicing. (taken from Heinrich and Lum, 2000) 
Neurotrophins have multiple functions. The best-studied role in mammals is their control of 
apoptosis, the mechanism of programmed cell death. During development, neurons and glial 
cells are initially overproduced and then selectively eliminated by programmed cell death. This 
is regulated by neurotrophic factors during target innervations (Lotto et al., 2001). Two major 
members of the neurotrophins are nerve growth factor (NGF) and brain-derived neurotrophic 
factor (BDNF). 
1.2.1 Nerve growth factor (NGF) 
 
NGF belongs to the group of neurotrophic factors. It was first discovered in the snake venom 
and the salivary gland of a male mouse (Franck et al., 1983; Weis, 1972). It is involved in the 
migration, differentiation, and maturation of sensory and sympathetic neurons in the developing 
and the adult peripheral nervous system (Levi-Montalcini and Hamburger, 1951; Johnson and 
Gorin, 1980; Levi-Montalcini, 1987; Longo et al., 1992). Further findings show that NGF is 
involved in regeneration, physiology, and survival of retinal ganglion cells (Turner et al., 1987). 
In general, NGF has powerful biological activities, such as the promotion of neurite outgrowth 
and the prevention of neuronal death. NGF is also crucial to maintain and coordinate the 
neuronal functionality (Obara and Nakahata, 2002). 
1.2.2 Brain-derived neurotrophic factor (BDNF) 
 
The growth factor BDNF is another protein from the group of neurotrophins and is closely 
related to the nerve growth factor (Binder and Scharfmann, 2004). BDNF affects various 
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neuronal cell types in the central and peripheral nervous system. It helps to protect existing 
neurons and synapses and promotes the growth of new ones (Acheson et al., 1995; Huang and 
Reichardt, 2001). BDNF is active in brain areas that are essential for memory and abstract 
thinking, such as the hippocampus, the cerebral cortex and the forebrain (Yamada and 
Nabeshima, 2003). BDNF also plays a major role in long-term memory (Bekinschtein et al., 
2008). It is one of the most active neurotrophins in adult neurogenesis (Barde et al., 1982). By 
that BDNF is involved in supporting survival of present neurons and it also provides growth 
and differentiation of new neurons and synapses via axonal and dendritic outgrowth. The high 
affinity receptor of BDNF is TrkB. 
1.2.3 The family of tropomyosin receptor kinases 
 
Tropomyosin-related receptors kinases (Trks) play an important role in the development and 
function of the vertebrate nervous system. Three distinct members are identified in mammals: 
TrkA (Klein et al., 1991), TrkB (Klein et al., 1990) and TrkC (Lamballe et al., 1991). Trks 
control the survival of neurons (Klein, 1994; Barbacid, 1994). They have an impact on the 
function of synapses (Lindholm et al., 1994), the maturation of synapses (Wang et al., 1995) 
and contribute to the neuronal response of injury (Persson and Ibanez, 1993). TrkA is one 
member of the tropomyosin-related kinase receptor family, which is characterized by a fusion 
of tropomyosin with an unknown tyrosine kinase (Heinrich and Lum, 2000). The intracellular 
domain of the tyrosine kinase is related to the FGF/ EGF/ PDGF/ insulin receptor family. The 
kinase domain is highly conserved.  
All immature neurotrophins, called precursor peptides, can bind the low affinity neurotrophin 
receptor p75 NTR (Binder and Scharfman, 2004). P75 NTR is related to proteins of the tumor 
necrosis factor (TNFR) superfamily (Binder and Scharfman, 2004). It has a glycosylated 
extracellular region that is involved in the binding of ligands, a transmembrane region, and a 
short cytoplasmic sequence, which lacks an intrinsic catalytic activity (Chao and Hempstead, 
1995; Dechant and Barde, 2002). The binding of neurotrophins to p75 activates various 
intracellular signal transduction pathways (Dechant and Barde, 2002). P75 signaling provides 
biologic actions distinct from those of the Trk receptors, in patricular the initiation of 
programmed cell death (apoptosis) (Casaccia-Bonnefil et al., 1996; Dechant and Barde, 2002).  
p75NTR binds all five neurotrophins, but the affinity is low. On the other hand, the receptors 
of the Trk family are more affine and can specifically bind certain neurotrophins: TrkA can 
bind NGF, TrkB can bind BDNF, NT4 and NT5 and TrkC can bind NT3. The binding of 
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neurotrophins to p75NTR lead to programmed cell death (apoptosis) of the cell. In contrast, the 
binding to receptors of the Trk family, triggers a cascade of kinases with anti-apoptotic effects.  
1.2.4 NGF-TrkA-Signaling 
 
NGF is released by target cells and activates the 
high affinity receptor TrkA (Klein et al., 1991) 
(Figure 2). NGF binding to TrkA initiates 
dimerization, followed by an autophosphorylation 
of the tyrosine residue and activation of the 
intracellular signaling cascade (Kaplan et al., 
1991; Jing et al., 1992). The neurotrophin 
signaling is transmitted via the activation of the 
tropomyosin-related kinase (Cordon-Cardo et al., 
1991; Loeb et al., 1991; Zhou et al., 1994) and 
affects a variety of downstream signal cascades 
involved in cell survival, axon and dendritic 
growth and the specification and synapse 
formation of sympathetic and sensory neurons 
(Harrington and Ginty, 2013). The different 
downstream signaling cascades become activated after autophosphorylation of the TrkA 
receptor, which has ten conserved tyrosine residues in the cytoplasmic domain. Phosphorylation 
of the tyrosines Y670, Y674 and Y675 enhance the kinase activity (Cunningham and Greene, 
1998; Stephens et al., 1994). Phosphorylation of the tyrosine Y490 activates binding of an 
adaptor called proteins of the Src homology and Collagen family (Shc) or Fibroblast growth 
factor receptor substrate 2 (Frs2), which activates Mitogen-activated protein kinases (MAPK) 
and Phosphoinositid-3-Kinases (PI3K) signaling. On the other hand, phosphorylation of Y785 
activates Phosphoinositid-Phospholipase C (PLCᵧ) (Obermeier et al., 1993; Stephens et al., 
1994). Activated MAPKs target the Extracellular-signal Regulated Kinases (Erk1/2) pathways, 
which are able to signal through cAMP response element-binding protein (CREB), ETS Like 
protein 1 (Elk1) and myocyte enhancer factor-2 (MEF2) to regulate target gene expression, 
which influence neuronal differentiation and survival (Pearson et al., 2001; Riccio et al., 1999). 
On the other hand, activation of PI3K is important for cell survival via signal transduction 
through the serine/threonine kinase 1 (Akt) and phosphorylation of apoptosis-enhancing 











Figure 2: Schematic drawing of the NGF/TrkA 
signaling cascade. Binding of NGF to its high affinity 
receptor TrkA leads to dimerization and 
autophosphorylation of the cytosolic region of TrkA 
and the activation of the kinase region. This activation 
is causing the initiation of several downstream 
cascades, including MAPK, PLCᵧ and PI3K. 
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3 (GSK3β) (Datta et al., 1999; Hetman et al., 2000). Another downstream pathway of 
NGF/TrkA signaling is mediated by PLCᵧ, which leads to the production of inositol 
trisphosphate (IP3) and dystroglycan (DAG). This promotes Ca2+ mobilization and an 
activation of different protein kinases C (Kaplan and Miller, 2000). 
Neurotrophins could serve as possible activator of regeneration by activating several 
downstream signaling cascades. But the high molecular mass disables them to cross the BBB. 
Lower molecular weight metabolites are getting more and more into the focus of research. 
These lower molecular weight metabolites were isolated as secondary metabolites from fungi 
(as natural products), like the family of fungi Hericium, which were known from Chinese 
medicine as medication against nervous system disorders, cancer, and weak immune system. 
But it could also be shown that secondary metabolites isolated from fungi and plants are able 
to stimulate neurotrophins (La et al., 2013; Naidu et al., 2007). 
1.3 Secondary metabolites isolated from an edible fungus could overcome the BBB 
problems. 
 
Since neurotrophins are not able to pass the blood-brain barrier, they cannot be used for external 
treatment (Pardridge, 2002). Therefore, molecules of small molecular weights are needed that 
can induce the expression of neurotrophic signaling molecules.  
Medicinal mushrooms have been characterized for potential neurotrophic metabolites for about 
25 years, and in particular, the genus Hericium erinaceus has raised major attention as food 
supplements and alternative medicine (Thongbai et al., 2015). But not only the mushroom H. 
erinaceus, was studied intensively, also other medical mushrooms, like Antrodia camphorate, 
Ganoderma spp., Lignosus rhinocerotis and Pleurotus giganteus, were characterized 
extensively. But most of the potential neuroactive compounds, which could serve as possible 
medication against neurodegenerative disease, have been reported from H. erinaceus. Hericium 
species are basidiomycota which belongs to the family Hericiaceae. It was demonstrated that 
extracts from both, basidiomes and mycelial cultures of Hericium erinaceus, are able to induce 
expression of neurotrophins in astrocytic cells. Two major substance classes can be isolated 
from H. erinaceus: hericenones and erinacines. A recent publication reveals that isolated 
cyathane diterpenoid compounds of Hericium erinaceus extracts are able to mediate 
neurotrophin-inducing activities (Wang et al., 2019). Other publications in regard to secondary 
metabolites of this edible mushroom report various biological properties, such as antibacterial, 
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cytotoxic and neuritogenic effects (Kawagishi et al., 1990; Kawagishi et al., 1994; Kawagishi 
et al., 2006; Ma et al., 2010; Kim et al., 2012).  
Different other substances are in focus for medical treatment options and discussed in this 
thesis. Corallocins, for example, are isolated from Hericium coralloides. These fungi have 
fruiting bodies which looks like a white coral. There are only a few reports of the metabolite 
production of H. coralloides (Kim et al., 2018; Saito et al., 1998; McCracken and Dodd, 1971; 
Zou et al., 2012). The second group of compounds that will be characterized in this thesis are 
the erinacines. Erinacines are cyathane diterpenoids, which were only produced in the cultures 
and can be isolated from mycelial cultures H. erinaceus and H. flagellum, the most famous 
representatives of this genus. It has been used in traditional Chinese medicine for a long time 
and is processed into food supplements and alternative medicines (Ying et al., 1987; Thongbai 
et al., 2015). It could be shown that erinacine S and erinacine A, which was isolated from the 
mycelial ethanol extract of H. erinaceus, are able to significantly increase the level of insulin-
degrading enzyme (IDE) in cerebral cortex and by that reduce the AB10-stained plaques (Chen 
et al., 2016). But substances isolated from other medical mushrooms were reported, to influence 
neurotrophin production (Eik et al., 2012; Seow et al., 2013; Phan et al., 2012; Mitschke 2017; 
Bai et al., 2015; Cao et al., 2018). On the other hand, the mode of action remains to be clarified. 
So, it is known that extracts isolated from Hericium erinaceus are able to induce neurotrophins, 
but how they are able to induce the expression of neurotrophin and what is the direct signaling 
answer is unknown. This important question will be investigated in this thesis. 
1.4 Signaling cascades 
 
In biochemistry and physiology, processes are referred to signal transduction or signaling 
cascades, when cells have to react, for example, to external stimuli, convert them, transmit them 
as a signal into the cell interior and lead to a cellular effect via a signal cascade. A large number 
of enzymes and secondary messengers (second messengers) are often involved in these 
processes, in one level or on several successive levels (signal cascade). The original signal can 
be amplified considerably under certain circumstances (signal amplification). Signals from 
different signal paths are often related to and integrated by “crosstalk” in the cytoplasm or in 
the cell nucleus (Alberts et al., 2001).  
The start of a signal transduction process is initiated or triggered by an intracellular or 
extracellular stimulus. Extracellular stimuli can be substances such as hormones, growth 
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factors, extracellular matrix, cytokines, chemokines, neurotransmitters and neurotrophins. 
However, nothing is said about the molecular nature of these substances and the signaling 
molecules can be whole proteins, steroids or small organic molecules such as serotonin. In 
addition, environmental stimuli can also trigger signal transduction. Intracellular stimuli, such 
as calcium ions (Ca2+), are often themselves part of signal transduction cascades (Alberts et al., 
2001). 
With the help of proteins in the cell membrane and inside the cell (receptors), the extracellular 
signals are recorded and processed inside the cell. These receptors can be differentiated 
according to their location, structure and function: Cytosolic receptors, such as steroid 
receptors, retinoid receptors and soluble guanylyl cyclase, are the primary targets for steroids, 
retinoids and small, soluble gases such as nitrogen monoxide (NO) and carbon monoxide (CO), 
which can pass through the cell membrane due to their lipophilicity or small molecular size. 
Activation of steroid receptors leads, for example, to the formation of receptor dimers which, 
after binding to a response element, e.g. B. Sterol Response Element (SRE) act on the DNA 
itself as transcription factors. Membrane-based receptors are proteins, such as transmembrane 
proteins, which are located in the membrane and have both an outside and an inside domain. 
This enables them to bind signal molecules outside the cell and to trigger a signal inside the cell 
due to the change in conformation. The signal molecule does not cross the membrane, but binds 
to the extracellular domain, which leads to biochemical changes in the receptor molecule that 
also have an intracellular effect. The next family are the ion channels. Ion channels are voltage-
, light- and ligand-dependent channels. These are transmembrane proteins that are either 
activated or deactivated as a result of the binding of a ligand as a signal substance, which 
increases or decreases the permeability of the membrane for certain ions. This is particularly 
important when transmitting electrical nerve signals to chemical synapses. The next family are 
the G-protein coupled receptors. The signaling pathways via G-proteins are among the best 
investigated signaling pathways. They are involved in many sensory physiological processes, 
such as visual recognition (via phototransduction), smelling and tasting, as well as the effects 
of numerous hormones and neurotransmitters. The last group of receptors are the enzyme-
linked receptors. Enzyme-linked receptors are the third important group of cell surface 
receptors. To this group the receptor tyrosine kinases belong, which can activate, for example, 
the MAP kinase pathway and the PI3 kinase signaling pathway. TrkA and TrkB are prominent 
members of this class (Knippers, 2006).  
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The aim of the signal transduction process is the activation of effector proteins that trigger a 
specific cellular response. Effector proteins are, for example, transcription factors that activate 
the transcription of certain genes. Transcription factors are proteins, being able to bind to 
specific sequences in the DNA, which are normally located in front of the promotor of a gene. 
After binding these factors enhance or inhibit the expression of this gene. 
1.5 ETS signaling 
 
In the field of molecular biology, the ETS family (E26 transformation-specific (Nunn et al., 
1983) or E-26 (Leprince et al., 1983)) belongs to the largest family of transcription factors. The 
ETS gene family is named after the first gene that was identified from the leukemia virus E26 
and plays an important role in the development of various tissues. All proteins of the ETS family 
consist of a highly conserved DNA binding domain, the ETS domain, which is a winged helix-
turn-helix structure (Papas et al., 1989; Wasylyk et al., 1993; Werner et al., 1995), which is able 
to bind to DNA sites with a central DNA sequence of GGA (A / T). In addition to the DNA 
binding function, the ETS domain is responsible for protein-protein interactions. However, ETS 
proteins differ significantly in the sequences that flanks the core motif.  
The ETS protein family is implicated in a variety of functions including regulation of cell 
differentiation, cell cycle control, cell migration, cell proliferation, apoptosis (programmed cell 
death) and angiogenesis. Two major groups within the ETS family have been described: the 
ETS group, including Ets1, Ets2 and Pointed, and the ternary complex factors (TCFs), which 
include Elk1, Sap1a, Sap1b, Fli1 and Net. Ets1, Ets2 and Pointed (Pt2). Each of this contains a 
C-terminal conserved DNA binding domain and an N-terminal domain, which is described as 
a pointed domain. This group of members of the ETS family has a single MAPK 
phosphorylation site near the pointed domain (Brunner et al., 1994; Wasylyk et al., 1997). 
TCFs, on the other hand, contain a transactivation domain, which can be phosphorylated on 
several serine and threonine residues (Hipskind et al., 1994; Treisman, 1994). In addition, in 
vertebrates, Pea3 is an essential player in the differentiation of dopaminergic neurons in both 
C. elegans and in olfactory bulbs of mice (Flames and Hobert, 2009).  
ETS1 is a prominent member of the ETS family. ChIP-Seq studies have shown that ETS1 can 
bind to both, AGGAAG and CGGAAG, motifs (Cauchy et al., 2016). ETS1 binds to DNA as 
a homodimer or heterodimer (Samorodnitsky et al., 2015). The phosphorylation of serine 
residues of the C-terminal domain makes ETS1 inactive, known as autoinhibition (Besnard et 
al., 2011). There are several ways to activate ETS1. First, ETS1 can become dephosphorylated 
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(Cowley and Graves, 2000). Second, two ETS1 can be activated when two ETS molecules 
homodimerize. Homodimerization occurs, when the DNA binding sites are in a correct 
orientation and have the right distance. Thus, the specific location of the binding sites within 
an enhancer or promoter segment can have a strong impact on whether ETS1 can bind or not 
(Hollenhorst et al., 2017). Third, ETS1 proteins can be activated by Erk2 and Ras at threonine 
Thr38. Many Ras-responsive genes contain combinatorial ETS/AP1 recognition motifs by 
which ETS1 and AP1 synergistically activate the transcription after the stimulation of Ras 
(Wasylyk et al., 1998). ETS1 interacts directly with various transcription factors. Their 
interaction leads to the formation of multiprotein complexes. When ETS1 interacts with other 
transcription factors (like Runx1, Pax5, TFE3 or USF1), its final impact on transcription 
depends on whether its C-terminal domain is phosphorylated. The acetyl transferases CBP and 
the p300 protein bind to the transactivation domain. AP1, STAT5 and VDR bind to the C-
terminal domain. 
Cumulative data have shown that ETS proteins are considered to be subordinated to the Ras-
MAPK signaling cascade (Wasylyk et al., 1998). The phosphorylation of ETS factors by 
MAPKs controls their downstream activity, but also the protein partnerships, target specificity 
or transactivation. 
1.6 Danio rerio as model organism 
 
Thinking about the importance to study the effect of compounds being able to induce 
neurotrophins and other cascades during neurodegeneration and neuroregeneration, a model 
system is needed. Danio rerio is a perfect model when thinking about screening compounds 
and is also a vertebrate model, which apart from that surprisingly show neuroregeneration until 
the juvenile age. In this thesis the zebrafish was used for initial quantification of substances 
isolated from the medical mushroom Hericium. 
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The zebrafish (Danio rerio) is a freshwater 
fish from the family of carps (Cyprinidae) and 
is resident in the rivers of the Indian 
subcontinent. It is a prominent model 
organism in the research of vertebrates.  The 
research of genetic mechanisms elucidating 
the morphogenesis of vertebrates has been 
pioneered especially by the work of George 
Streisinger and later by Christiane Nüsslein-
Volhard (Streisinger et al., 1981; Nüsslein-
Volhard, 1995). Pharmacological studies, 
toxicological material classifications and 
many other essential applications in the field 
of genetics have used zebrafish as model 
systems (Janning and Knust, 2008). 
The zebrafish is easy to maintain due to its 
small size (3-4 cm) and produces a high 
number of offspring within a short time. A 
female is able to lay up to 200 eggs at least 
two times per week. The zebrafish is very 
suitable for genetic experiments, because it 
has a short maturation time of three to four 
months to reach sexual maturity. 
The fertilization and the embryonic 
development occur outside of the mother and 
the embryo is transparent. This allows a 
detailed analysis of embryonic development 
starting with a fertilized oocyte to developed larvae within 72 hours (Figure 3). The role of 
genes and cells during organogenesis cab be analyzed in detail by the use of time-lapse 
microscopy (William et al., 2009).  
The genome of the zebrafish (1700 Mbp) is completely sequenced and available in public 
databases. Even though the fish is genetically further distant to mammals, it is nevertheless 
suitable as a model for mammalian development. As a vertebrate, the zebrafish shares a high 
Figure 3: Development of the Zebrafish during the first 72h 
post fertilization. (Kimmel et al., 1995) 
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degree of conserved genes and protein functions and signaling cascades. The zebrafish brain is 
highly conserved to the brain of mammalians (Bandmann and Burton, 2010; Panula et al., 
2010). 
Many methods of reverse and forward genetics are well established in zebrafish research. Due 
to the transparency of the embryo, phenotypes can easily be analyzed. In the zebrafish field 
many transgenic lines and mutants are available or can be generated with ease (Howe et al., 
2013). 
In addition, fish are able to generate new neurons in all stages of life. This can help to 
understand the role of neurotrophic factors, their receptors and signaling cascades in detail 
during the lifetime. Furthermore, many compounds can be added to the water and analyzed for 
their pharmacological benefits, making the zebrafish an ideal organism to study the stimulating 
effect of neurotrophic factors.   
The similarity of neuronal death in fish and higher vertebrates, as well as the conserved 
neurotrophic factors and their receptors, suggest equally prominent regulators of neuronal 
apoptosis in fish (Heinrich and Lum, 2000). One neuronal population that performs 
programmed cell death in fish are the Rohon Beard neurons. They are primary sensory cells, 
known as first established neurons that are located in the dorso-lateral spinal cord. When they 
die, they become replaced by sensory neurons in the dorsal root ganglia (Metcalfe et al., 1990). 
Depending on their peripheral targets, Rohon Beard neurons either die or migrate from the 
spinal cord (Weis, 1968). Cell death is also visible in all three layers of the embryonic retina 
(Hoke and Fernald, 1998). New cells are continually generated in the marginal zone of the retina 
in adult and growing fish. Even the cerebellum shows an active adult neurogenesis (Soutschek 
and Zupanc, 1996). The proliferation and maturation of neurons in the developing and adult 
fish is accompanied and balanced by a regulated neuronal death.  
In addition, NGF and BDNF signaling is found in the adult brain of adult teleost fish near 
neurogenic niches, suggesting a potential a role in adult neurogenesis in the vertebrate brain 
(Cacialli and Lucini, 2019). 
It is known, that extracts isolated from Hericium species are able to influence neurotrophin 
production, but until now only one neurotrophin was characterized, NGF. In this thesis another 
neurotrophin will be characterized, whether it is upregulated upon addition of pure substances. 
Also, the different direct cellular answers after addition are not characterized yet. This thesis 
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will give the first insights into characterization of signaling response upon compound treatment 
in vitro. 
Apart from that, in vivo models to characterize compound dependent neurotrophin upregulation 
are missing. The zebrafish is, as shown before, a perfect model for compound screening. A 
model for quantifying NGF mediated influence on degeneration and regeneration will be 









2. Material and Methods 
2.1 Materials 
 
Table 1: List of Primer 
Primer name Sequence 5’-3’ 
mGAPDH up ACCACAGTCCATGCCATCAC 
mGAPDH low TCCACCACCCTGTTGCTGTA 
hNGF sense CCAAGGGAGCAGTTTCTATCCTGG 
hNGF antisense GGCAGTTGTCAAGGGAATGCTGAAGTT 
hBDNF sense TAACGGCGGCAGACAAAAAGA 






Table 2: List of used Plasmids 
Plasmid name Discription 
pCS-rat dnTrkA-CitrineERex N-terminus of rat TrkA until Serine 477 fused to mCitrine 
connected with an Endoplasmic reticulum export signal 
pBSII-Tol2-4xNFkb-EIb-Luc2 4x NFkappaB binding sites (GGGAATTCCC) followed by 
E1b-luciferase2-pA 
pTol2-4xGli-EIb-Luc2 4x GLi1 binding sites (GACCACCCA) followed by E1b-
luciverse2-pA 
pTol2-4xRBP-EIb-Luc2 4x RBPJ bindings sites (CGTGGGAA) followed by E1b-
luciferase2-pA 




4x Pea3b (ETS) binding sites (GGAAATTCCTTTCC) 
followed by E1b-luciferase2-pA 
pTol2-4xCREB-EIb-Luc2 4x CREB binding sites (CTGACGTCA) followed by E1b-
luciferse2-pA 
pTol2-4xTCF/LEF-E1b-Luc2 4x TCF/LEF binding sites (AGATCAAAGGG) followed by 
E1b-luciferase2-pA 
pTol2-4xLhx2/Sox2-EIb-Luc2 4x Lhx2-Sox2 bindings sites (CTAATTAAAGAACAAAG) 
followed by E1b-luciferase2-pA 
pTol2-4xSBE-Eib-Luc2 4x TGFbeta SBE binding sites (AG(C/A)CAGACA) 
followed by E1b-luciferase2-pA 
pTol2-4xHIF1-EIb-Luc2 4x HIF1 binding sites (TGTGTACGTGCTG) followed by 
E1b-luciferase2-pA 
pTol2-4xNBRE-EIb-Luc2 4x NBRE binding sites (AAAAGGTCA) followed by E1b-
luciferase2-pA 
pTol2-4xSF1-E1b-Luc2 4x SF1 binding sites (TCAAGGTCA) followed by E1b-
luciferase2-pA 




pTol2-4xHSE-E1b-Luc2 4x HSF1 binding sites (HSE sites AGAACGTTCTAGAAC) 
followed by E1b-luciferase2-pA 
pTol2-4xUAS-E1b-Luc2 4x Gal4 binding sites (UAS CGGAGTACTGTCCTCCG) 
followed by E1b-luciferase2-pA 
pTol2-4xSTAT3-E1b-Luc2 4x STAT3 binding sites (ATTTCCCGGAAAT) followed by 
E1b-luciferase2-pA 
pTol2-4xARE-E1b-Luc2 4x ARE binding sites 
(GGAAATGACATTGCTAATGGTGACAAAGCAACTTT) 
followed by E1b-luciferase2-pA 
pTol2-4xELK1-E1b-Luc2 4x ELK1 bindings sites (G/A ACCGGAAGT) followed by 
E1b-luciferase2-pA 
pTol2-4xNFY-E1b-Luc2 4x NFY bindings sites (AGCCAATCGG) followed by E1b-
luciferase2-pA 
pTol2-4xKLF-E1b-Luc2 4x ETS bindings sites for SP1-KLF (GGCCCCGCCCCC) 
followed by E1b-luciferase2-pA 
pTol2-4xNRF-E1b-Luc2 4x NRF bindings sites for ROS-signaling 
(CTGCGCATGCGC) followed by E1b-luciferase2-pA 
pTol2-4xE2F-E1b-Luc2 4x E2F bindings sites for E2F-signaling (CTGGCGGGAA) 
followed by E1b-luciferase2-pA 
pTol2-4xbHLH-E1b-Luc2 4x bHLH bindings sites for bHLH-signaling 
(AAACAGCTGT) followed by E1b-luciferase2-pA 
pTol2-4xbzip-E1b-Luc2 4x bzip bindings sites for bZIP-signaling (AAACAGCTGT) 
followed by E1b-luciferase2-pA 
pTol2-4xSoxPou-E1b-Luc2 4x Sox-Pou bindings sites for bZIP-signaling 
(CATTGACATGCTAAT) followed by E1b-luciferase2-pA 
pTol2-4xKLF5-E1b-Luc2 4x KLF5 bindings sites for KLF5-signaling 
(AGGGTGTGGC) followed by E1b-luciferase2-pA 
pTol2-4xETS-E1b-Luc2 4x ETS bindings sites for ETS-signaling (CACTTCCGGT) 
followed by E1b-luciferase2-pA 
pTol2-4xNARE-E1b-Luc2 4x NARE bindings sites for Egr1-signaling 
(CTCCCCCCAC/CGCCCCCGC) followed by E1b-
luciferase2-pA 
pTol2-4xNFAT/AP-E1b-Luc2 4x NFAT/AP bindings sites for NFAT-signaling 
(TGGAAAATTTGACTCATAG) followed by E1b-
luciferase2-pA 
pTol2-4xERE-E1b-Luc2 4x ERE binding sites for Estrogenreceptor-signaling 
(GGTCACAGTGACC) followed by E1b-luciferase2-pA 
pTol2-4xRunt-E1b-Luc2 4x Runt binding sites for Runx-signaling (CTGTGGTTT) 
followed by E1b-luciferase2-pA 
pTol2-4xFez-E1b-Luc2 4x Fexf2 binding sites for Fez-signaling (CAGCAACC) 
followed by E1b-luciferase2-pA 
pTol2-4xlexA-E1b-Luc2 4x lexA binding sites for Runx-signaling 
(CTGTACATCCATACAG) followed by E1b-luciferase2-
pA 
pTol2-4xNFAT-E1b-Luc2 4x NFAT binding sites for NFAT-signaling 
(GGATTTTCCA) followed by E1b-luciferase2-pA 
pTol2-4xSim2-E1b-Luc2 4x Sim2 binding sites for Sim2-signaling 
(TTGTTATGCAAA) followed by E1b-luciferase2-pA 
pTol2-4xTbox-E1b-Luc2 4x T-box binding sites for T-box-signaling (TCACACCT) 
followed by E1b-luciferase2-pA 
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pTol2-4xFOXO-E1b-Luc2 4x FOXO binding sites for FOXO-signaling 
(TCCTGTTTACCA) followed by E1b-luciferase2-pA 
pTol2-4xBRE-E1b-Luc2 4x BRE bindings sites for BMP-signaling 
(CTGG(C/A)GCC) followed by E1b-luciferase2-pA 
pTol2-4xTAED-E1b-Luc2 4x TAED bindings sites for YAP-TAZ-signaling 
(ACATTCCAC) followed by E1b-luciferase2-pA 
pTol2-4xa1ACT-E1b-Luc2 4x a1ACT binding site ATTATAAGATG followed by E1b-
luciferase2-pA 
pTol2-2xUAS-E1b-Luc2 2x Gal4 binding sites (CGGAGTACTGTCCTCCG) 
followed by E1b-luciferase2-pA 
pTol2-6xUAS-E1b-Luc2 6x Gal4 binding sites (CGGAGTACTGTCCTCCG) 
followed by E1b-luciferase2-pA 
pTol2-8xUAS-E1b-Luc2 8x Gal4 binding sites (CGGAGTACTGTCCTCCG) 
followed by E1b-luciferase2-pA 
pTol2-2xETS-E1b-Luc2 2x ETS binding site CACTTCCGGT followed by E1b-
luciferase2-pA 
pTol2-6xETS-E1b-Luc2 6x ETS binding sites (CACTTCCGGT) followed by E1b-
luciferase2-pA 
pTol2-8xETS-E1b-Luc2 8x ETS binding sites (CACTTCCGGT) followed by E1b-
luciferase2-pA 
pCS-NLS-ETS(DB)-TA4 NLS-DNA-binding domain of human ETS1 fused to TA4 
pCS-NLS-ETS(DB)-TA2 NLS-DNA-binding domain of human ETS1 fused to TA2 
pCS-NLS-ETS(DB)-KRAB NLS-DNA-binding domain of human ETS1 fused to KRAB 
repressor domain 
p-Tngf-Luc2 Tetraodon nigorividis 2.1kb upstream sequence of ngf-b 
drving Luciferase 2 expression 
p-Tngf(1500)-Luc2 Tetraodon nigorividis 1.5kb upstream sequence of ngf-b 
driving Luciferase 2 expression 
p-Tngf(1000)-Luc2 Tetraodon nigorividis 1.0kb upstream sequence of ngf-b 
driving Luciferase 2 expression 
p-Tngf(500)-Luc2 Tetraodon nigorividis 500bp upstream sequence of ngf-b 
driving Luciferase 2 expression 
pTol2-Tngf500-E1B-Luc2 Tetraodon ngfb enhancer (-2.000-1.500)-E1b-Luciferase2 
pTol2-Tngf1000-E1B-Luc2 Tetraodon ngfb enhancer (-2.000-1.000)-E1b-Luciferase2 
pTol2-Tngf1500-E1B-Luc2 Tetraodon ngfb enhancer (-2.000-500)-E1b-Luciferase2 
 
2.2 Cell culture methods 
 
2.2.1 Cultivation of PC12 cells  
 
PC12 is a cell line, which was derived from a tumor of the adrenal medulla 
(pheochromocytoma) in rats (Greence and Tischler, 1976). Pheochromocytoma has an 
embryonic origin from neural crest, which is represented by a mixture of neuroblastic and 
eosinophilic cells. PC12 cells are widely used as a model system for neuronal cells with a 
variety of neuronal processes, such as neurite outgrowth, which can by studied. Under normal 
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cell culture conditions, these cells have mostly no extensions. Through addition of nerve growth 
factor (NGF), neuronal differentiation can be initiated, which leads directly to a change in the 
actin cytoskeleton and within a few hours to a plating and the outgrowth of several long neurite-
like extensions. Differentiated PC12 cells with extensions are postmitotic and produce 
neurotransmitters (noradrenalin) and neuronal marker proteins, such as gap-43. 
PC12 cell culture medium 
5 ml Fetal calf serum (Capricorn Scientific) 
10 ml Horse serum (Capricorn Scientific) 
1 ml Penicillin-streptomycin solution (GibcoTM; 100x) 
1 ml Glutamine (GibcoTM; 100x) 
add RPMI-1640 (GibcoTM)medium to 100 ml. 
At the beginning of the experimental phase, cells are taken from a stock culture (stored at -
196°C) and transferred to a collagen-coated collagen cell culture dish for propagation for at 
least 7 days before starting an assay. About 1x107 cells are added to 10 ml PC12 cell culture 
medium in a cell culture plate. Cells are incubated at 37°C and 5% CO2 concentration in an 
incubator. The medium is changed every two days and cells are splitted if necessary. 
2.2.2 Cultivation of 1321N1 astrocytoma cells 
 
1321N1 are human astrocytoma cells, which were isolated in 1972 as a subclone of another cell 
line called 1181N1 which was derived from malignant gliomas by Pontén (Pontén et al., 1968).  
1321N1 cell culture medium 
10ml  Fetal calf serum (Capricorn Scientific) 
1ml  Penicillin-streptomycin solution (GibcoTM ; 100x) 
1ml  Glutamine (GibcoTM ; 100x) 
Add DMEM (GibcoTM) medium to 100ml. 
To start the cultivation of 1321N1 cells, cells are taken from a stock culture which are stored at 
-196°C and transferred to a 10 cm dish for propagation for at least 7 days before starting an 
assay. On a 10 cm dish around 1x106 cells are added in 10 ml cell culture medium. Cells are 
incubated at 37°C and 5% CO2 concentration in an incubator. The medium are changed every 
two days and the cells had to be splitted if about 80-90% confluence was visible. 
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2.2.3 Collagen-coating of cell culture plates for PC12 cell cultivation 
 
Cells isolated from animals as primary cells as well as cell lines may not easily be attached to 
plastic. Cell culture dishes are therefore normally positively charged to enable cells to attach to 
the ground by the negatively charged proteins. Especially, primary cells or cells which are 
grown in suspension, which are normally cell isolated from cancerous origin, have problem to 
attach without any structural proteins. Especially, primary cells or cells which are grown in 
suspension, which are usually derived from cancers, need supplementation by structural 
proteins, such as collagen. 
Since PC12 cells are derived from a pheochromocytoma these cells are not able to attach to 
normal treated cell culture dishes. Collagen is used to pretreat the cell culture plate before PC12 
cells are added. A suspension of 10µg/ml Collagen (Roche) is produced following the protocol 
of the costumers. This suspension is added on the required cell culture dish an incubated for 4h 
at 37°C. After 4h the suspension is removed and can be reused again. The cell culture dishes 
are dried at room temperature overnight under the clean bench and disinfected with UV light. 
After that PC12 cells was added directly. 
2.2.4 Pretreatment of cover slips for cell cultivation 
 
Adherent cells normally cannot attach to glass surfaces. And the second problem when 
cultivating cells on glass cover slips is that they need to be washed and sterilized before 
introducing them in culture. That is why glass cover slips need to be cleaned, washed and 
sterilized before. 
To rinse them glass slides are incubated for 10 min in 0.1% HCl at room temperature (RT). 
This step is followed by an intense step of washing with PBS. To sterilize the glass slide they 
are stored in 70% EtOH until usage. For experiments slides are transferred to 24 well plate. To 
make it possible that cells attach to the ground, the surface needed to be coated. In this thesis a 
10 µg/ml collagen (Roche) solution is used. The surface is coated as explained before. 
2.2.5 Determination of cell number using a Neubauer’s counting chamber 
 
The total number of grown cells is determined with a small volume of cell suspension and a 
Neubauer’s counting chamber. A cover slip is moistened and pressed on the counting chamber 
and it should be secure and may no longer be possible to move. This is usually the case when 
Newton’s rings get visible. A small volume of cell suspension is pipetted beneath the cover slip 
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placed, so that the drop can flow under the cover slip. The net quantity of the Neubauer’s 
chamber is determined by exactly 1 µl. On the chamber itself, a grid of 16 small and in total 4 
large squares is recorded. To determine the cell number, cells of all 4 large squares were counted 
under a light microscope. The total number in suspension is determined by applying the 
following formula: 
𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 =  ((
𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟
4
) ∙ 104) ∙ 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 
 
2.2.6 Cytotoxicity measurement of pure compounds – MTT Assay 
 
The cytotoxicity of the test compounds needed to be determined prior to the neurotrophin 
studies. 
Cells are incubated with the required cell number in a 96 well plate and incubated with the for 
the cell type specific media for 24h. After the attachment of the cells, the different treatments 
are added and incubated for 24 – 48h. After that, the toxicity measurements, using CK04 – Cell 
Counting Kit 8 (Dojindo Molecular Technologies), is performed. 
The assay is performed according to the manufacturer information. On 100µl media 10µl CCK8 
is added and incubated for 1 – 4h in the cell culture incubator. For PC12 cells an incubation 
time for 3h is sufficient, whereas 1321N1 astrocytoma cells needed only 2h of treatment. During 
this time an orange color is developed, and the absorbance was measured using a microplate 
reader (Tecan) with a wavelength of 450 nm. The value of cells incubated with normal media 
is set to 100% survival.  
Compounds are tested with increasing concentration and with the solvent control in addition. 
The highest nontoxic concentration is used for further experiments.  
2.2.7 Assay for analysis of direct PC12 cell differentiation  
 
PC12 cells undergo the extension of neurites, when nerve growth factor (NGF) is added to the 
medium This was published before (Greence and Tischler, 1976). This experiment is used for 
analyzing potential neurotrophic activity of substances. If Hericium compounds have direct 
neurotrophic activity (Mori et al., 2008), there should be a neurite outgrowth of PC12 cells. 
35 
 
For preparation, 24 well plates are coated with 10µg/ml collagen as descripted before. After 
that, 3x104 cells in 1ml Medium were plated in each well and incubated overnight at 37°C, 5% 
CO2 in an incubator. On the next day, Hericium probes and NGF (human ß-NGF, Sigma, 
SRP3015) with a concentration of 200ng/ml are dissolved in 1ml serum-reduced medium and 
added to cells. Then, cells are incubated at 37°C with 5% CO2 and documented after 48 hours 
with a bright field microscope.  
2.2.8 Assay for analysis of indirect stimulation of PC12 cell differentiation with 
conditioned media 
 
The experiment is used to analyze the neurotrophin inducing capacity of different isolated 
Hericium compounds. If these substances are able to induce neurotrophin production, like 
NGF, these polypeptides are secreted into the media. Then the so-called conditioned media is 
added on PC12 cells, these cells should differentiate afterwards (Mori et al., 2008). 
1321N1 astrocytoma cells are seeded with a density of 5x105 cells per well on a 6-well plate 
an incubated for 24h to leave the cells to attach to the surface. After 24h incubation medium 
was replaced to serum-reduced media and incubated for another 24h. Then the different 
Hericium compounds are added in their highest non-toxic concentration in serum-reduced 
media to the 1321N1 in the 6well plate. These cells were incubated for 48h. PC12 cells were 
plated on a 24well with a density of 3x104 cells per well plate 24h before the conditioned media, 
produced by the astrocytoma cells incubated for 48h with the different Hericium substances, 
were added. After 48h of incubation to produce the so-called conditioned media this media is 
added on the PC12 cells. These cells were incubated for another 48h and afterwards 
documented with a bright field microscope. The amount of differentiated cells as well as the 
neurite length is analyzed using FIJI. A differentiated cell is defined by neurites longer than the 
cells diameter. For the amount of differentiated cell, the number of differentiated cells in percent 
is calculated from each picture contain around 100 cells. The neurite length is quantified by 
measuring of 10 neurites of each picture. The ANOVA test was done using GraphPad Prism. 
Serum-reduced medium 
1ml  Fetal calf serum (Capricorn Scientific) 
1ml  Penicillin-streptomycin solution (GibcoTM; 100x) 
1ml  Glutamine (GibcoTM; 100x) 
Add DMEM (GibcoTM) medium to 100ml. 
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2.2.9 Reverse Transfection of PC12 cells using Fugene® HD (Promega) 
 
Transfection is the introduction of DNA or RNA into cells. There are different chemical ways 
to transfect cells: with Calcium-Phosphate-Precipitation, where a mixture of calcium chloride 
and sodium phosphate leads to the binding of the precipitating calcium phosphate, which then 
is added on the cell. Cationic polymers can be also used to introduce DNA into a cell, where 
positively charged, highly branched polymers can build complexes to the plasmid DNA, which 
is then taken up by the cells. In this thesis lipofection was used, where the genetic material can 
be introduced into the cell by liposomes, which are vesicles being able to bind to cells 
membranes. 
The transfection is done referring to the user guide (Promega) in the following order: 
 Per well in 96 well Per well in 24 
well 
Opti-MEMTM (Thermo Fisher Scientific) 7.75 µl 38.75 µl 
DNA (0.1 µg/ml) 2µl 10 µl 
Fugene® HD (Promega) 0.25 µl 1.25 µl 
 Mix serval times by pipetting up and 
down 
 
The mixture is incubated for 10-15 min at RT. Afterwards, the DNA-Fugene® HD complex is 
added into the appropriated well. 
In the next step cells are seeded with a density of 1x104/well (96 well) or 6x104/well (24 well) 







2.2.10 Reverse transfection of 1321N1 cells using Lipofectamine® 3000 (Thermo Fisher 
Scientific) 
 
The transfection is done referring to the user guide (Invitrogen) in the following order: 
 Per well in 96 well Per well in 24 
well 
Opti-MEMTM (Thermo Fisher Scientific) 3.8 µl 19 µl 
DNA (0.1 µg/ml) 1µl 5 µl 
P3000 (Thermo Fisher Scientific) 0.2 µl 1 µl 
 Mix serval times by pipetting up and 
down 
Opti-MEMTM (Thermo Fisher Scientific) 4.75 µl 23.75 µl 
Lipofectamine® 3000 Reagent (Thermo 
Fisher Scientific) 
0.25 µl 1.25 µl 
 Mix serval times by pipetting up and 
down 
 
DNA solution and the Lipofectamine® solution had to be mixed in the following step by 
pipetting up and down. This mixture is incubated for 10-15 min at RT. Afterwards, the DNA-
Lipofectamine® complex is added into the appropriated well. 
In the next step cells are seeded with a density of 2x104/well (96 well) or 1x105/well (24 well) 
an incubated for 48h in the transfection mixture in an incubator at 37°C with 5% CO2. 
2.1.11Transfection of cells using electroporation 
 
Since with other transfections methods only a small number of cells (20-30%) are transfected, 
a different transfection method was used. Electroporation is a method of making cell 
membranes temporarily permeable in order to introduce DNA into cells. An electrical field, 
which is usually generated as a short pulse by the discharge current of a capacitor, permeabilizes 
the cell membrane of cells in the capacitor due to various effects. 
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To electroporate cells, the cells are diluted in PBS with a cells number of 2x106 cells/ml. 
Afterwards, 1x106 cells are transfected in a 4mm electroporation cuvette with 10 µg DNA with 
a specific voltage and capacitance shown in the table underneath (Table 3). To the approximated 
transfection volume of 500µl another 500µl normal cell culture media is added after 
transfection. The required amount of cells are plated in the needed size of cell culture plate. The 
cells are incubated at 37°C with 5% CO2 in an incubator and after 24h the media should be 
exchanged to wanted cell culture media. 
Table 3: Electroporation conditions. 
Name Voltage [V] Capacitance [µF] 
PC12 250 950 
1321N1 300 1000 
2.2.12 Analysis of PC12 cells differentiation using different inhibitors 
 
Pharmacological inhibitors are factors which can prevent a substance to bind to the target 
protein. Most of the inhibitor reactions are reversible. Two types of inhibitions are known: The 
competitive inhibition is when the inhibitor competes with the substrate. The second one is the 
allosterically inhibition where the inhibitor changes the molecular structure of the protein, so 
that the substrate can no longer be bound. Signal transduction inhibitors are inhibitors which 
are able to interfere with or inhibit important cellular signal transduction pathways. Signal 
transduction refers to the biochemical transfer of information or information from the cell 
membrane into the cell interior, or from one cell compartment to another. Different inhibitors 
for signaling cascades were analyzed in this thesis (Table 4). 
Table 4: Used inhibitors. 
Inhibitor name Target Concentration Producer 
PD98059 MAPK 40 mM in DMSO Sigma 
U0126 Erk1/2 50 µM in DMSO Sigma 
LY294002 PI3K 50 mM in DMSO Sigma 
k252a TrkA 50 µM in DMSO Sigma 




PC12 cells are seeded at the appropriated density and incubated for 24h at 37°C with 5% CO2 
to plate the cells. 1h before NGF or the conditioned media is added they are preincubated with 
the described concentration. NGF or the conditioned media is added with the addition of the 
different inhibitors. Cells are incubated for 48h and afterwards documented with a bright field 
microscope. The amount of differentiated cells as well as the neurite length is analyzed using 
FIJI. A differentiated cell is defined by neurites longer than the cells diameter. For the amount 
of differentiated cells, the number of differentiated cells in percent is calculated from each 
picture contain around 100 cells. The neurite length is quantified by measuring of 10 neurites 
of each picture. The ANOVA test is done using GraphPad Prism. 
2.2.13 Experiment to analyze different signaling cascades 
 
Signaling cascades are processes which is coupled normally with multiple different 
transcription factors which are activating or downregulating the activity. Substances which are 
presented to the cells are activating or inactivating different signaling cascades. To analyze the 
effect, an assay to quantify the activity of different signaling cascades have to be established. 
Therefore, 1321N1 astrocytoma cells are reverse transfected with Lipofectamine®. The 
transfection mix will be shown in the following: 
Opti-MEMTM   49.4 µl 
P3000    0.2 µl 
Renilla Standard [0.1 µg/ml] 3.9 µl 
Firefly construct [0.1 µg/ml] 9.1 µl 
The DNA dilution is mixed with the Lipofectamine® dilution: 
Opti-MEMTM   61.75 µl 
Lipofectamine®  3.25 µl 
The mixture is afterwards given in 96 well plate with 10µl each on 12 wells. 
To analyzed different signaling cascades a standard transfection with a standard renilla 
luciferase cotransfected with a standard firefly luciferase had to be done every assay, to get a 
standard for all independent experiments. The standard is set for each experiment to 1. All 
different transfections (for the standard or for the different signaling cascades) are incubated 
after transfection for 48h for another 24h with serum-reduced media (control) or with ethanol 
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(0.5%) or erinacine C (5µg/ml; 0.5% ethanol) in addition. After the 24h of incubation the 
luciferase activity is measured. 
For the cotransfection experiments the firefly luciferase construct is used with only 1:2 or 1:5 
amount and filled up for normal incubation with a vehicle plasmid or with the different ETS 
variant constructs. 
2.2.14 Measurement of the luciferase activity 
 
Luciferases are structurally different enzymes, through the catalytic activity of which luciferins 
react with oxygen to form high-energy, unstable dioxetanes or dioxetanones. The 
decomposition of these substances leads to bioluminescence and can be measured. 
To analyze the activity of luciferase the PJK System is used. After the incubation time, the cells 
are lysated with 25µl of a passive lysis puffer, which has to be diluted firstly 1:1 with water. 
The cells are incubated with lysis buffer for 15 min. After the cells are detached, which can be 
improved by freezing at -20°C for 5-10 min. During this time the Beetle Juice® which was 
prepared regarding the constructor protocol and the Renilla juice® which was also prepared by 
that, with additionally set the buffer pH to 5.0, are heated up to 37°C. The lysate is afterwards 
transferred to a white 96 well plate (Tecan). With the Beetle juice® the firefly luciferase is 
measured and with the Renilla juice® the renilla luciferase can be analyzed. When the juices 
are heated up, 50µl first of the Beetle juice® and after measurement from the Renilla juice® is 
added and mixed to the lysate in the 96 well plate. 
2.2.15 Calculation for the results from the luciferase assay 
 
The standard, which is performed in all experiments, was set to 1, to standardize every 
experiment. The background level is characterized by two different firefly constructs, the Gal4 
construct and the LexA construct. The Gal4 level is for every experiment subtracted from the 
measured luciferase activity from the different signaling cascades. 
For the cotransfection experiments the Gal4 background is also cotransfected with the different 
ETS variants as the same values and each was subtracted from the respected firefly luciferase 
activity of the signaling cascades. 
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2.2.16 In vitro model of the blood-brain barrier 
The blood-brain barrier consists of three different cell types: pericytes, astrocytes and 
endothelial cells. To build a strong blood-brain barrier in vitro, the different cell types have to 
be co-cultivated in the right order.  
The complete experiment is done by Verena Ledwig in the institute of pharmaceutical 
technology of the Technical University of Braunschweig under the control of Prof. Dr. Stephan 
Reichl. To establish the co-culture the different cell types are isolated from porcine primary cell 
culture and cultivated to get purity. The purity is checked with specific markers for the different 
cell types: Endothelial cells are marked with the Van-Willebrand-factor. Pericytes can be 
specifically marked with alpha-smooth muscle actin and the astrocytes can be analyzed with 
GFAP (glial fibrillary acid protein). 
For the triple culture the different nearly 
pure cell types are co-cultivated on 12 
well inserts, as shown in Figure 4. The 
cells are incubated in a culture media 
(developed by Verena Ledwig) at 37°C 
with 5%CO2 for three days. After that 
the permeabilization is performed. 
Before the permeabilization is done, the 
media above and underneath the border is exchanged by Krebs-Ringer Buffer (KRB). The cells 
are incubated for another 30 min at 37°C with 5% CO2. After that, the permeabilization is done. 
Therefore, the KRB solution above and underneath the border is removed. Firstly, 1500 µl of 
the acceptor solution is added underneath the border, followed by addition of 500 µl of the 
donator solution containing 10µg/ml erinacine C in DMSO is added above. This is done for 
analysis of the apical to basolateral diffusion. For the basolateral to apical diffusion the 
experimental design was done by adding, firstly, the donor solution containing erinacine C 
underneath and afterwards addition of the donor solution above. The cells are incubated at 37°C 
with 5% CO2. After 30, 90, 150, 210, 270 and 330 minutes of incubation 500µl of the acceptor 
solution is removed and the amount of erinacine C is measured using HPLC. The removed 
media is displaced by new 500 µl of the KRB solution. 
 




Figure 4: Schematic drawing of the triple culture for analysis of 




NaCl    6.8 g 
NaH2PO4 x H2O  0.14 g 
NaHCO3   2.1 g 
D-Glucosemonohydrate 1.1 g 
CaCl2 x 6H2O   0.26 g 
HEPES   3.575 g 
KCl    0.4 g 
MgSO4 x 7H2O  0.2 g 
fill up with ddH2O to 1000 ml. 
For the analysis of the P-gp efflux transporter the inhibitor, Verapamil (Sigma; 200µM), is 
added 30 min before starting the permeabilization experiment. 
2.3 Molecular biological methods 
2.3.1 RNA Isolation from 1321N1 cells using peqGOLD RNAPure 
 
Obtaining high-quality RNA is the first and the most critical step in performing many molecular 
techniques such as reverse transcription PCR, transcriptome analysis using next-generation 
sequencing, array analysis and cDNA library construction. Most RNA isolation procedures take 
place in the presence of RNase inhibitory agents. During this process, the sample is 
homogenized in a phenol-containing solution and separated after centrifugation step into three 
phases: a lower organic phase, a middle phase containing denatured proteins and genomic 
DNA, and an upper aqueous phase that contains RNA. The upper aqueous phase is recovered, 
and RNA is collected by alcohol precipitation and rehydration. 
For isolation of total mRNA from astrocytoma cells incubated with the different substances 
1321N1 cells are seeded at a density of 1x105 cells / 3.5 cm cell culture dish and incubated for 
24h at 37°C with 5% CO2 in an incubator. After that cells are incubated for another 24h in 
serum-reduced media following by the incubation for the estimated time with the different 
compound. 
For 3.5 cm dish 1 ml peqGOLD RNAPure is used. peqGOLD RNAPure is a reagent required 
for extraction of total RNA. By pipetting up and down the cells were homogenized in the 
reagent and then incubated for 5 minutes at room temperature. In the following step 200 µl of 
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chloroform is added to separate the phases and the solution is mixed vigorously. After this step 
the samples are incubated for 10 minutes on ice and centrifuged for 5 minutes at 12,000 rpm. 
Three phases were visible: The interphase and the lower phenol phase contain proteins and 
genomic DNA. The isolated RNA was present in the upper aqueous phase. This phase is 
transferred into a new reaction tube by using a pipette. The RNA is precipitated by adding the 
same volume of isopropanol and the mixture is incubated for 15 minutes at 4°C. Subsequently, 
the suspension is centrifuged at 4°C for 15 minutes at 12,000 rpm. Then the precipitate is 
washed twice with 1 ml 70% ethanol (trough centrifugation 10 min at 12,000 rpm). The last 
step involved drying of the RNA pellet at RT for 5 minutes and dissolving in 50 µl RNase-free 
water. The concentration is measured photometrically and the quality is analyzed by 
gelelectrophoresis. 
2.3.2 Photometric determination of DNA/RNA concentration 
 
To determine the concentration of recovered or purified DNA/RNA the corresponding sample 
is measured using an UV photometer. Usually 1:50 or 1:100 dilutions of nucleic acids are 
measured using the photometer at wavelengths of 230 nm, 260 nm and 280 nm. DNA absorbs 
light of a wavelength of 260 nm, the other two values determine protein impurities (280 nm) or 




] =  
𝑂𝐷260 ∙ 𝑑𝑒𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 ∙  𝜗 
1000 µ𝑙
 
ϑ – Conversion factor (DNA: 50; RNA: 40) 
The purity of DNA/RNA was calculated from the ration of OD260 and OD280, wherein the 
value of 1.8 indicates a pure DNA (Sambrook and Russell, 2001). 





2.3.3 Electrophoretic separation of DNA/ RNA fragments in agarose gels 
 
To analyze DNA, newly synthesized RNA by size or to determine the concentration of 
DNA/RNA the horizontal gel electrophoresis is used. Principle of the method is a separation of 
DNA/RNA in an electrical field based on their size. DNA/RNA is separated by moving through 
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an immobilized matrix (agarose) with certain pore size by reason of their negatively charge in 
an electric field. DNA or RNA samples in GelLoading Dye Purple (6x) are placed in the loading 
wells of the agarose gel. Then the fragments are separated according to their size, with smaller 
fragments running faster than larger. The separation of the fragments is adjusted to the 
concentration of the agarose gel. Normally 1% agarose is used for analyzing DNA/RNA with 
a size of 500 bp to 6 kbp. After electrophoretic separation the agarose gel is placed in an 
ethidium bromide bath (0.05%) and incubated for 15 min. Ethidium bromide is intercalating 
between bases of nucleic acids and allows detection of nucleic acids under UV light.  
2.3.4 Synthesis of cDNA using AMV reverse transcriptase 
 
For preparation of cDNA, the isolated RNA is transcribed with viral reverse transcriptase to 
produce a double stranded DNA. Oligo dT primer, which hybridize to the poly A tail of RNA 
is used to start the transcription reaction.  
The following solutions were mixed for the reaction: 
1 µl Oligo dT primer [50 µM] 
2 µg Total RNA 
x µl RNase-free water 
10 µl ∑ 
The mixture is incubated for 5 minutes at 70°C to split the double strands and secondary 
structures and in the following incubated for 10 minutes on ice to allow the attachment of the 
primer to the RNA. 
The following substances are added to the premix: 
5 µl AMV reaction Buffer (5x) 
2 µl dNTP mix [10 mM] 
1 µl RNase inhibitor Ribolock [40 U/µl] 
1 µl DTT [100 mM] 
4 µl RNase-free water 
1 µl AMV Reverse Transcriptase [10 U/µl] 
25 µl ∑ 
The entire reaction mix is incubated for 1 hour at 42°C in a water bath and then an aliquot is 
analyzed on a 1% agarose gel. The successful cDNA synthesis is reviewed by a polymerase 
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chain reaction (PCR) for detecting β-actin to analyze the cDNA synthesis efficiency, and to 
adjust the concentration of different synthesis reaction. GAPDH is an ubiquitous expressed 
gene and therefore can be used to compare the concentration. The cDNA is stored at -20°C. 
After this procedure, the cDNA is used for a semi-quantitative PCR reaction. 
2.3.5 Control of cDNA synthesis by a gapdh PCR reaction 
 
The semi-quantitative gapdh PCR is used to compare the concentration of different samples. 
Specific primers for gapdh are used for the PCR to hybridize complementary cDNA. The 
quality and efficiency of the reverse transcription can be determined with this method. 
The following substances are mixed for this reaction: 
2 µl cDNA 
0.1 µl Primer I (mGAPDH up; [100 µM]) 
0.1 µl Primer II (mGAPDH low; [100 µM]) 
0.5 µl dNTP mix [10 mM] 
5 µl Go Taq Buffer (5x) 
1 µl cDNA 
0.2 µl Go Taq polymerase [100 U/µl] 
17.1 µl RNase-free water 
25 µl ∑ 
Substances are mixed in a PCR tube and amplified in a Thermocycler by using the following 
program: 
PCR program 
95°C 2 min 
95°C 30 sec 
60°C 30 sec 
72°C 45 sec 
72°C 5 min 
16°C ∞ 
After the amplification, the synthesized product is analyzed on a 1% agarose gel. The expected 




2.3.6 Reverse Transcriptase PCR for ngf, bdnf and ets1 
 
Substances isolated from medical fungi are suspected to alter neurotrophin production. Two of 
these neurotrophins are analyzed in this thesis (NGF and BDNF). To quantify the mRNA level 
of ngf and bdnf, a PCR for this mRNA should be done, using specific primer, as well as for ets1 
mRNA 
The following substances are mixed for this reaction: 
2 µl cDNA 
0.1 µl Primer I (hNGF sense/ hBDNF sense/ ETS sense; [100 µM]) 
0.1 µl Primer II (hNGF antisense/ hBDNF antisense/ ETS antisense; [100 µM]) 
0.5 µl dNTP mix [10 mM] 
5 µl Go Taq Buffer (5x) 
1 µl cDNA 
0.2 µl Go Taq polymerase [100 U/µl] 
17.1 µl RNase-free water 
25 µl ∑ 
Substances are mixed in a PCR tube and amplified in a Thermocycler by using the following 
program: 
PCR program for ngf 
95°C 2 min 
95°C 30 sec 
61°C 30 sec 
72°C 30 sec 









PCR program for bdnf 
95°C 2 min 
95°C 30 sec 
58°C 30 sec 
72°C 30 sec 
72°C 5 min 
16°C ∞ 
PCR program for ets1 
95°C 2 min 
95°C 30 sec 
58°C 30 sec 
72°C 30 sec 
72°C 5 min 
16°C ∞ 
After the amplification, the synthesized product is analyzed on a 2% agarose gel. The expected 
PCR product for ngf had a size of 189 bp and for bdnf 101 bp and for ets1 370 bp. 
2.4 Zebrafish methods 
 
2.4.1 Maintenance and crossing of zebrafish 
 
The breeding and maintenance of zebrafish took place in an approved fish room where the 
temperature in the chamber is adapted to the ambient temperature of the natural habitat of Danio 
rerio and is obtained at constantly 28°C. Also, a day-night-cycle is generated by a time-
controlled room lighting. For production of embryos, a couple of wild type fish (Brass, AB or 
TLF) or transgenic lines (trkA:mClover, ca8:RFP) is placed in crossing tanks. At the beginning, 
they are isolated by gender using a separation slide in the middle. Furthermore, a mesh-like 
ground is used to separate eggs from the parents, so that the parental fishes cannot eat them up. 
The date of ovulation is timed precisely by removing the separation slide. During the next half 
hour, eggs are laid and can be collected with a sieve. Eggs are cleaned with special water and 





or up to the required days in an incubator. To protect from pigmentation fishes can be treated 
with 0.03% phenylthiourea (PTU) in 30% Danieau (Westerfield, 1993) starting at 24 hpf.  
30% Danieau 
300% Danieau   100ml 
fill up to 1000 ml with deionized H2O 
300% Danieau 
2.9 M NaCl    60 mL 
70 mM KCl    30 mL 
40 mM MgSO4  30 mL 
60 mM Ca(NO3)2   30 mL 
0.5 M HEPES (pH 7.2)  30 mL 
fill up to 1000 ml with deionized H2O 
0.03% PTU in 30% Danieau 
PTU 3g 
add 1 l 30% Danieau. 
2.4.2 In vivo blood-brain barrier model 
 
After crossing of wildtype zebrafish (Brass), zebrafish larvae are maintained and grown up until 
the required developmental stages (4dpf, 7dpf, 10dpf) is reached. After the time point is attained 
the fishes are incubated with erinacine C with a concentration of 5µg/ml in 0.5% ethanol, or 
with 0.5% ethanol alone. The media is renewed every day. The fishes are feeded every day 
starting at 7dpf with Paramecium. After 24h, 48h or 72h of incubation at least 50 fishes are 
cooled down in ice for 10min and afterwards washed ten times with ice cooled Washing media. 
The first and last Washing Media is kept for further analysis after washing. After the last 
washing step, the fishes are transferred into 4%PFA/PBST in a 3 cm petri dish and incubated 
for 10 min at room temperature. After incubation the brains are isolated under a dissection 
microscope with e dissection pin and forceps. The isolated brains are transferred into a 2 ml 
Eppendorf tube and together with the Washing media stored at -80°C until transportation to the 




The aqueous solutions of the Washing Media samples are concentrated at 39° C in a stream of 
nitrogen. Thereafter, the residues of the washing samples and the selected brains are taken up 
in 1 ml of methanol and extracted for 35 minutes in an ultrasonic bath. After centrifuging the 
samples (5 min, 10,000 rpm), the supernatants are removed, and the solvent evaporated at 39 ° 
C in a stream of nitrogen. The residues thus obtained are dissolved in 70 μl of methanol and 
analyzed by HPLC-UV / Vis and HPLC-ESI-MS. 
The content determinations are carried out by HPLC-UV / Vis on an Agilent 1260 Infinity 
System with diode array detector and a Waters Acquity UPLC BEH C18 column (2.1 × 50 mm, 
1.7 μm). Eluent A: H2O + 0.1% formic acid, eluent B: acetonitrile + 0.1% formic acid; Gradient 
1: 5% B for 0.5 min, increasing to 100% B in 19.5 min, isocratic 100% B for 5 min; Gradient 
2: 40% B for 4 min, increasing to 60% B in 16 min, increasing to 100% B in 5 min, isocratic 
100% B for 5 min; Flow rate = 0.6 mL min-1, UV detection at 200-600 nm. For the HPLC-
ESI-MS data, a Dionex Ultimate 3000 system with coupled ion trap mass spectrometer amaZon 
speed from Bruker is used. The same running conditions and analytical column as on the 
Agilent 1260 Infinity System are chosen. The ESI-MS spectra are recorded alternately in 
positive and negative ionization. The chemicals and solvents used are obtained from 
AppliChem GmbH, Avantor Performance Materials, Carl Roth GmbH & Co. KG and Merck 
KGaA in analytical and HPLC purity grade. 
Washing media 
Methanol 10% 
in 30% Danieau. 
keep on ice until usage. 
4% PFA/PBST 
Paraformaldahyde 40 g 
10 x PBS  100 ml 
Tween20  100 ml 
fill up with ddH2O to 1000 ml. 
Paraformaldehyde and water are mixed at max. 60°C, additionally 4M NaOH (sodium 
hydroxide) can be added, to clear the solution. The solution was filtered afterwards. Set the pH 
to 7 – 7.5. If the pH was too low, it can be set by using H3PO4 (phosphoric acid). Afterwards 
add PBS and Tween20. Aliquots can be maintained at -20°C. 
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10 x PBS 
Potassium chloride   0.2 g 
Potassium dihydrogen phosphate 0.2 g 
Sodium chloride   8 g 
Sodium hydrogen phosphate  1.15 g 
add ddH2O to 1 l 
autoclave 
2.4.3 Isolation and Fixation of an adult zebrafish brain 
 
Adult zebrafish are maintained as described before in a special room at 28.5°C. To isolate the 
brain, the fishes are anesthetized with Tricaine and cooled down on ice and afterwards 
decapitated. To isolate the brain the tissue from the bottom, like the gills, had to be removed. 
Afterwards, the bone over the brain would be broken by two forceps taking care, to not destroy 
the brain. Following, the brain could take out easily by careful pulling at the nerve of the eyes. 
The eyes are removed afterwards, and the brain was transferred into ice cold 4%PFA/PBS and 
incubated over night at 4°C. 
2.4.4 Sectioning of the adult zebrafish brain with a vibratome 
 
After fixation the brains are washed several times with PBS on a shaker. To remove the water 
one brain is transferred into a 2ml Eppendorf tube with 1% low melting agarose (Pronadisa) in 
PBS and incubated at 37°C for 30min. Afterwards, the brain are transferred in a special 
embedding mold and the low melting agarose is removed and directly exchanged by 3% 
Agarose in PBS. The orientation has to be directly after adding of the 3% agarose since it colds 
down very fast and by that it gets hard. After alignment of the brain, the agarose block had to 
be cold down completely at room temperature and afterwards for at least 5 min at 4°C. 
At the same time, the vibratome (Leica VT1000S vibratome) is prepared. The object box is 
filled with PBS and the blade is installed. The brain in the agarose block is orientated to cut 
from the anterior to posterior in sagittal orientation. Section of 50µm are done and dried on a 






Paraformaldahyde 40 g 
10 x PBS  100 ml 
fill up with ddH2O to 1000 ml. 
Paraformaldehyde and water are mixed at max. 60°C, additionally 4M NaOH (sodium 
hydroxide) was added, to clear the solution. The solution is filtered afterwards. Set the pH to 7 
– 7.5. If the pH was too low, it can be set by using H3PO4 (phosphoric acid). Afterwards PBS 
is added. Aliquots was maintained at -20°C. 
10 x PBS 
Potassium chloride   0.2 g 
Potassium dihydrogen phosphate 0.2 g 
Sodium chloride   8 g 
Sodium hydrogen phosphate  1.15 g 
add dH2O to 1 l 
autoclave 
PBS 
10 x PBS 100 ml 
add dH2O to 1 l 
2.4.5 Fluorescence in situ hybridization of vibratome slides 
 
After vibratome sectioning the sagittal sections are transferred in a chamber full with PBS and 
was maintained for several days at 4°C. 
Day 1 
The sections are washed at least 10 min with PBST at room temperature. Afterwards, the slides 
are laid horizontal with the section on the top and incubated for 35 min in 6% H2O2 in PBST 
with a parafilm on the top. To remove the H2O2 the slides are washed in a chamber for 10 min 
with PBST. The permeabilize section the slides are treated for 10min 0.5% TritonX100/PBST 
(parafilm) and followed by a washing step for 10 min with PBST (chamber). The block 
unspecific RNA bindings the sections were prehybridize with Prehybridization buffer 68°C in 
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an oven for at least 1h (Parafilm). The hybridization is done with 100ng/ml RNA probe for 
NGF or TrkA in Hybridization buffer ON 68°C (Parafilm). 
Day 2 
The parafilm is removed and the slides were washed for 15 min in prewarmed 2 x SSC pH 4.5 
at 68°C (chamber) followed by two times washing for 30min in prewarmed 0,2 x SSC pH 4.5 
at 68°C (chamber). Afterwards, the slides are cooled down to room temperature. 
The sections are washed for 10 min in PBST (chamber) and equilibrated for 10min Maleic acid 
buffer (chamber). To block unspecific bindings the sections are incubated in 1xBM blocking 
reagent/Maleic acid buffer at least for 1h (Parafilm). The antibody reaction is done with anti 
Dig-POD at a concentration of 1:300 in 1 x BM blocking reagent/Maleic acid buffer (Parafilm) 
at 4°C overnight. 
Day 3 
The unbound antibody is washed away by washing 6 times for 20min with PBST (chamber). 
The first fluorescence reaction is done in the following mixture: 
FITC-tyramide  5 μl 
0.3% H2O2    10 μl 
50% dextran sulfate/H2O  40 μl 
PBST    945 μl 
Add the reaction mix to the slides (1ml per sample) and incubate for 30–40min in the dark 
without agitation. Protect the FITC fluorophore from light during and after the reaction. 
Afterwards, the leftover of the reaction mix is washed away by washing two times with PBST 
for 5min (chamber) and  3 times for 20min (chamber).With this fluorescence reaction a green 
fluorescence can be created another mixture has to be used, when the fluorescence should be 
red: 
TAMRA-tyramide  4 μl 
0.3% H2O2    10 μl 
50% dextran sulfate/H2O  40 μl 
PBST     946 μl 





20% Tween20   1 ml 
add 1 x PBS to 200 ml 
20%Tween20 
100%Tween20   10 ml 
add sterile dH2O to 50 ml 
keep in the dark 
6% H2O2 in PBST  
30% H2O2   2 ml 
add PBST to 10 ml 
keep in the dark 
0.5% TritonX100/PBST  
10% TritonX100  500 µl 
add PBST to 10ml 
10%TritonX100 
100%TritonX100  5 ml 
add sterile ddH2O to 50ml 
keep in the dark 
Prehybridization buffer  
Formamide    25ml 
20X SSC pH 4.5  12.5ml 
1M citric acid   640μl 
50mg/ml heparin   50μl 
yeast tRNA    500µl 
20%Tween 20    250μl 





20 x SSC pH 4.5 
Sodium chloride  175.3 g 
Sodium citrate  88.2 g 
set the pH to 4.5 with 1 M Citric acid 
add dH2O to 1 l 
autoclave 
1M citric acid 
Citric acid   105.07 g 
add dH2O to 500 ml 
50mg/ml heparin 
50 mg dissolved in 1 ml DEPC water. 
yeast tRNA 
50 mg dissolved in 1 ml DEPC water. 
Hybridization buffer 
Formamide    25ml 
SSC 20 x pH 4.5   12.5ml 
50% dextran sulfate/H2O  2.5ml 
1M citric acid   640μl 
50mg/ml heparin   50 μl 
yeast tRNA    500µl 
10%Tween 20   250 μl 
Fill up with ddH2O to 50ml. The solution can be kept at -20°C for several month. 
50% dextran sulfate/H2O 
Dextran sulfate   5 g 
dd H2O    10ml 
Dissolve the dextran sulfate in H2O overnight on a shaker at room temperature and store 




2 x SSC pH 4.5 
20 x SSC (4.5)  50 ml 
add dH2O to 500 ml 
0,2 x SSC pH 4.5 
20 x SSC (4.5)  5 ml 
add dH2O to 500 ml 
Maleic acid buffer 
Maleic acid    116.07 g 
NaCl     87.66 g 
Adjust to 1000ml with ddH2O. 
Dissolve the maleic acid and NaCl in 800ml of ddH2O. Afterwards add solid NaOH tablets to 
increase the pH. Autoclave stock solution and store at room temperature. 
1 x BM blocking reagent/Maleic acid buffer 
10 x BM blocking reagent 1ml 
add Maleic acid buffer to 10ml. 
10 x BM blocking reagent 
BM blocking reagent  10 g 
add Maleic acid buffer to 100ml. Autoclave and aliquot. The aliquots can be stored at -20°C. 
0.3% H2O2 
30% H2O2   100 µl 
add dH2O to 10 ml. Store in the dark. 
2.4.6 Tyramide synthesis from protocol of Dr. Jakob von Trotha 
 
The fluorophore esters 5-carboxyfluorescein succinimidyl ester (FITC; Thermo Scientific 
46410) and 5-(and-6)-Carboxytetramethylrhodamine (TAMRA; Thermo Scientific C1171) are 
conjugated to tyramine hydrochloride (Sigma-Aldrich T2879) in a 1.1 times equimolar reaction 
(see below and Hopman et al.,1998; Lauter et al., 2011). The esters are very unstable and should 
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be protected from light, or better, dissolve them directly in Dimethylformamide (DMF; Sigma-
Aldrich D4551) and use at once. 
FITC–tyramide synthesis (adapted from L. Davidson) 
FITC-DMF – Solution A: 
FITC ester [10mg/ml]   100mg 
Dimethylformamide (DMF)   10ml 
DMF–TEA – Solution B 
DMF      6ml 
Triethylamine (TEA)   60 μl 
Tyramine DMF–TEA – Solution C 
Tyramine hydrochloride [10mg/ml]  50mg  
DMF–TEA (Solution B)   5ml 
End reaction 
FITC-DMF (Solution A)   8ml 
Tyramide DMF–TEA (Solution C)  2.74ml 
The solution A and C should be mixed and incubated for 2 h in the dark at room temperature. 
Afterwards, 9.2 ml of absolute ethanol should be added to the synthesized tyramide–FITC 
conjugates to obtain 20ml of stock solution. The solution can be maintained as aliquots at -
20°C. For reaction the mixture should be diluted 1 : 200. 
TAMRA–tyramide synthesis (adapted from Lauter et al. (2011) and P.Affaticati) 
TAMRA-DMF – Solution A3 
TAMRA ester [10mg/ml]   25mg 
Dimethylformamide (DMF)  2.5ml 
DMF–TEA – Solution B 
DMF      6ml 
Triethylamine (TEA)   60 μl 
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Tyramine DMF–TEA – Solution C 
Tyramine hydrochloride [10mg/ml]  50mg 
DMF–TEA (Solution B)   5ml 
End reaction 
TAMRA-DMF (Solution A)   2.5ml 
Tyramine DMF–TEA (Solution C)  762 μl 
The solution A and C should be mixed and incubated for 2 h in the dark at room temperature. 
Afterwards, 21 ml of absolute ethanol should be added to the synthesized tyramide– TAMRA 
conjugates to obtain 24ml of stock solution. The solution can be maintained as aliquots at -









With an aging population, neurodegenerative diseases, like Alzheimer’s or Parkinson’s diseases 
are getting more and more a severe problem. And a big problem for diseases like this is that 
there is no medication for them. In most cases only the symptoms can be treated but not the 
cause of the disease itself. Common in many neurodegenerative diseases is the death of neurons. 
Keeping in mind that small secreted polypeptides, called neurotrophins, was a possible 
medication, neurotrophins are known to have an influence on the survival and regeneration of 
neurons in the nervous system. By that they are important key regulator of the of the 
maintenance of this system. Unfortunately, the high molecular weight of this peptides does not 
enable them to cross the blood-brain barrier (BBB), a barrier to separate the blood system from 
the central nervous system. Smaller molecular weight molecules, which are able to cross the 
BBB and can have an influence on neurotrophins are getting more and more in the focus of 
research.  
3.1 Secondary metabolites isolated from Hericium are able to induce PC12 cell 
differentiation 
 
Medical mushrooms from the genus Hericium, which were known from traditional Chinese 
medicine as medication against gastric and respiratory problems, nervous disorders, high 
cholesterol, cancer and a weak immune system, are discussed frequently in research (Thongbai 
et al., 2015). Recent publications show that compounds isolated from different Hericium 
species contain highly bioactive compounds that could work as antibiotics, but also as 
stimulators of neurotrophin expression (Wang et al., 2019).  
The present thesis was aimed at the isolation and characterization of new metabolites from both 
cultures and basidiomes of Hericium species. The first study deals with some new 
meroterenoids that were obtained from H. coralloides. The second study characterize cyathane 
diterpoids, called erinacines, isolated from cultures of the rare and unstudied species H. alpestre 
and H. erinaceus.  
3.1.1 Corallocines are able to induce PC12 differentiation by stimulation of 
neurotrophin production in astrocytes 
 
Corallocins are substances isolated from the fruiting body of Hericium coralloides. H. 
coralloides obtained its name from the coral-like shape of its fruiting body and this mushroom 
belongs to the family Hericiaceae. Three previously undescribed meroterpenoids were isolated 
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and purified from H. coralloides by Dr. Zeljka Rupcic and were further analyzed in this thesis. 
corallocin A has a benzofuranone structure, whereas corallocin B and C are isoindolinone 
derivatives (Fig. 5). 
 
Figure 5: Structure of the isolated corallocins. The substances corallocin A-C were isolated from Hericium coralloides. By 
analysis with spectral methods the structure was characterized. (1) corallocin A shows a benzofuranone arrangement, whereas 
(2) corallocin B and (3) corallocin C can be classified as isoindolinone derivates. 
Secondary metabolites isolated from different medicinal mushrooms are suggested to have an 
influence on the nervous system. In the nervous system neurotrophins, like NGF, have a major 
impact on neuronal survival as well as on neuroregeneration (Hennigan et al., 2007). To test if 
the isolated fungal metabolites exert a neurotrophin-like function in the nervous system directly 
on neuronal cells, pheochromocytoma derived from rat adrenal medulla (PC12) cells were used. 
PC12 cells are obtained from a rat adrenal medullary tumor. This cell type normally has a 
rounded shape but when NGF is contained in the media the cells produce neurites, which is a 
sign for differentiation of PC12 cells into neuron-like cells (Green and Tischler, 1976; 
Arsenijevic and Weiss, 1998; Sucher et al., 1993; Sugita et al., 1999; Tyson et al., 2003). The 
three pure substances isolated from Hericium coralloides were tested directly on PC12 cells to 
analyze if these compounds have a neurotrophin-like function on these cells (Figure 6). Before, 
the highest non-toxic concentration was characterized. Therefore, PC12 cells were seeded on a 
collagen-coated platen and incubated with increasing concentrations of the different substances 
and incubated for 48h. Dying cells normally detach and start to float in the middle of the plate. 
By that, the highest non-toxic concentration showing no floating cells was characterized. To 
analyze now if the compounds have direct neurotrophic function, the different substances were 
added in the highest not lethal concentration of 20 µg/ml for corallocin A, 30 µg/ml for 
corallocin B and 9 µg/ml for corallocin C, to the PC12 cells in serum-reduced media. Since 






possible causing the usage of serum-reduced media, containing only 1% fetal calf serum (FCS). 
The cells were incubated with the compounds for 48h, and after the incubation period the 
amount of differentiated cells and the neurite length was examined by brightfield microscopy. 
In Figure 6 the control, which was incubated with serum-reduced media, shows the normal 
rounded shape of PC12 cells (Figure 6, black arrow). When incubated with nerve growth factor 
(NGF) in the media the cells start to develop extensions called neurites (Figure 6, white arrow). 
Compared to the cell morphology of differentiation when incubated with NGF, none of the 
substances were able to induce neurite outgrowth directly from PC12 cells. This led to the 
conclusion that none of the tested corallocins are able to induce PC12 cell differentiation 
directly. 
 
Figure 6: Differentiation of PC12 cells incubated directly with the different corallocins. (−) DMSO: negative control with 
DMSO; (+) NGF: positive control with 200 ng/ml human NGF. A nondifferentiated cell is marked with a black arrow, whereas 
a differentiated cell is marked with a white arrow. Scale bar 100 µm. 
Since PC12 cells do not produce neurotrophins on their own, the next step was to characterize, 
if corallocins are able to induce neurotrophin expression in other cells of the nervous system. 
To evaluate this, a second cell line derived from a glial tumor was used as an astrocytic cell line 
to produce conditioned media. It was decided to use a glial cell line since in the brain glial cells 
support neurons. A human astrocytoma cell line was employed. After clarifying the not toxic 
concentration using astrocytic cell line, the media of these cells was supplemented with 
corallocins at the highest not toxic concentration solved in DMSO in serum-reduced media and 
the cells were allowed to condition the media for 48h. These conditioned supernatants were 
added to PC12 cells which were incubated for another 48h in these media. The results were 
shown in Figure 7. The control, which are PC12 cells incubated with normal serum-reduced 
media, showed the normal rounded silhouette of PC12 cells. When NGF is added to the serum-
reduced media, the cells acquired long protrusions, called neurites. Neurites are also visible, 
when the media of corallocin A and C conditioned 1321N1 astrocytoma cells were used. Only 
corallocin B was not able to induce the production of neurites from PC12 cells. In conclusion, 
it was shown that two of three corallocins (A and C) are able to induce the differentiation of 




Figure 7: Differentiation of PC12 cells incubated with conditioned astroglial media incubated with the different 
corallocins. (−) DMSO: negative control conditioned media produced by 1321N1 incubated with DMSO; (+) NGF: positive 
control with 200 ng/ml human NGF. A nondifferentiated cell is marked with a black arrow, whereas a differentiated cell is 
marked with a white arrow. Scale bar 100 µm. 
To quantify the obtained results, the amounts of differentiated cells and the neurite lengths were 
analyzed (Figure 8). Two negative controls were obtained: conditioned media from 1321N1 
cells incubated with no additives and conditioned media from 1321N1 cells incubated with 1% 
DMSO. Both controls showed only a low number of differentiated cells of 1.2 ±0.1% and 2.1 
± 0.2% cells bearing neurites and an average neurite length of 10.2 ± 2.5 µm and 11.7 ± 2.7 µm 
was visible. In comparison to that is the positive control: human NGF (200 ng/ml). The number 
of differentiated cells of 35.2 ±2.5% as well as the neurite length with 71.2 ± 1.7 µm was 
significantly increased compared to the controls. The supernatant, of corallocin A and C treated 
1321N1 astrocytoma cells, was also able to significantly increase the number of differentiated 
cells (to 23.2 ±5% and 30.7 ±4.8%) as well as the neurite length, to a length of 45.7 ± 2.3 µm 
and 51.3 ±2.5 µm. These values are weaker than the positive control, but clearly show a 
significant induction of differentiation and neurite outgrowth over non-treated controls. Only 
corallocin B conditioned astroglial media was not able to induce PC12 cell differentiation, 
which was visible in the number of differentiated cells (1.1 ±0.1%) as well as in the neurite 











Figure 8: Quantification of the level of differentiation when incubated with conditioned media of the corallocins. A) 
Quantification was done by counting the amount of differentiated cells and is shown as a percentage. B) Quantification was 
done by analyzing neurite length and is given in µm. Control: conditioned media produced by 1321N1 without any additives. 
DMSO: conditioned media produced by 1321N1 incubated with 1% DMSO (solvent control). NGF: direct incubation of PC12 
cells with human NGF (200 ng/ml). corallocin A-C: conditioned media produced by 1321N1 incubated with the different 
corallocins. (n = 4; ± SEM; One-way-Anova: *** p ≤ 0.001; **** p ≤ 0.0001) 
It was shown that corallocin conditioned astrocytoma cell supernatants were able to stimulate 
PC12 cell differentiation. Nevertheless, so far, it is not known what is causing this 
differentiation. Yet, Hericium extracts are known to induce neurotrophin expression (Wang et 
al., 2019) and PC12 cells respond to the neurotrophin NGF with differentiation. Therefore, 
whole mRNA of astrocytes incubated for 6h with the different corallocins was isolated and a 
semi quantitative RT-PCR for ngf and bdnf expression was performed (Figure 9). Figure 9A 
shows the pictures of the agarose gel after RT-PCR against gapdh, ngf and bdnf was done. 
Expression of gapdh (Glyceraldehyde 3-phosphate dehydrogenase) was analyzed as a loading 
control, because this gene is a housekeeping gene being an enzyme involved in the catalyzation 
of glycolysis, expressed in equal amounts. Analyzing the results from ngf PCR in the control 
showing 1321N1 astrocytoma cells incubated for 6h with serum-reduced media, the amount of 
ngf mRNA is relatively low. When these cells were incubated with 1% DMSO in the serum-
reduced media the expression of ngf mRNA was slightly increased. When incubated with the 
different corallocins the highest increase was visible for corallocin C, followed by corallocin 
A. corallocin B was also able to increase the amount of the ngf mRNA. Characterizing the 
results for bdnf mRNA, the control, as well as the DMSO treated cells, and the corallocin A 
treated cells show a similar amount of bdnf expression. Corallocin B and C were able to cause 
the increase of the bdnf mRNA. Again, corallocin C was the strongest inducer, increasing the 
amount of bdnf by about 4-fold compared to the other corallocins and about 40-fold over non-








































































































































































in Figure 9A the control shows a basal level of ngf mRNA, and this value was set to 1 ±0. The 
other results were shown as fold induction over control value. When the 1321N1 astrocytoma 
cells were incubated with DMSO the level of ngf expression increases up to 2.4 ±0.6 times 
compared to non-treated 1321N1 cells. When incubated with the different corallocins, all of 
them were able to significantly increase the ngf mRNA level. The highest inducer of ngf mRNA 
is corallocin C with an increase of 20.1 ± 3.7-fold, followed by corallocin A with an increase 
of 10.6 ±2.6 fold and corallocin B with 7.5 ±0.7. The bdnf level in the control cells are relatively 
low and was set to 1 ±0. When incubated with DMSO the amount of bdnf mRNA was increased 
until 2.6 ±0.6. Incubation with the different corallocins: corallocin A and B increased the 
amount of bdnf mRNA up to 10.2 ±2.7 and 12.4 ±1.5, respectively but this increase was 
statistically not significant. Strikingly, corallocin C is able to significantly increase the bdnf 
mRNA on the value of 41.3 ±8.9 on the transcriptional level. The results lead to the conclusion, 
that corallocin A and B are able to induce NGF expression. corallocin B is surprisingly able to 
induce NGF production, but despite the fact that ngf level PC12 cells did not show signs of 
differentiation, this suggest that there is a threshold of NGF, which needs to be overcome in 
order to trigger differentiation of PC12 cells, like it was suggested also by Mori and colleagues 
(2008). Corallocin C is able to induce transcriptional both neurotrophins, NGF and BDNF. In 
the PC12 cell differentiation assay the BDNF activity could not be analyzed, since PC12 cells 
do not express the responding receptor, TrkB (Squinto et al., 1991), which represents the high 




Figure 9: Analysis of the mRNA levels in astrocytes, when incubated with corallocins. A) Representative agarose gel 
picture of the semi quantitative RT-PCR. Control means astrocytoma cells incubated without any additive; DMSO – 1321N1 
incubated with 1% DMSO; corallocin A-C – astrocytoma cells incubated with the different corallocins. gapdh was used as a 
loading control and to induce ngf and bdnf mRNA levels. The lower bands show the ngf and bdnf pattern, when astrocytes were 
incubated with the different additives. A quantification is shown in B) and C). (n = 3; ±SEM; t Test * p ≤ 0.05) 
Summarizing the results above, the corallocins are not able to induce PC12 cell differentiation 
directly. Yet, it was shown that two of these three compounds are able to induce differentiation 
after incubating 1321N1 astrocytoma cells with these cells allowing them to condition their 
media and subsequently adding their supernatant to PC12 cells. This shows that corallocins 
induce neurotrophin expression in glial but not in neural cells. corallocin A and C are able to 
induce differentiation of PC12 cells by inducing ngf expression. Also, corallocin B is able to 
induce NGF production, but it is unable to overcome the NGF threshold needed for initiating 
significant PC12 cell differentiation. In addition, corallocin C is able to induce BDNF 
production. 
3.1.2 Erinacines are able to induce PC12 differentiation by stimulation of neurotrophin 
production in astrocytes 
 
erinacines were isolated from the mycelia of Hericium erinaceus and Hericium flagellum by 
Dr. Kathrin Wittstein and Dr. Zeljka Rupcic. Structurally the erinacines belong to the group of 
cyathane diterpenoids. In this work seven pure of such cyathanes were analyzed and two of 






























































































































































































Figure 10: Structure of the isolated erinacines. (1) erinacine Z1; (2) erinacine Z2; (3) erinacine A; (4) erinacine B; (5) 
erinacine C; (6) erinacine E; (7) CJ14.258; (8) erinacine F. Erinacin Z1 can be only isolated from Hericium erinaceus, erinacine 
Z2, CJ14.258 and erinacine F can be only isolated from Hericium flagellum and erinacine A, B, C and E can be found in both 
Hericium species. All substances have the characteristics of diterpenoids. 
These isolated erinacines were first analyzed for their direct neurotrophin-like effect on PC12 
cells. Before starting the experiments, the highest non-toxic concentration was measured as 
described before. The different erinacines were added directly on PC12 cells with increasing 
concentration. When cells start to float the toxic concentration was reached and the highest non-
toxic concentration was analyzed. To characterize if the erinacines had direct neurotrophic 
activity, the different erinacines were added in their highest nontoxic concentration (erinacine 
A 12 µg/ml, B 0.8 µg/ml, C 5 µg/ml, CJ14.258 1 µg/ml, erinacine E 10 µg/ml, Z1 1µg/ml and 
Z2 3 µg/ml) directly in serum-reduced media on PC12 cells and incubated for 48h. After the 
incubation time, the control cells, which were incubated in serum-reduced media showed a 
rounded shape (Figure 11) characteristic for undifferentiated PC12 cells, whereas the positive 
control, which were cells incubated with NGF (200 ng/ml) in the media, showed many 
membrane protrusions characterized as neurites – a typical sign for PC12 cell differentiation. 
As it was observed for the corallocins, all of the tested erinacines showed no neurite outgrowth 





Figure 11: Differentiation of PC12 cells incubated with the different erinacines. (−) Ethanol: negative control with 0.5 
%Ethanol; (+) NGF: positive control with 200 ng/ml human NGF. A nondifferentiated cell is marked with a black arrow and a 
differentiated cell with a white arrow. 
Consequently, the erinacines were also tested for their neurotrophin producing effect using 
1321N1 astrocytoma cells. Therefore, the astrocytoma cells were incubated with the different 
erinacines with their highest non-toxic concentration (measured before using the 1321N1 
astrocytoma cell line and performed as described before) in serum-reduced media and incubated 
for 48h to condition the medium. The media conditioned by 1321N1 astrocytoma cells was 
added afterwards to PC12 cells. These cells were incubated for another 48h. After the 
incubation time, the control cells incubated with serum-reduced media with 0.5% ethanol as 
solvent control showed a rounded shape, which is characteristic for undifferentiated PC12 cells 
(Figure 12, black arrow). All tested erinacines at different concentrations showed the effect 
with the media conditioned by astroglial cells on PC12 cells to induce membrane protrusions, 
which were called neurites, implying that they are able to induce neurotrophin production and 
thereby the differentiation of PC12 cells. 
Control (-) 
NGF 200ng/ml 
erinacine C 5 µg/ml Erinacin Z2  3 µg/ml 
Erinacin Z1 1 µg/ml CJ14.258 1 µg/ml 
erinacine E 10 µg/ml 
erinacine B 0.8 µg/ml 









Figure 12: Differentiation of PC12 cells incubated with media conditioned by 1321N1 astrocytoma cells incubated with 
the different erinacines. (−) Ethanol: negative control conditioned media produced by 1321N1 incubated with Ethanol; (+) 
NGF: positive control with 200 ng/ml human NGF. A differentiated cell is marked with a white arrow. Scale bar 100 µm. 
To quantify these results, the number of differentiated cells containing neurites and the average 
length of the neurites were measured (Figure 13). Compared to the negative controls, which 
showed only a small amount of differentiated cells of 1.2 ±0.1% (serum-reduced media) and 
5.2 ±1.1% (0.5% ethanol) with short neurites having an average length of 10.2 ±2.5 µm (serum-
reduced media) and  10.5 ± 3.1 µm (0.5% ethanol), all erinacines as well as the positive control 
(NGF) were able to significantly induce PC12 cell differentiation shown by the amount of 
differentiated cells as well as by the average length of neurite extensions that they induced. The 
NGF positive control induced differentiation of 35.2 ±2.5% of the cells and these cells were 
extending neurites with an average length of 71.2 ± 1.7 µm. The strongest differentiation-
inducing supernatant conditioned by astroglial cells was erinacine A with 39.5 ±5.7% 
differentiated cells which had neurites with an average length of 57.2 ±5.9 µm. This was 
followed by the weaker inducing erinacine B (37.2 ±10.7%; 51.9 ±3.2 µm), erinacine C (39.2 
± 3.2%; 50.8 ±2.8 µm), CJ14.258 (36.7 ± 10.2%; 48.2 ±3.1 µm), erinacine E (31.8 ±3.1%; 48.1 
±2.8 µm), erinacine Z1 (18.2 ±3.3%; 18.7 ±2.8 µm) and erinacine Z2 (17.5 ±3.3%; 19.2 ±2.7 
µm). So, it was shown that the already known structures erinacine A, B, C, E and CJ14.258 are 
able to induce differentiation equivalent to the positive control. Both, erinacine Z1 and Z2 are 
weaker in the induction of PC12 differentiation compared to the positive control or the already 
known erinacines. 
EtOH control (-) erinacine C 5 µg/ml Erinacin Z2  3 µg/ml 
Erinacin Z1 1 µg/ml CJ14.258 1 µg/ml 
erinacine E 10 µg/ml 
erinacine B 0.8 µg/ml 









Figure 13: Quantification of the level of differentiation of PC12 cells when incubated with media conditioned by 1321N1 
astrocytoma cells incubated with different erinacines. A) Quantification was performed by counting the amount of 
differentiated cells shown as percentage. B) Quantification was performed by analyzing neurite length which is given as average 
value in µm. Control: conditioned media produced by 1321N1 without any additives. EtOH: conditioned media produced by 
1321N1 incubated with 0.5% Ethanol alone (solvent control). NGF: direct incubation of PC12 cells with human NGF (200 
ng/ml). The grade of differentiation of PC12 cells is shown when these were incubated with conditioned media produced by 
1321N1 incubated with the different erinacines. (n = 4; ± SEM; One-way-Anova: * p ≤ 0.05; *** p ≤ 0.001; **** p ≤ 0.0001) 
The next step was to explore if erinacines caused differentiation of PC12 cells by media 
conditioned by erinacine-treated 1321N1 astrocytoma cells. This differentiation is potentially 
triggered through stimulation of neurotrophin expression and secretion by these astrocytic cells. 
Consequently, 1321N1 astrocytoma cells were incubated with the various erinacines for 6h in 
serum-reduced media. After the incubation time the RNA was isolated, reverse transcribed to 
cDNA which was further analyzed by semi-quantitative RT-PCR against gapdh, ngf and bdnf 
mRNA level was evaluated (Figure 14). Figure 14A shows the RT-PCR results of the gapdh, 
ngf and bdnf mRNAs, no clear difference of the ngf level and bdnf level was visible compared 
to the controls. Therefore, a quantification of three independent experiments was done, shown 
in Figure 14 B and C. The ubiquitously expressed gapdh is used as a loading control. The 
amount of ngf and bdnf mRNA isolated from the control cells being incubated with serum-
reduced media with ethanol as solvent control was set to a value of 1, the following results are 
shown as x times to the control. Surprisingly, not all of the erinacines were able to increase the 
ngf mRNA level. The strongest inducer of ngf expression is erinacine C with a value of 2.5 
±0.2, followed by erinacine A with a value of 2.1 ±0.04. Additionally, erinacine B was able to 
induce NGF production by a 2.03 ±0.1fold upregulation, followed by erinacine E with a value 
of 2 ±0.1. All of these upregulations were statistically significant. Furthermore, the new 
structure erinacine Z2 was able to induce ngf expression by 1.4 ±0.2, but this increase was not 



















































































































































































































































expression. In addition to the fact that only one erinacine was able to significantly increase bdnf 
mRNA levels and this was erinacine C with a value of 2.5 ±0.2. All of the other erinacines were 
not able to significantly induce the bdnf expression, exemplified by the values for erinacine A 
(1.1 ±0.1), erinacine B (1.2 ±0.03), CJ14.258 (1.3 ±0.1), erinacine E (1.2 ±0.1), erinacine Z1 
(1.1 ±0.02) and erinacine Z2 (1.2 ±0.1). This leads to the conclusion that only erinacine A, B, 
C and E are able to induce significantly expression of ngf in astrocytic 1321N1 cells. All 
erinacines are able to induce with the conditioned media of incubated astrocytoma cells the 
PC12 cells. erinacine C is in addition to the influence on the expression of ngf also able to 
significantly stimulate the bdnf mRNA production, which cannot be analyzed by the PC12 cell-
based differentiation due to the lack of TrkB receptor expression. The other erinacines were not 
able to increase bdnf expression. 
 
Figure 14: Analysis of the mRNA level of neurotrophin expression on 1321N1 cells, when incubated with erinacines. A) 
Representative agarose gel picture of a semi quantitative RT-PCR analysis. EtOH – 1321N1 cells incubated with 1% Ethanol 
followed by astrocytoma cells incubated with the different erinacines. gapdh was used as a loading control. The lower bands 
show the ngf and bdnf expression pattern, when astrocytes were incubated with the different additives. A quantification is 
shown in B) and C). (n = 3; ±SEM; t Test * p ≤ 0.05) 
Over all these findings confirm that erinacines and corallocins are not able to induce PC12 cell 
differentiation directly, but after the media was conditioned by astrocytoma cells treated with 
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these erinacines. Besides, neurotrophins such as NGF and BDNF are stimulated in their 
expression. For further analysis the signaling cascade by which PC12 cell differentiation is 
initiated, the most prominent member, erinacine C, which is able to cause the activation of NGF 
and also BDNF expression should be further analyzed. 
3.1.3 Analysis of signaling cascades involved in the induction of PC12 cell differentiation 
by erinacine C-conditioned medium. 
 
It was shown before that PC12 cells differentiate when the conditioned media of erinacine C 
incubated 1321N1 astrocytoma cells is added onto PC12 cells. In this work the signaling 
cascades, which mediate this differentiation, are evaluated. 
As erinacine C induces ngf expression in 
astrocytic cells and PC12 cells are known to 
differentiate upon NGF signaling, the signal 
transduction cascade downstream of NGF was 
evaluated. NGF binds to its high affinity 
receptor, called tropomyosin receptor kinase A 
(TrkA). Upon ligand binding this receptor 
forms a homodimer. TrkA is a transmembrane 
rector kinase and ligand binding results in 
cross-autophosphorylation of its own cytosolic 
domain. Due to this autophosphorylation the 
intracellular kinase is activated and causes the 
activation of different downstream signaling 
cascades, like Phosphoinositid-Phospholipase C 
γ (PLCγ), Phosphoinositid-3-Kinase (PI3K), 
Mitogen-activated protein kinase (MAPK) 
which activates the extracellular signal–
regulated kinases 1/2 (Erk1/2) further 
downstream (Obermeier et al., 1993; Stephens et al., 1994; Pearson et al., 2001; Riccio et al., 
1999; Datta et al., 1999; Hetman et al., 2000; Kaplan and Miller, 2000). Using the known 
autophosphorylation properties a dominant negative (dn) variant of TrkA can be established 
(Figure 15), like it was shown for the FGF receptor (Amaya et al., 1991). The dominant negative 








Figure 15: Scheme of how the dnTrkA System works. 
Normally, when NGF binds to its high affinity receptor TrkA 
this binding leads to an autophosphorylation of the 
transmembrane receptor (TrkA) shown in the upper 
picture. This phosphorylation activated several signaling 
cascades, which causes in PC12 cells the production of 
neurites and differentiation. In the dnTrkA variant (lower 
picture) the kinase region is exchanged by a citrine to mark 
all cells expressing the variant. When the kinase region is 
not part of the transmembrane receptor the 
autophosphorylation cannot take place, so the signaling 
cascades cannot be activated and the PC12 cells should not 
be able to differentiate NGF/TrkA dependent. 
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kinase domain. When this truncated variant is overexpressed, it forms heterodimers with the 
endogenous TrkA upon ligand binding. This heterodimer cannot cross-phosphorylate each 
other because the kinase domain and the target domain is missing. Therefore, ligand binding 
does not activate TrkA downstream signaling. To monitor the expression of the dominant 
negative TrkA variant, the domain was replaced by the fluorescent protein mCitrine, which 
contains an ER exit sequence (FCYENEV) at its C-terminus to promote incorporation into the 
cytoplasmic membrane. 
 
Figure 16: Construct of rat dnTrkA for PC12 cells transfection. The Plasmid consists of a pCS backbone where the N-
terminus of the rat TrkA receptor is cloned fused to a mCitrine, which is connected to an Endoplasmic reticulum export signal 
(ERex). 
The above described construct was used to analyze, if the differentiation caused by conditioned 
media of erinacine C treated 1321N1 astrocytoma cells is triggered by NGF/TrkA signaling. 
Therefore, 1321N1 cells were incubated with erinacine C (5 µg/ml) for 48h. During this time 
PC12 cells were transfected and incubated for 48h with the expression construct to overexpress 
the dominant negative TrkA receptor. These PC12 cells were exposed to the conditioned 
supernatant of the 1321N1 cells. In addition, transfected cells were also incubated with NGF as 
positive control. The cells were cultured for another 48h, afterwards the cells were analyzed for 
differentiation by neurite outgrowth. Transfected cells demonstrated a green fluorescence in the 
membrane, not transfected cells did not display fluorescence (Figure 17). Cells incubated with 
only serum-reduced media and 0.5% ethanol as solvent control showed the rounded shape of 
normal PC12 cells, both transfected and non-transfected cells. After incubation with NGF at a 
concentration of 200 ng/ml the non-transfected cells indicated the generation of neurites (Figure 
17, second picture, black arrow), but the transfected green cells did not extend such membrane 
protrusions (Figure 17, white arrow). When the PC12 cells were treated with the conditioned 
media of erinacine C incubated astrocytoma cells the non-transfected cells exhibited neurites 
(Figure 17, third picture, black arrow), whereas in the transfected green fluorescent cells no 
neurites were visible (Figure 17, white arrow). The weakly expressing PC12 cells confirmed 
elongations, but shorter than the non-transfected cells (Figure 17, red arrow). This confirms that 
dnTrkA expressing cells indicated no differentiation, when human NGF was added to these 
cells, whereas the non-transfected cells indicated differentiation. The same applied for the 
conditioned media, of note some transfected cells with weak expression also displayed a weak 
differentiation profile. 




Figure 17: Effect of NGF or erinacine C conditioned media on dnTrkA transfected PC12 cells. Figure shows transfected 
PC12 cells with the before explained dnTrkA construct. A heterogeneous cell population is visible. Green fluorescent cells 
represent transfected PC12 cells expressing the dominant negative variant of the TrkA receptor. EtOH control (-) shows PC12 
cells incubated with normal media with 1% Ethanol as solvent control. NGF shows transfected PC12 cells incubated with NGF 
in normal media. Non-transfected cells, marked with a black arrow, show differentiation, whereas transfected cells, marked 
with a white arrow, are not differentiated. The picture erinacine C show transfected PC12 cells, which were incubated with 
conditioned media of Erinacin C. Non-transfected cells (black arrow) are differentiated. Some transfected cells with green 
fluorescence show no differentiation (white arrow), whereas other show weak differentiation (red arrow). 
The results were quantified regarding the amount of differentiated cells and the neurite length 
(Figure 18). The control where PC12 cells were only treated with serum-reduced media or with 
0.5% ethanol in addition demonstrate only a small number of differentiated cells of 4.3 ±0.5% 
with short neurites having an average length of 12.3 ±1.2 µm. When the PC12 cells were 
incubated with NGF the quantity of differentiated cells and the neurite length were significantly 
increased with an average value of 36.3 ±4.2% and 72 ±2.7 µm, the same was seen for the 
conditioned media treated PC12 cells. 23.2 ±4.3% PC12 cells were differentiated and had 
neurites with an average length of 57.2 ±2.3 µm. When the PC12 cells were transfected with 
the construct of the dnTrkA and treated after transfection with NGF or the conditioned media, 
the amount of differentiated cells was significantly decreased with an average value of 12.5 
±3.9% and 11.9 ±3.8% differentiated cells a nearly 4-fold decrease compared to the non-
transfected cells. These cells had neurites with an average length of 18.2 ±1.3 µm and 21.8 ± 
1.5 µm, respectively (Figure 18). 










Figure 18: Quantification of the percentage of differentiated cells when PC12 cells were transfected with dnTrkA and 
treated with neurotrophin. Quantification was performed by counting the amount of differentiated cells compared to all cells 
shown as percentage. B) Quantification was done by analyzing neurite length which is given in µm. Control: conditioned media 
produced by 1321N1 without any additives. NGF: direct incubation of PC12 cells with human NGF (200 ng/ml). NGF + TrkA 
DN means PC12 cells, which where transfected with the dominant negative TrkA variant and incubated with NGF in the media. 
The same was performed with conditioned media using erinacine C (erinacine C + TrkA DN). EtOH: conditioned media 
produced by 1321N1 incubated with 1% Ethanol (solvent control). erinacine C stands for PC12 cells which were incubated 
with conditioned media of Erinacin C. (n = 4; ± SEM; One-way-Anova: * p ≤ 0.05; ** p ≤ 0.001; *** p ≤ 0.001; **** p ≤ 
0.0001) 
These results confirmed that using a construct to repress NGF/TrkA signaling the differentiation 
of PC12 cells is decreased. This confirms that the differentiated PC12 cells is triggered by the 
NGF-TrkA signaling pathway. As similar results were obtained for erinacine C cultured 
astrocytic media it is plausible that this conditioned media introduced PC12 cell differentiation 
via TrkA receptor. Because transfection only effects 20-30% of the cells non-transfected cells 
serves as direct control, it was decided to utilize also a pharmacological approach by using an 
inhibitor to analyze the dependence of the differentiation to the NGF/TrkA signaling. An 
inhibitor directly for the kinase activity of TrkA was used (K252a): K252a is an alkaloid 
isolated from Nocardiopsis bacteria and is a potent cell permeable inhibitor of kinases and 
phosphorylase kinase, as well as for serine/threonine protein kinases (Figure 19). Apart from 
that, NGF/TrkA signaling activates different downstream cascades, which are involved in 






































































































































































cascades  were used to characterize the effect on 
the different downstream pathways (shown also 
in Table 5): Phosphoinositid-3-Kinase (PI3K; 
LY294002), Phosphoinositid-Phospholipase C γ 
(PLCγ; Bisindolylmaleimide I), Mitogen-
activated protein kinase (MAPK; PD98059), 
extracellular signal–regulated kinases 1/2 
(Erk1/2; U0126) (Obermeier et al., 1993; 
Stephens et al., 1994; Pearson et al., 2001; 
Riccio et al., 1999; Datta et al., 1999; Hetman et 
al., 2000; Kaplan and Miller, 2000). LY294002 
(PI3K) is a potent, cell permeable inhibitor of 
phosphatidylinositol 3-kinase (PI3K) that 
functions at the ATP binding site of the enzyme. 
Bisindolylmaleimide I (PLCγ) enables the 
binding of ATP to PKC and by that it enables 
the activity of PLCγ. PD98059 (MAPK) is a 
potent and selective inhibitor of MAP kinase 
kinases (MAPKK – MAPK kinase). It binds to 
the inactive form of MAPKK and inhibits activation by upstream activators such as c-Raf. 
U0126 (Erk1/2) inhibits activation of MAPK (ERK 1/2) by preventing the kinase activity of 
MAP Kinase Kinase (MAPKK or MEK 1/2). 
Table 5: List of different used inhibitors. 
Name Inhibition of Function 
K252a TrkA inhibits the kinase region of TrkA where the 
autophosphorylation takes place 
Bisindolylmaleimide 
I 
PLCγ enables the binding of ATP to PKC 
enables the activity of PLCγ 
LY294002 PI3K acts on the ATP binding site of phosphatidylinositol 
3-kinase (PI3K) 
PD98059 MAPK binds to the inactive form of MAPKK  
prevents activation by upstream activators 
U0126 Erk1/2 inhibiting the kinase activity of MAP Kinase Kinase 
Figure 19: Illustration of the different downstream signaling 
cascades being activated by NGF/TrkA signaling causing the 
differentiation of PC12 cells. The different inhibitors are 
acting on different downstream cascades of TrkA. K252a is an 
inhibitor for different kinases, which inhibits the 
autophosphorylation of the TrkA kinase region. Three main 
cascades are activated in PC12 cells that are involved in 
differentiation: MAPK/Erk1/2 signaling, PLCγ and PI3K. To 
inactivate MAPK/Erk1/2 signaling two different inhibitors 
were used: for MAPK (PD98059) and for Erk1/2 (U0126). The 
PLCγ signaling was impaired with Bisindolylmaleimide I and 














Astrocytoma cells were treated with erinacine C for 48h and the conditioned media was added 
afterwards onto PC12 cells. 1h before these PC12 cells had been treated with the different 
inhibitors, while the supernatant in addition to the different inhibitors was added 1h later. The 
cells were treated for another 48h to allow differentiation in the presents of different inhibitors 
and analyzed afterwards. After this incubation time the amount of differentiated cells was 
quantified (Figure 20). The cells processed as the control were incubated in serum-reduced 
media with 0.5% ethanol and 1% DMSO. These showed a low amount of differentiated cells 
of 0.8 ± 0.01%, with short neurites (average length of 5.2 ±0.1 µm). When PC12 cells were 
incubated with NGF or with the erinacine C conditioned media the amount of differentiated 
cells ranged around a value of 35.2 ± 5.2% and 23.7 ±5.7% respectively, as well as the neurite 
length (65.7 ±5.1 µm and 48.7 ±5.2 µm), increased significantly. In comparison to that, the 
amount of differentiated cells, as well as the average neurite length, were significantly reduced 
when the different inhibitors were added. The inhibitor for TrkA is able to significantly decrease 
the neurite length (for NGF treatment 42.7 ±3.5 µm and for conditioned media 32.8 ± 4.2 µm) 
and the amount of differentiated cells (12.7 ±5.4% and 9.8 ±3.7%), comparable to the findings 
of the dnTrkA expression in PC12 cells. The other inhibitors for MAPK, Erk1/2, PLCᵧ and 
PI3K were also able to significantly reduce the differentiation amount of the NGF treated cells, 
as well as of PC12 cell incubated in the erinacine C conditioned media, compared to the positive 
controls. Regarding MAPK inhibition (PD98059), the amount of differentiated cells was 
decreased down to 8.7 ±0.01% and 7.9 ±2.3% and these cells had neurites with an average 
length of 30.7 ±7.3 µm and 32.7 ±5.8 µm respectively. Inhibition of Erk1/2 (U0126) lead to a 
decrease of the amount of differentiated cells to 7.8 ±2.5% and 8.1 ±1.5% and the neurites had 
an average length of 33.8 ±6.8 µm and 32.9 ± 4.7 µm respectively. When PLCᵧ 
(Bisindolylmaleimide I) was inhibited the differentiation of the PC12 cells incubated with NGF 
or the conditioned media was also significantly decreased to values of 2.5 ±1.2% and 11.1 ± 
5.2% of differentiated cells respectively, and these cells had neurites with an average length of 
5.2 ±2.5 µm and 32.5 ±5.5 µm. The last used inhibitor for preventing downstream signaling 
cascades was LY294002 to inhibit PI3K, the amount of differentiated cells was decreased down 
to 18.7 ±1.2% for NGF incubation and 5.7 ±1.5% for supernatant from erinacine C treated 
astroglial cells. These cells had neurites with an average length of 55.2 ±1.5 µm for NGF and 
31.2 ±1.5 µm. Summarizing these results, all used inhibitors were able to significantly decrease 
the amount of differentiation of PC12 cells incubated with NGF or the supernatant of erinacine 
C treated 1321N1 astrocytoma cells. Not all inhibitors showed the same efficiency, a stronger 




Figure 20: erinacine C conditioned astrocytic media mediates PC12 differentiation via TrkA signaling. Quantification 
was performed by counting the amount of differentiated cells compared to undifferentiated cells shown as percentage. B) 
Quantification was performed by analyzing the average neurite length which is given in µm. Control: media produced by 
1321N1 without any additives. NGF: direct incubation of PC12 cells with human NGF (200 ng/ml). Followed by incubation 
of different inhibitors together with NGF, a strong decrease in the amount of differentiated cells is visible for PD98059, U0126 
and Bisindolylmaleimide and a weaker decrease for LY294002 and K252a is visible.  The neurite length is strongly reduced 
for Bisindolylmaleimide and weaker decreased for the other inhibitors. erinacine C: incubation of PC12 cells with the 
conditioned media of erinacine C treated 1321N1 cells. This media was used alone or was supplemented with the different 
inhibitors. A strong decrease in the amount of differentiated cells is visible for all inhibitors and also the average neurite length 
is reduced but weaker compared to pure NGF. (n = 4; ± SEM; One-way-Anova: * p ≤ 0.05; ** p ≤ 0.001; *** p ≤ 0.001; **** 
p ≤ 0.0001) 
The demonstrated results lead to the suggestion that the differentiation caused by the media of 
erinacine C treated 1321N1 cells occurred by NGF/TrkA mediated signaling. Regarding the 
efficiency of the induction of differentiation there is a clear difference between pure NGF and 
erinacine C conditioned media. The differentiation mediated by NGF can be reduced by the 
different inhibitors but compared to the differentiation caused by the erinacine C-conditioned 
media, the reduction is stronger. However, with the dn TrkA experiment, a comparable 
reduction of the differentiation for NGF incubated PC12 cells as well as with the conditioned 
media of erinacine C treated astrocytic cells was demonstrated. 
This shows that erinacine C conditioned media of astrocytic cells induces PC12 differentiation 
via TrkA signaling and further downstream through the activation of PLCᵧ, PI3K and MAPK 
signaling. This suggests that there is a connection between the erinacine C incubation and 
induction of NGF production. The next step will be to analyze the direct effect of erinacine C 
on 1321N1 astrocytoma cells. 
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3.2 Analysis of the response of astrocytoma cells to erinacine C 
3.2.1 Analysis of different signaling cascades in astrocytoma cells treated with  
erinacine C 
 
Signal transduction combines several biochemical and physiological processes, for example 
cells respond to external stimuli, transform them, pass them as signal into the cell interior and 
lead through a biochemical signal chain to a cellular response. In this thesis the activation of 
different signaling cascades upon the exposure of astrocytic cells to erinacine C as analyzed. 
This was shown by binding of transcription factors to the DNA and activating the expression 
of target genes. DNA binding sites for different transcription factors have been described, like 
NFkappaB sites or SBE for TGFβ signaling and are listed in openly available databases (Kuri 
et al., 2017; Dennler et al., 1998).  
Activity analysis can be easily performed by using a luciferase expression approach followed 
by quantifying luciferase enzyme activity via generating a bioluminescent product. 
Quantification of photon yield directly relates to expression strength. Therefore, four times 
repeat of different already known DNA binding sites of transcriptional activators was cloned in 
front of an E1b basal promotor initiating the expression of firefly luciferase (Figure 21). 
Binding sites of a variety of transcriptional activators of prominent signal transduction cascades 
were cloned into this construct backbone.  
 
Figure 21: Schematic overview of reporter construct design containing 4x tandems of transcriptional activators. The 
consensus binding site construct backbone contains a 4 times repeat of already known DNA binding sites cloned in front of an 
E1b promotor which initiates expression of firefly luciferase. 
It was shown up to now, that erinacine C is able to induce ngf and bdnf expression in astroglial 
cells, but it is not known, how in astroglial cells respond on the transcriptional level to erinacine 
C incubation. STAT3 is among the transcriptional activators known to be culpable of inducing 
ngf expression. The consensus binding sites of STAT3 have been identified (Langlais et al., 
2008; Vallania et al., 2009). STAT3 belongs to the family signal transducer and activator of 
transcription (STAT) proteins. This group mediates many facets of cellular immunity, 
proliferation, apoptosis and differentiation (Vinkemeier et al.,1998; Tkach et al., 2013). STAT3 
4x DNA-bdg. site 
firefly luciferase E1b 
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initiates the expression of a variety of genes, and by that it plays a key role in many cellular 
processes, such as cell growth and apoptosis (Yuan et al., 2004).  
Another known binding site is recognized by NFkappaB (Kuri et al., 2017). NFkappaB is 
implicated in cellular responses to stimuli such as stress, cytokines, free radicals, and bacterial 
or viral antigens (Gilmore, 2006; Brasier, 2006; Perkins, 2007; Gilmore, 1999; Tian and 
Brasier, 2003). NFkappaB plays a key role in regulating the immune response to infection. NF-
κB has also been involved in processes of synaptic plasticity and memory (Albensi and Mattson, 
2000; Meffert et al., 2003; Freudenthal et al., 1998; Merlo et al., 2002; Park and Youn, 2013).  
Also, different ETS binding sites were cloned (Webb et al., 2016; Boros et al., 2009; Odrowaz 
and Sharrocks, 2012; Brown et al., 1999). ETS belongs to the E26 transformation-specific or 
E-twenty-six family, the largest family of transcriptional activators, containing of highly 
conserved DNA binding domain (ETS domain). By binding to DNA and it is involved in 
regulation of cellular differentiation, cell cycle control, cell migration, cell proliferation, 
apoptosis and angiogenesis.  
Another consensus binding site was used that is recognized by NFAT (Zhang et al., 2018; Chen 
et al., 1998). NFAT stands for Nuclear factor of activated T-cells. The NFAT transcription 
factor family is important for the immune response, but is also involved in development of 
cardiac, skeletal muscle, and nervous systems. Calcium signaling is critical to NFAT activation 
because Calmodulin, a calcium sensor protein, activates the serine/threonine phosphatase 
Calcineurin. Activated Calcineurin dephosphorylates NFAT proteins, which results in a 
conformational change that exposes a nuclear localization signal, resulting in NFAT nuclear 
import.  
Another binding site which was used in the luciferase reporter is BRE (Morikawa et al., 2011). 
BMP responsive element (BRE) is a bone morphogenetic protein (BMP) signaling cascade 
which is recognized by Smad proteins, which are part of the transforming growth factor ß 
(TGFß) family. These proteins are involved in proliferation, differentiation and apoptosis of 
several types of cells (Wozney and Rosen, 1998; Reddi, 2001).  
In this thesis also the estrogen responsive element (ERE) binding site was used for analysis 
(Gorelick and Halper, 2011). This represents a DNA consensus sequence to which the estrogene 
receptors can bind. The estrogene receptor is a ligand-activated cytoplasmic enhancer protein, 
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a member of the steroid nuclear receptor family. It transactivates gene expression in response 
to estradiol.  
Another DNA consensus binding site which was used in this thesis is HIF1 (Greenald et al., 
2015; Kulkarni et al., 2010). HIF stands for hypoxia inducible factor that respond to decreases 
in available oxygen in the cellular environment, and it is responsible for the cellular adaptation 
response to oxygen availability (Smith et al., 2008; Wilkins et al., 2016).  
Also, the function of Dyrk1A binding to DNA was analyzed (Di Vona et al., 2015). The dual 
specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) is usually known as a 
catalysator for autophosphorylation on serine/threonine and tyrosine residues and by that it 
plays a important role in signaling pathways regulating cell proliferation and is involved in 
brain development. In addition to that it was shown that the kinase is also recruited to promoters 
of genes which are transcribed by RNA polymerase II. By that, this transcriptional activator is 
associated with translation, RNA processing, and cell cycle (Di Vona et al., 2015).  
Additional to the already introduced binding sites, the consensus binding sequence of FOXO 
was also employed (Webb et al., 2016). Forkhead-Box-Protein O is involved in cell growth, 
proliferation, differentiation, and longevity (Tuteja and Kaestner, 2007).  
Also, the binding site of Gli1 transcription factor was analyzed (Kinzler and Vogelstein, 1990). 
Gli is a zinc finger protein, which is an effector of the Hedgehog signaling cascade. It was 
shown to be involved in cell fate determination, proliferation and patterning in several different 
cell types.  
RBP binding sites, which are mediating Notch signaling, were used (Tun et al., 1994; 
Minoguchi et al., 1997; Parsons et al., 2009; Schiavone et al., 2014). Recombination signal 
binding protein (RBP) is part of the Notch signaling pathway (Artavanis-Tsakonas et al., 1999). 
Notch signaling promotes proliferation during neurogenesis, and when its activity is inhibited 
by Numb this leads to neural differentiation. It plays also an important role in the regulation of 
embryonic development. Apart from that it is also involved in neuronal development and 
function (Gaiano and Fishell, 2002; Bolós et al., 2007; Aguirre et al., 2010; Hitoshi et al., 2002).  
The FGF mediated signaling was also analyzed using a Pea3b DNA binding site (Znosko et al., 
2010). The fibroblast growth factors (FGF) are a group of cell signaling proteins which are 
involved in a wide variety of processes, like neural stem cell proliferation, neurogenesis, axon 
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growth, differentiation and neuronal survival (Reuss et al., 2003). Surprisingly, the binding site 
included sequences highly conserved to ETS sites.  
CREB mediated signaling was also analyzed in this thesis using CREB specific DNA binding 
sites (Moore et al., 2016; Bobinet et al., 2013). CREB is a cAMP response element-binding 
protein, which is a cellular transcriptional activator. CREB is known to be involved in mediating 
neuronal plasticity as well as in promoting long-term memory (Silva et al., 1998).  
The activity of Wnt signaling can be analyzed by using the DNA binding sites of TCF/LEF 
(Shimizu et al., 2012; Moro et al., 2012). It was shown that Wnt is involved after binding to its 
receptor Frizzled in activation of Dishevelled which subsequently inhibits constructive ß 
Catenin degradation. The stabilized accumulating ß catenin moves into the cellular nucleus, 
where it directly binds to TCF/LEF binding sites. By that the signaling has an influence on cell 
fate determination, cell proliferation and migration (Nusse and Varmus, 1992; Nusse, 2005).  
In this thesis also TGFß signaling was addressed using SBE binding sites (Dennler et al., 1998; 
Schiavone et al., 2014). Smad-binding elements (SBE) are Transforming Growth Factor-β 
(TGFβ) responsive elements. TGFβ belongs to the group of growth factors including Activins, 
Bone morphogenic proteins (BMP) and Glial Derived Neurotrophic Factors (GDNF) (Attisano 
and Wrana, 2002). TGFβ is widely expressed in the embryonic and adult organism and takes 
over function in regulating cell-proliferation and differentiation, extracellular matrix 
production, wound healing, immune function, apoptosis, angiogenesis, chemotaxis and 
hematopoiesis.  
The thesis deals also with NBRE binding site activity (Wilson et al., 1993; Callard et al., 2001). 
Nerve growth factor inducible-B protein (NBRE) is also known as nuclear receptor subfamily 
4 group A member 1 (NR4A1) with a known DNA consensus binding site. NR4A1 is involved 
in cell cycle mediation, inflammation and apoptosis (Pei et al., 2006). But one has to mention 
that NR4A1 is itself an activator of TGF-β/SMAD signaling (Zhou et al., 2014).  
Also, Krüppel like factor 5 (KLF5) was characterized in this work exporting the known KLF5 
DNA consensus binding site (Webb et al., 2016). The family of KLFs are zinc finger DNA 
binding proteins, which are able to regulate protein expression, and by that they are able to 
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influence proliferation, differentiation, and apoptosis, as well as the development and 
homeostasis of several types of tissue.  
The NFY binding site for analyzing the CCAAT/enhancer-binding protein beta (CEBP) 
signaling was also cloned in this work (Webb et al., 2016). Proteins which are expressed after 
CEBP binding and activation of transcription are involved in immune and inflammatory 
responses.  
Also, the binding site for early response factor (Egr1) also known as nerve growth factor 
inducible protein A (NGFI-A) was analyzed in this thesis (Wolfe and Call, 1999). EGR1 can 
activate the transcription of several hundred genes. Depending on the cell type and the stimulus, 
EGR1 induces the expression of growth factors, growth factor receptors, extracellular matrix 
proteins, proteins involved in the regulation of cell growth or differentiation, and proteins 
involved in apoptosis, growth arrest, and stress responses.  
Binding sites which are recognized by Single-minded homolog 2 (Sim2) were also 
characterized in this work (Letourneau et al., 2015). Sim2 is a basic helix-loop-helix (bHLH) 
protein which is important for neurogenesis (Shamblott et al., 2002).  
E2F which belongs to a group of eukaryotic transcription factors was also analyzed regarding 
their activity (Webb et al., 2016). These transcriptional activators are involved in the cell cycle 
regulation and synthesis of DNA in mammalian cells.  
With such experiments it should be characterized, whether signaling cascades become 
stimulated in astrocytoma cells when they are exposed to erinacine C and before NGF is 
expressed. To answer this question 38 different constructs were established using the already 
introduced firefly reporter plasmid. These firefly luciferase constructs were co-transfected with 
an ubiquitously expressed renilla luciferase and in addition to that, a transfection of an 
ubiquitously expressed firefly luciferase together with the renilla luciferase construct was used, 
as a reference, to make the independent experiments comparable with respect to different 
transfection efficiencies. The transfected constructs were allowed to express for 48h in serum-
reduced media as control, with 0.5% ethanol as solvent control. Alternatively, erinacine C was 
added to the transfected cells which were incubated for another 24h. After this incubation time 
the cells were lysed and the luciferase activity of the firefly and the renilla luciferases were 
measured independently by different luminescence substrates. Binding sites recognized by the 
yeast transcription factor Gal4 were the transcription factors which were used to detect the 
background activity of this approach. Therefore, a construct with 4x UAS sites was used. This 
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DNA binding site is specific for galactose-responsive transcription factor (GAL4). GAL4 is a 
yeast specific transcription factor and is not expressed in other model organisms (Kakidani and 
Ptashne, 1988). 
First, the basic level of the different signaling cascade activity in 1321N1 astrocytoma cells was 
characterized. Therefore, 1321N1 cells were transfected with the different constructs together 
with a renilla standard expression vector as a reference for the different transfection efficiencies. 
The transfected cells were incubated with serum-reduced media, to make the results comparable 
to the experiments of neurotrophin induction in astrocytoma cells before, since fetal calf serum 
contains a high amount of growth factors, which can change the results, for another 24h. After 
this incubation time the cells were lysed and the luciferase activity of the firefly and the renilla 
luciferase activity was measured. The results were quantified as the quotient of firefly luciferase 
activity to renilla luciferase activity to normalize the firefly luciferase values to the respective 
transfection efficiency. The background activity was quantified by using a UAS construct. The 
background level was deducted from the quotient and the obtained results are shown in Figure 
22. Some transcription factor consensus binding sites generated relatively high firefly luciferase 
activity values in 1321N1 cells, for example NRF (nuclear respiratory factor; reactive oxygen 
species (ROS) signaling; 217.6 ±53.3), ARE (antioxidant response element; antioxidant 
signaling; 217.6 ±20.3), Elk1 (ETS like protein 1; E-twenty six (ETS) signaling; 164.6 ±11.6), 
ETS (87 ±5) and KLF5 (Krueppel-like factor 5; epidermal growth factor (EGF) signaling; 62.9 
±23.6). This indicates that these transcription factors are endogenously expressed by 1321N1 
cells. It was suggested that some cascades are more active, like ETS or KLF5, since these 
cascades are involved in proliferation and cell cycle. In addition, there were a number of 
transcription factor binding sites, which had moderate activity firefly luciferase, such as: 
NFAT/AP1 (nuclear factor of activated T cells co-binding site with the activator protein 1; 
NFAT signaling; 42.8 ±7.9), Dyrk1A (binding site for Dual-specificity tyrosine 
phosphorylation-regulated kinase 1A; Dyrk1A mediated signaling; 39.5 ±5.8), Pea3b 
(fibroblast growth factor (FGF) signaling; 36.7 ±3.6), HRE (hypoxia responding element; 
hypoxia; 26.8 ±3.3), SP1/KLF (Sp1-like/Kruppel-like factors; 25.8 ±5.5); CREB (cAMP 
response element-binding protein; 21.1 ±2.1), NFkappaB (nuclear factor 'kappa-light-chain-
enhancer' of activated B-cells; 17.9 ±2.4), bZIP (basic leucine zipper; 17.5 ±2.2), SRE (serum-
respond element; 8.4 ±0.4), NFY (nuclear transcription factor Y; 6.3 ±0.6), Egr1 (early growth 
response protein 1; 4.7 ±0.6) and Sim2 (Single-minded homolog 2; 3.7 ±0.6) suggesting a low 
endogenous expression of these transcription factors in astrocytic cells. Furthermore, the 
majority of the analyzed binding sites were not producing any significant firefly luciferase 
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activity showing that these signaling cascades are inactive in 1321N1 cells, among them: NBRE 
(nuclear receptor binding respond element; 1.1 ±0.2), TEAD (TEA domain family member; 
Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) 
signaling; 1 ±0.4), STAT3 (signal transducer and activator of transcription 3; 0.8 ±0.3), HSE 
(heat shock element; 0.8 ±0.1), Lhx2-Sox2 (LIM homeobox gene and SoxB1 related family 
members; 0.6 ±0.3), bHLH (basic helix-loop-helix motif; 0.6 ±0.2), FOXO (forkhead-Box-
Protein O; 0.6 ±0.2) , SF1 (steroidogenic factor 1; 0.6 ±0.3), Gli1 (Zinc finger protein GLI1, 
hedgehog signaling; 0.6 ±0.05), ERE (estrogene responding element, estrogene signaling; 0.4 
±0.06), E2F (0.4 ±0.1), TCF/LEF (transcription factor/lymphoid enhancer-binding factor 1; 
Wnt signaling; 0.4 ±0.1), NFAT (nuclear factor of activated T-cells; 0.3 ±0.03), a1ACT (alpha-
1-antichymotrypsin; 0.2 ±0.1), Runx (runt-related transcription factor 1; 0.2 ±0.09), Sox-Pou 
(0.2 ±0.07), BRE (BMP responsive element; BMP signaling; 0.2 ±0.03), RBP7 (retinol binding 
protein 7; Notch signaling; 0.2 ±0.09) and Fexf2 (Fez signaling; 0.08 ±0.05).  
 
Figure 22: Activity of signaling cascades in 1321N1 de novo. The graph shows the activity of different signaling cascades in 
1321N1 astrocytoma cells incubated with serum-reduced media. The values were shown as the absolute firefly activity divided 
by the renilla activity values. The UAS level was used as background. All values were normalized for the background activity 
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After the basic luciferase activity for the different transcription factor binding sites in the 
reporter construct were evaluated, the effect of ethanol on the reporter gene expression was 
quantified, since ethanol was used as the solvent for erinacine C. 1321N1 astrocytoma cells 
were transfected as described before with the different reporter constructs and the renilla 
luciferase plasmid. The cells were incubated for 48h. After transfection serum-reduced media 
only or supplemented with 0.5% ethanol as additive was added. The cells were incubated for 
another 24h. After this time the luciferase activity was determined to quantify the expression 
strength mediated by the different transcription factor binding sites. In Figure 23 the x fold 
upregulation in comparison to the serum-reduced media incubated control cells. This showed 
that ethanol treatment has an influence on several transcription factor recognizing their 
respective binding site on the reporter construct. One expression level was significant increased, 
the E2F (5.3 ±1.1) binding site reporter. Others were significantly decreased, like for Pea3B 
(Fibroblast growth factor (FGF) signaling; 0.7 ±0.1), BRE (BMP responsive element; BMP 
signaling; 0.5 ±0.2), Egr1 (early growth response protein 1; 0.5 ±0.07), FOXO (forkhead-Box-
Protein O; 0.4 ±0.09), SRE (serum-respond element; 0.1 ±0.02), NBRE (nuclear receptor 
binding respond element; 0.09 ±0.03) and Tbox (0.05 ±0.02). This influence of ethanol has to 





Figure 23: Effect of 0.5% EtOH on the signaling activity in 1321N1. The graph shows the activity of different signaling 
cascade reporter constructs in 1321N1 astrocytoma cells incubated with serum-reduced media compared to 0.5% ethanol treated 
cells. The values are shown as x time upregulation compared to the control cells. (n = 4; ± SEM; One-way-Anova: * p ≤ 0.05; 
** p ≤ 0.001; *** p ≤ 0.001; **** p ≤ 0.0001) 
After the basic activity level and the effect of 0.5% ethanol was analyzed, the effect of erinacine 
C on the reporter construct activity was classified to elucidate the response of the astrocytoma 
cells to erinacine C on the transcriptional level followed by incubation in serum-reduced media 
as control, with 0.5% ethanol as additive to include a solvent control and erinacine C for 24h. 
After this incubation time the cells were lysed and the luciferase activity was determined. Figure 
24 shows the x fold increase compared to the ethanol control. Clearly, activated firefly 
luciferase expression compared to the ethanol control were visible, such as: ERE (estrogene 
responsive element; 2.7 ±0.8), FOXO (forkhead-Box-Protein O; 2.3 ±0.7), NFY (nuclear 
transcription factor Y; 2.2 ±0.7), NBRE (nuclear receptor binding respond element; 2.2 ±0.5), 
ETS (E-twenty six (ETS) signaling; 2.1 ±0.5), Tbox (2 ±0.7), Gli1 (Zinc finger protein GLI1, 
hedgehog signaling; 1.9 ±0.4), NFkappaB (nuclear factor 'kappa-light-chain-enhancer' of 
activated B-cells; 1.8 ±0.4), STAT3 (signal transducer and activator of transcription 3; 1.8 
±0.3), BRE (BMP responsive element; BMP signaling; 1.7 ±0.5), HRE (hypoxia responding 
element; hypoxia; 1.6 ±0.7), Elk1 (ETS like protein 1; E-twenty six (ETS) signaling; 1.5 ±0.2), 
bHLH (basic helix-loop-helix motif; 1.4 ±0.3), Pea3b (fibroblast growth factor (FGF) signaling; 
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1.4 ±0.2) and KLF5 (Krueppel-like factor 5; epidermal growth factor (EGF) signaling; 1.3 
±0.4). A significant increase in the firefly luciferase activity was detected for: ERE, ETS, Gli, 
STAT3, Elk1 and Pea3B. 
On the other hand some transcription factor binding sites did not respond with alteration in 
luciferase expression levels, such as: Dyrk1A (binding site for Dual-specificity tyrosine 
phosphorylation-regulated kinase 1A; Dyrk1A mediated signaling; 1.3 ±0.2), CREB (cAMP 
response element-binding protein; 1.2 ±0.3), Sim2 (Single-minded homolog 2; 1.2 ±0.2), 
TEAD (TEA domain family member; Yes-associated protein (YAP) and transcriptional 
coactivator with PDZ-binding motif (TAZ) signaling; 1.2 ±0.5), SRE (serum-respond element; 
1.2 ±0.3), Lhx2-Sox2 (LIM homeobox gene and SoxB1 related family members; 1.18 ±0.5), 
a1ACT (alpha-1-antichymotrypsin; 1.1 0.4), Egr1 (early growth response protein 1; 1.1 ±0.1), 
bZIP (basic leucine zipper; 1.0 ±0.2), HSE (heat shock element; 1.0 ±0.3), NRF (nuclear 
respiratory factor; reactive oxygen species (ROS) signaling; 1.0 ±0.1), SP1/KLF (Sp1-
like/Kruppel-like factors; 1.0 ±0.2), NFAT/AP1 (nuclear factor of activated T cells co-binding 
site with the activator protein 1; NFAT signaling; 1.0 ±0.1), ARE  (antioxidant response 
element; antioxidant signaling; 0.9 ±0.2) and E2F (0.9 ±0.2). In addition a number of 
transcription factor binding sites mediated a downregulation of firefly expression upon 
erinacine C exposure like: Sox-Pou (0.7 ±0.1), SF1 (steroidogenic factor 1; 0.7 ±0.3), RBP7 
(retinol binding protein 7; Notch signaling; 0.6 ±0.3) and TCF/LEF (transcription 
factor/lymphoid enhancer-binding factor 1; Wnt signaling; 0.5 ±0.1). It has be to mentioned at 
this timepoint, that some bindings site did not result in any expression of firefly luciferase, even 
after erinacine C incubation, like: SBE (Smad-binding elements), Runx (runt-related 




Figure 24: Effect of erinacine C on the activity of reporter constructs with transcription factor binding sites driving 
firefly luciferase expression in 1321N1. The graph shows the activity of different reporter constructs in 1321N1 astrocytoma 
cells incubated with 0.5% ethanol onto serum-reduced media compared to erinacine C treated cells. The values are shown as x 
fold upregulation compared to the 0.5% ethanol treated cell. (n = 4; ± SEM; One-way-Anova: * p ≤ 0.05; ** p ≤ 0.001; *** p 
≤ 0.001; **** p ≤ 0.0001) 
The results suggest that treatment of astrocytoma cells with erinacine C causes a profound 
change in their transcriptional activity. Several constructs for transcriptional activation were 
significantly increased in their firefly luciferase expression, like ETS, Gli1, STAT3, Elk1 and 
Pea3B. Since several times the conserved sequence of ETS is highly activated upon erinacine 
C treatment (in ETS, Elk1 and Pea3B), a prominent member to analyze was the ETS-mediated 
signaling cascades. In order to characterize the ETS signaling more in detail further analysis 
will be done. 
3.2.2 Analysis of ETS signaling 
 
The ETS transcription factor family is a highly conserved group of helix-turn-helix DNA 
binding factors (Lee et al., 2005). These transcription factors are the major downstream 
effectors of the Ras-MAPK signaling cascades (Tetsu and McCormick, 2017). Their 
transcription is regulated by MAPK. In this thesis the effect of erinacine C on ETS mediated 
expression in 1321N1 astrocytoma cells was analyzed in more detail. 
To establish a constitutive activator and repressor of the transcription factor the ETS DNA 
binding domain was established from cDNA of 1321N1 cells (Figure 25). ETS1 is a prominent 
member of the ETS transcription family and is constructed by two protein parts: the DNA 
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binding domain and the transcriptional activation domain. The cDNA of the DNA binding 
domain was cloned in front and in frame of two different strong transcriptional activator 
domains derived from the Herpes simplex viral protein VP16 (TA4 and TA2) (Baron et al., 
1997). These two constructs were used as constitutively active transcriptional activators of ETS 
downstream signaling. To construct a constitutive repressor plasmid, the cDNA of the ETS1 
DNA binding domain was cloned in front and in frame of a strong transcriptional inhibitor 
domain from NFkappaB termed KRAB, which is thought to mediate its inhibitory activity by 
DNA methylation. Expression of the transgenes was driven by the CMV promotor included in 
the pCS2+ expression vector (Rupp et al., 1994). 
 
Figure 25: Overview of the different constructs for analysis of the ETS signaling. The constructs contains the cDNA of 
the DNA binding domain of the transcription factor ETS1 including a nuclear localization signal. This binding site was cloned 
in front of two transcriptional activator domains of different strength (TA4 and TA2) as well as in front of a KRAB DNA 
methylating domain. The transgenes are expressed by a CMV promotor. 
These constructs were co-transfected with an expression construct containing an 8 times repeat 
of the ETS binding sites followed by the basal promotor E1b driving firefly luciferase as 
reporter in 1321N1 astroglial cells. After transfection, the cells co-transfected with the two 
activators (ETS1DBD-TA4 and ETS1DBD-TA2) as well as with only the 8xETS luciferase 
expression vector were treated with serum-reduced media, the cells transfected with only the 
8xETS luciferase construct and co-transfected with the KRAB construct were incubated 
afterwards with 0.5% ethanol and erinacine C and incubated for another 24h. After that, the 
luciferase expression was measured as described before. When the ETS binding site reporter 
construct was transfected in astroglial cells, which were afterwards incubated with normal 
serum-reduced media, ethanol and erinacine C the already described upregulation of ETS 
mediated transcription was visible (Figure 26A). The control showed an average quotient of 
luciferase activity of 111 ±15, whereas the ethanol control showed 101 ±7.5. When cells were 
treated with erinacine C the activity was increased up to 235 ±14.7, which means that there was 
ETS1
DBD
-KRAB pA CMV 
ETS1
DBB
-TA2 pA CMV 
ETS1
DBD
-TA4 pA CMV 
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a significant average upregulation of 1.9 ±0.2 times compared to the control incubated with 
serum-reduced media only (Figure 26B). The two activator constructs were co-transfected 
together with the 8 times ETS binding site luciferase reporter construct in two different ratios 
of vectors (1:1 and 1:5). When the ETS luciferase reporter construct was transfected with the 
two activator constructs (ETS1DBD-TA4 and ETS1DBD-TA2) an increase in the activation of 
luciferase was observed: TA4 (1:1) 154 ±7.3; TA4 (1:5) 305 ±21; TA2 (1:1) 201 ±6.9; TA2 
(1:5) 353 ±30.1 (Figure 26A). The findings lead to the suggestion that TA4 was a weaker 
transcriptional activator domain, whereas TA2 was a stronger transcriptional activator domain, 
which has been described before (Baron et al., 1997). The above values translate into a fold-
activation of (Figure 26B): TA4 (1:1) 1.4 ±0.1, TA4 (1:5) 2.6 ±0.3, TA2 (1:1) 1.9 ±0.2 and TA2 
(1:5) 3.1 ±0.5. When different ratios (1:1 and 1:5) of the construct ETS1DBD-KRAB were co-
transfected and afterwards incubated with serum-reduced media, ethanol and erinacine C, a 
strong decrease in the activation of the reporter construct was visible (Figure 26A). Once the 
ETS reporter construct was co-transfected with the ETS1DBD-KRAB inhibitor construct using 
a ratio of 1:1, the luciferase activity in cells incubated with serum-reduced media was decreased 
down to 5 ±0.1, which was 20 times weaker than in the control cells, which expressed the 
luciferase reporter construct with 8xETS binding site only (Figure 26B). The activity of the co-
transfected cells being incubated with ethanol was 7 ±0.5 and for erinacine C incubated cells 
11 ±1.2. The results of the co-transfection with a high amount of ETS inhibitor construct 
demonstrated the same as for the lower value, which shows that the KRAB domain exhibits a 
strong transcriptional inhibition activity. These findings suggest that the binding site indeed 
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responds to ETS binding and transcriptional activation and erinacine C is not able to increase 
ETS signaling when the ETS dependent transcription is inactivated. 
 
Figure 26: Effect of constitutive ETS activator and inactivator expression on ETS luciferase reporter. A) The graph 
shows the quotient of the firefly luciferase activity, which was calculated to the standard quotient of ubiquitous expressed 
firefly luciferase activity to the renilla luciferase activity. Later on, the values were correlated to the background level of the 
luciferase activity elicited by UAS binding site reporter. The first three bars show 1321N1 astrocytoma cells transfected only 
with an 8 times repeat ETS binding site firefly luciferase reporter construct. These cells were incubated with control (serum-
reduced media), ethanol (0.5% ethanol) and erinacine C. An increase of the activity when these cells were incubated with 
erinacine C (5 µg/ml) is visible. The bars four and five show a co-transfection with the first activator construct (ETS1DBD-TA4) 
in two different ratios (1:1 binding site reporter to activator and 1:5). With the 1:5 ratio a significant upregulation of 2.5 times 
can be seen. The bars six and seven relate to a co-transfection with the second activator (ETS1DBD-TA2) in the same two ratios. 
A significant upregulation is visible for both ratios. The bars eight, nine and ten and the three bars afterwards demonstrate two 
values of the repressor of ETS both incubated with serum-reduced media (control), ethanol (0.5%) and erinacine C. A strong 
activity decrease is noticable. The second graph shows a x fold upregulation compared to the control, which are cells transfected 
with the 8xETS luciferase construct and incubated afterwards with serum-reduced media only. Incubation with erinacine C (5 
µg/ml) causes a significant upregulation as well as with the two activators constructs (as described before). With the ETS1DBD-
KRAB repressor the activity is decreased instead. (n = 4; ± SEM; One-way-Anova: * p ≤ 0.05; ** p ≤ 0.001; *** p ≤ 0.001; 
**** p ≤ 0.0001) 
The next step was the quantification of the upregulation of ETS signaling upon erinacine C 
incubation. First, the time-dependent upregulation of ETS-binding site mediated luciferase 
activity and this ETS-mediated transcriptional activation upon erinacine C exposure was 
analyzed (Figure 27). Consequently, 1321N1 astrocytoma cell were transfected with 8 times 
repeat of the ETS binding sites construct driving firefly luciferase expression. 48 h after the 
transfection the cells were incubated with 0.5% ethanol and erinacine C (5 µg/ml). The 
luciferase activity was measured after 3, 6, 10, 16 and 24h of erinacine exposure. There was no 
significant upregulation in the luciferase activity after 3h (1.5 ±0.2 times compared to the 
ethanol control), 6h (1.1 ±0.2), 10h (1.2 ±0.2) and 16h (1.4 ±0.4) of incubation with erinacine 
C but a trend forwards increasing luciferase activity was observed. Yet, after 24h of incubation 
with erinacine C the luciferase activity was significantly increased by 2.7 ±0.6 fold compared 
to the ethanol control. These results showed that erinacine C induced upregulation of ETS 
92 
 
mediated transcription was time-dependent and started after about 24h of incubation with the 
compound. 
 
Figure 27: Time-dependent activation of ETS-mediated transcription by erinacine C. The graph shows 1321N1 
astrocytoma cells, which were transfected with the 8 time repeat of ETS DNA binding sites driving firefly luciferase expression 
and incubated after transfection with either 0.5% ethanol or erinacine C (5 µg/ml). The bars display an x fold upregulation 
compared to the ethanol control (0.5%). (n = 4; ± SEM; One-way-Anova: * p ≤ 0.05; ** p ≤ 0.001; *** p ≤ 0.001; **** p ≤ 
0.0001) 
After analysis of the time-dependent upregulation of ETS-mediated firefly luciferase reporter 
expression, the concentration dependence of erinacine C induced ETS-mediated firefly 
luciferase transcription was analyzed (Figure 28). Hence, the 8 times repeat of ETS DNA 
binding site luciferase construct was transfected into 1321N1 astrocytoma cells, which were 
subsequently incubated either with ethanol or erinacine C in different concentrations (1 µg/ml 
– 15 µg/ml) (Figure 28A). At this timepoint it has to be mentioned that a new batch of purified 
erinacine C was used containing a higher amount of erinacine C, which was diluted in ethanol. 
The highest non-toxic concentration was measured again using a MTT-assay. The non-toxic 
concentration changed in its value up to 20 µg/ml. Possibly, cytotoxicity was reduced because 
of the increased purity of the compound. At this timepoint a higher amount of erinacine C was 
added on the cells (now up to 15 µg/ml). Therefore, it was shown that with increasing 
concentrations of erinacine C the ETS-mediated luciferase expression and thus the resulting 
luciferase activity was also increased compared to the ethanol control (1 µg/ml  1.2 ±0.2; 2 
µg/ml 1.3 ±0.3; 3 µg/ml 1.7 ±0.3; 4 µg/ml 1.9 ±0.3) up to a significant average upregulation of 
2.9 ±0.9 fold. Using concentration higher than 5µg/ml the luciferase activity decreased down 
to an average value of 0 (10 µg/ml 1.6 ±0.5; 15 µg/ml 0.005 ±0.001), probably caused by an 
adverse effect of erinacine C. To analyze if the concentration dependence was also responsive 























amount of ETS binding sites (2 – 8x) followed by a basal promotor driving firefly luciferase as 
reporter were transfected into 1321N1 astrocytoma cells. After the transfection the media was 
exchanged by media containing either 0.5% ethanol or erinacine C at two different 
concentrations 3 and 5 µg/ml respectively. With an increasing amount of ETS binding sites the 
luciferase activity of this enzyme increased indicating elevated expression levels of luciferase 
as shown in Figure 28B. Also, increasing concentrations of erinacine C, raised the activity of 
luciferase of constructs containing the same number of ETS binding sites in front of the 
luciferase. In detail, when a 2 times ETS binding site reporter plasmid was transfected the 
quotient of firefly to renilla luciferase activity was 1.2 ±0.2 for 3µg/ml and 1.6 ±0.2 for 5µg/ml. 
With the double amount of binding sites (4x) the luciferase activity increased further (3 µg/ml 
1.7 ±0.3; 5 µg/ml 2.1 ±0.2). With 6 and 8 repeats of the ETS consensus binding site the 
luciferase activity was increased even further (6 times: 3 µg/ml 2.1 ±0.2, 5 µg/ml 2.1 ±0.4; 8 
times: 3 µg/ml 2.6 ±0.1, 5 µg/ml 3.3 ±0.7). This allows one to conclude that with rising 
concentrations of erinacine C the ETS-mediated transcription was enhanced similarly to an 
increasing amount of ETS consensus binding sites. 
 
Figure 28: Concentration-dependent activation of ETS signaling by erinacine C. A) The graph shows the concentration 
dependence of the ETS mediated luciferase activity when increasing concentrations of erinacine C were added to 8x ETS 
reporter transfected astroglial cells, shown here as x fold upregulation compared to the ethanol control. The ethanol 
concentration in all experiments was 0.5%. With increasing concentrations of erinacine C the ETS-mediated expression 
increased as well. The highest activity was recognized with erinacine C concentrations of 5µg/ml leading to a significant 
upregulation of around 3-fold in expression and thus enzymatic activity of luciferase. B) The graph shows the dependence of 
luciferase expression in respect to increasing numbers of ETS DNA binding sites in the firefly luciferase reporter construct. In 
all experiments the same concentration of erinacine C (3 µg/ml and 5 µg/ml) was added. With an increasing amount of ETS 
DNA binding sites, the activity increased as well. (n = 4; ± SEM; One-way-Anova: * p ≤ 0.05; ** p ≤ 0.001; *** p ≤ 0.001; 
**** p ≤ 0.0001) 
It was shown that the ETS mediated luciferase activity increased upon erinacine C incubation 
suggesting that the upregulation of this reporter is indeed mediated by ETS transcription factor 
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binding and activation of expression. Using constitutive ETS activator and repressor variants it 
was possible to activate and inactivate ETS dependent luciferase activity. With increasing 
concentrations of erinacine C it was possible to increase the luciferase activity mediated by ETS 
signaling as well. This consistently argues for endogenous ETS mediated transcription 
activation of gene expression induced in astrocytoma cells by erinacine C. And with increasing 
numbers of ETS DNA binding sites the luciferase activity could also be increased. 
3.2.3 Analysis of the connection between neurotrophin upregulation and ETS signaling 
 
All findings shown until now, lead to the idea that ETS-mediated transcriptional activation and 
neurotrophin upregulation by erinacine C were connected. The two possibility was 
characterized now: The first possibility is that ETS transcriptional activation is connected to the 
shown ngf and bdnf induction of expression. The other possibility is that the activation of ets 
transcription is completely independent to the activation of the expression of the two 
neurotrophins. To quantify the potential connection between induced ETS signaling and ngf or 
bdnf upregulation upon erinacine C incubation, first the temporal relation between both 
processes were analyzed. 
Thus, time-dependent mRNA upregulation was examined by semiquantitative RT-PCR. 
Therefore, 1321N1 astrocytoma cells were incubated with serum-reduced media, ethanol or 
erinacine C and after 3, 6, 10, 16, 24, 32 and 48h the RNA of these cells was isolated to perform 
a RT-PCR for gapdh (as control), ngf and bdnf mRNA. The results for each time point and each 
treatment were correlated to the mRNA level of the housekeeping gene gapdh. The control, 
which were cells incubated with serum-reduced media for 48h, was set to 1. The amplified 
cDNA amounts were shown as x-fold upregulation compared to this control (Figure 29). The 
ngf mRNA level of cells being incubated with 0.5% ethanol as additive did not show a major 
difference compared to the control cells, being incubated with serum-reduced media (1.1 ±0.1). 
When the cells were incubated with erinacine C, the ngf mRNA levels were increased during 
the incubation periods (3h 1.9 ±0.1, 6h 2.5 ±0.2, 10h 2.3 ±0.3, 16h 2.3 ±0.3, 24h 3.2 ±0.5, 32h 
3.6 ±0.5, 48h 9.8 ±3.8), starting with a significant upregulation after 6h and the highest peak 
after 48h of erinacine C incubation. A significant upregulation of bdnf mRNA was observed 
only after 48h of erinacine C incubation with an increase of 5.8 ±2.5 fold compared to the 
control. At shorter incubation periods a trend towards bdnf mRNA upregulation was seen, yet 
it was statistically not significant until 48h of incubation times was reached (3h 1.1 ±0.005, 6h 
1.2 ±0.004, 10h 0.9 ±0.005, 16h 0.9 ±0.004, 24h 1 ±0.003, 32h 1.3 ±0.005). Changes in ets1 
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mRNA levels differed a bit from these results shown for ngf and bdnf mRNA. During the first 
6h there was an increase of ets1 mRNA starting at 3h (1.3 ±0.2) until a significant peak was 
visible after 6h of erinacine C incubation with a 7.1 ±1.6 times upregulation compared to the 
control. After this peak the ets1 mRNA level dropped down again (10h 2.7 ±0.5, 16h 1.6 ±0.3, 
24h 1.8 ±0.4), followed by a weaker increase starting at 32h with a 2.5 ±0.2 fold upregulation. 
The ets1 mRNA upregulation remained consistent until 48h (2.3 ±0.2). In summary the results, 
showed that ngf mRNA was significantly upregulated starting 6h after onset of incubation with 
erinacine C. The mRNA amount increased steadily until 48h of incubation. The first significant 
ngf mRNA upregulation was seen at the same time, when ets1 mRNA reached its highest 
elevation. The influence of erinacine C on bdnf mRNA production was not so drastic. The first 
significant upregulation of bdnf mRNA was visible after 48h of incubation. The highest rise in 
the ets1 mRNA production was seen already after 6h of erinacine C incubation. Afterwards, the 
ETS production decreased, but stayed significantly upregulated until 10h of incubation. In 
addition, a second smaller, but also significant upregulation in the ets1 mRNA expression 
occurred after 32h of erinacine C incubation and remained stable until 48h of incubation (Figure 
29). 
 
Figure 29: Time-dependent upregulation of ngf, bdnf and ets1 mRNA by erinacine C. 1321N1 astrocytoma cells were 
incubated with normal serum-reduced media, ethanol or erinacine C. After 3h, 6h, 10h, 16h, 24h, 32h and 48h incubation 
periods the mRNA was isolated, and the mRNA levels were quantified using semiquanitative RT-PCR. The graph shows the 
respective mRNA levels correlated to the gapdh (loading control) control. The amount for serum-reduced media incubated 
cells is set to 1 as reference. The dark bars represent the ngf mRNA levels. Control and ethanol show no difference. The first 
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significant increase of ngf mRNA levels are visible after 6h of erinacine C incubation with around 2.3 times upregulation. The 
ngf mRNA amounts increase until 48h when erinacine C mediated mRNA upregulation is significant increase of around 10 
fold is recognized. The bright bars show the bdnf mRNA levels. A significant increase is only visible after 48h of erinacine C 
incubation compared to the control. The bars to the right show the ets1 mRNA levels which display two peaks of increase. The 
first peak becomes visible at 6h of incubation until 10h, the second peak occurs at 32h until 48h. (n = 4; ± SEM; One-way-
Anova: * p ≤ 0.05; ** p ≤ 0.001; *** p ≤ 0.001; **** p ≤ 0.0001) 
In comparison, ets1 mRNA levels in 1321N1 cells rise before an upregulation of ngf and bdnf 
mRNA occurs in response to erinacine C exposure. To ask whether the activity of ETS signaling 
was sufficient for neurotrophin production, like NGF and BDNF, the already introduced 
constructs of constitutively active ETS signaling (ETS1DBD-TA4 and ETS1DBD-TA2) were used 
and transfected using electroporation in 1321N1 astrocytoma cells. Electroporation was used to 
obtain a high percentage of transfected astroglial cells up to 85%. After transfection, the media 
was changed to serum-reduced media and the cells were incubated for another 48h. After this 
incubation period the supernatant conditioned by the transfected astrocytoma cells was added 
to PC12 cells, to analyze the ability of this medium to induce PC12 cell differentiation. As 
control, PC12 cells were also incubated with serum-reduced media (negative control), and with 
200 ng/ml recombinant NGF (positive control). The PC12 cells were then incubated for 48h. 
The results are shown as brightfield pictures (Figure 30). The control picture shows PC12 cells 
in their normal round shape of undifferentiated cells. When NGF was added to these cells, the 
cells got protrusions showing initiation of differentiation. The PC12 cells, which were incubated 
with the conditioned media of astroglial cells transfected with the ETS activator constructs, 
ETS1DBD-TA4 and ETS1DBD-TA2, showed no sign of neurite outgrowth, suggesting that both 
constructs were not able to induce ngf transcription and thus NGF synthesis and secretion in 
astroglial cells and thereby were not able to induce PC12 cell differentiation. 
 
Figure 30: Effect of supernatant conditioned by 1321N1 cells transfected with elevated ETS transcriptional activators. 
The images show PC12 cell differentiation upon addition of conditioned media of ETS1DBD-TA4 and ETS1DBDTA2 transfected 
1321N1 astrocytoma cells. A) The first picture control cells represent PC12 cells incubated with normal serum-reduced media. 
B) PC12 cells incubated with the positive control of recombinant human NGF (200 ng/ml). Here, PC12 cells show the 
characteristic sign of differentiation (white arrow). C) and D) PC12 cells are incubated with conditioned media of 1321N1 
astrocytoma cells transfected with C) ETS1DBD-TA4 and D) ETS1DBDTA2 respectively. In both approaches no sign of 





Control (-) NGF 200ng/ml (+) ETS1DBD-TA4 ETS1DBD-TA2 
A B C D 
97 
 
To investigate whether ETS-mediated transcriptional activation is necessary for ngf and bdnf 
expression or if erinacine C activates ets1 transcription independently of inducing neurotrophin 
expression, different inhibitors for signaling cascades acting upstream of ETS were employed. 
1321N1 astrocytoma cells were incubated with serum-reduced media supplemented with either 
0.5% ethanol, erinacine C (5 µg/ml), or with erinacine C in addition to different inhibitors 
prohibiting MAPK signaling (PD98059) or Erk1/2 (U0126) signaling (Figure 31). These 
inhibitors were chosen because MAPK and Erk1/2 usually work upstream of the ETS 
transcription factor (Liu et al., 2018). After treatment for 48h, the RNA was isolated and 
semiquantitative RT-PCR for gapdh (as control), ngf and bdnf mRNA was performed. The 
value of amplified cDNA from 1321N1 astrocytoma cells that were incubated with 0.5% 
ethanol only was set to 1 as reference. The results are shown as x fold upregulation to the ethanol 
control. When the 1321N1 astrocytoma cells were incubated with erinacine C a significant 
upregulation of the ngf mRNA of 3.7 ±0.7 and bdnf mRNA of 1.5 ±0.2 was observed. When 
different inhibitors, for MAPK signaling (PD98059) and Erk1/2 signaling (U0126), were 
added, the amounts of ngf mRNA were weakly but not significantly decreased compared to 
erinacine C only treatment (+PD98059 3 ±0.4; +U0126 2.8 ±0.08; +PD98059+U0126 2.7 ±0.3). 
This is also true bdnf mRNA levels (+PD98059 1.6 ±0.6; +U0126 1.8 ±0.5; +PD98059+U0126 
1.5 ±0.5). In conclusion, erinacine C induced an upregulation of ngf and bdnf mRNA levels, as 
described before; and this increase was not affected whether by inhibiting MAPK nor Erk1/2 
activity. The same was observed when both inhibitors were applied together. This suggested 




Figure 31: Pharmacological inhibition of MAPK signaling and Erk1/2 signaling does not affect erinacine C mediated 
induction of ngf and bdnf transcription. 1321N1 astrocytoma cells were incubated with ethanol, erinacine C or erinacine C 
with different inhibitors in addition. After incubation for 48h semiquantitative RT-PCR was performed for ngf or bdnf mRNA 
and correlated to gapdh mRNA amounts as reference. The solvent control where cells were incubated with ethanol was set to 
1. Here the x times upregulation compared to the solvent control is shown. When incubated with erinacine C (5µg/ml in 0.5% 
ethanol) the average ngf mRNA was upregulated 3.5-fold and the average bdnf level was upregulated by 1.5 fold. When 
incubated with different inhibitors like PD98059 for MAPK and U0126 to impair Erk1/2 activity there was no significant 
difference to erinacine C only upregulation of neurotrophin transcription. (n = 4; ± SEM; One-way-Anova: * p ≤ 0.05; ** p ≤ 
0.001; *** p ≤ 0.001; **** p ≤ 0.0001) 
To further corroborate this finding, 1321N1 astrocytoma cells were transfected with the 
different activator and repressor constructs (ETS1DBD-TA4, ETS1DBD-TA2, ETS1DBD-KRAB 
and as control vector the plasmid pBluescriptII SK (pSK)) using electroporation. In comparison 
to the transfection method, which was used before, electroporation yielded a higher transfection 
efficiency of 80-85% cells, versus 20-25% of transfected cells obtained by lipofection.  After 
transfection, the media was exchanged to serum-reduced media for the ETS1DBD-TA4 and 
ETS1DBD-TA2 construct, and to serum-reduced media, ethanol or erinacine C for the control 
and the ETS1DBD-KRAB transfected cells. The cells were incubated for another 48h. After this 
period the RNA was isolated and semiquantitative RT-PCR for gapdh (as control), ngf and bdnf 
cDNA was performed. In Figure 32A, values for RNA isolated from ethanol treated cells was 
used as reference and were set to 1. The values are displays as x fold upregulation compared to 
the ethanol control. When cells were transfected with the vehicle (pSK) and afterwards treated 
with erinacine C the already described significant upregulation of ngf (2.8 ±0.5 fold compared 





visible. When the cells were transfected with the ETS1DBD-KRAB construct, the DNA 
downstream of ETS1 binding site are supposed to be methylated (Ma et al., 2014). The 
semiquantitative RT-PCR showed that the ngf (3 ±0.2 fold compared to the ethanol control) 
and bdnf mRNA levels (1.6 ±0.2 fold compared to the ethanol control) were not downregulated 
upon erinacine C incubation in the presence or absence of ETS1DBD-KRAB inhibitor. In Figure 
32B, RNA isolated from cells incubated with serum-reduced media was used in 
semiquantitative RT-PCR reactions as reference and set to 1. When the cells were transfected 
with a vehicle (pSK) and afterwards incubated with erinacine C, the cDNA levels for ngf (2.8 
±0.5 times) and bdnf (1.5 ±0.3 times) were upregulated compared to the control. Once, the cells 
were transfected with either one or both of the activator constructs (ETS1DBD-TA4 and 
ETS1DBD-TA2), there was no significant upregulation of ngf (TA4: 1.4 ±0.4 times; TA2: 1.5 
±0.5 times) or transcription of bdnf mRNA (TA4: 0.7 ±0.2 fold; TA2: 0.5 ±0.2 fold) compared 
to the control. Surprisingly, the bdnf mRNA level seemed to be slightly but not significantly 
downregulated. This led to the proposal that inhibition of ETS activity by using the ETS1DBD-
KRAB construct is not sufficient to decrease the neurotrophin expression upregulation upon 
erinacine C treatment, suggesting that ets1 transcription upregulation is not causing the 
upregulation of the neurotrophin expression. The results shown for the two activators support 
this idea was supported.  
 
Figure 32: Effect of constitutive ETS1 activation or inhibition in 1321N1 on ngf and bdnf transcription. 1321N1 
astrocytoma cells were transfected with a control plasmid or with the already introduced constructs for constitutive ETS1 
transcriptional activation or inhibition. The cells which were transfected with the control were incubated with serum-reduced 
media as control, ethanol or erinacine C. A) The first graph shows the x times upregulation of ngf or bdnf compared to the 
ethanol control whereas the second graph (B) shows the x times upregulation of these neurotrophin mRNAs compared to 
control cells, which were only incubated with serum-reduced media. An upregulation in the ngf and bdnf mRNA levels was 
observed upon incubation with erinacine C. When cells were incubated with the ETS1 inhibitor construct (A) no difference in 
the upregulation of ngf and bdnf mRNAs compared to the control transfected cells was obtained. B) After transfection with the 
different ETS signaling activator constructs (ETS1DBD-TA4 and ETS1DBD-TA2) the ngf and bdnf mRNA level were not 
significantly induced. (n = 4; ± SEM; One-way-Anova: * p ≤ 0.05; ** p ≤ 0.001; *** p ≤ 0.001; **** p ≤ 0.0001) 
100 
 
Summarizing the results shown in this chapter, it was shown that the mRNA levels, during 
erinacine C treatment in astroglial cells, of ngf mRNA were upregulated within 6h of incubation 
and reached their highest levels at 48h, whereas the bdnf mRNA was upregulated only after 48h 
erinacine C of treatment. When characterizing a possible dependence of neurotrophin 
transcription on ETS1 activity, the first mRNA peak of ets1 mRNA was significantly 
upregulated after 6h, suggesting that this upregulation had no connection to the first significant 
upregulation of ngf after 6h of erinacine C treatment. Since the mRNA has to be translated and 
folded until it is active. But it was that the ets1 upregulation is involved in the highest level of 
ngf mRNA upregulation after 48h of incubation. On the other hand, it is possible that the ets1 
upregulation was involved in bdnf mRNA transcription upregulation, since there was the 
highest level after 48h of erinacine C incubation. But it was suggested that ETS1 is not sufficient 
to induce neurotrophin transcription, since the transfected activators (ETS1DBD-TA4 and 
ETS1DBD-TA2) in 1321N1 cells, were not able to initiate PC12 cells differentiation as well as 
inducing transcription of the both neurotrophins. When ETS signaling was impaired by 
different pharmacological inhibitors of regulators of ETS1 activity the transcription of 
neurotrophins was induced by erinacine C could not be impaired, suggesting that ETS activity 
has no influence on the ngf transcription, but maybe a slight yet not significant influence on 
bdnf transcription. Furthermore, this led to the suggestion that ETS signaling is not necessary 
for ngf transcription, since ngf induction by erinacine C could not be inhibited by the 
constitutive ETS1 inhibitor ETS1DBD-KRAB construct. As ngf transcription could also not be 
increased by the different ETS1 activator constructs. ETS1 activity is also not sufficient to 
induce ngf transcription. Therefore, erinacine C induces ets1 as well as ngf and bdnf 
transcription independently from one another. 
3.3 Analysis of predicted NGF enhancer region 
 
Another approach, when answering the question about the effect of astrocytoma cells 
incubation with erinacine C and how the NGF production is upregulated was the analysis of the 
putative enhancer region of ngf. The potential enhancer region of ngf in humans or mouse is 
very complex, as the 5’ region contains a large intron. In contrast, the Tetraodon nigrovirdis 
coding region of ngf contains only a single exon, suggesting that regulatory elements of ngf are 
possibly located upstream of the coding sequence. The Tetraodon ngf region is 88% conserved 




Figure 33: Comparison of the 5’ region of humans, Fugu and Tetraodon. The 5’ region of the ngf genes are relatively 
conserved from human to Tetraodon, more than to the Fugu. 
About 2.1kb of genomic DNA directly upstream of the ngfß coding sequence from Tetraodon 
nigrovirdis were cloned into a reporter construct containing the open reading frame of firefly 
luciferase (Figure 34). Successive deletions at the 5’ end of this Tetraodon genomic DNA were 
generated to establish a series of related constructs. In addition, similar several deletions were 
generated at the 3’ end of this genomic DNA fragment. As these deletions likely destroyed the 
endogenous basal promotor of ngfß, the basal promotor E1b was inserted in front of the 
luciferase encoding cDNA fragment. 
 
Figure 34: Schematic drawing of serial deletion constructs of the potential ngfß enhancer sequence from Tetraodon 
nigrovirdis. The drawing shows different constructs for deleting potential regulatory elements in the 5’ region of ngfß from 
Tetraodon nigrovirdis. In green the 5’ genomic region is marked; the firefly region is depicted in yellow while the E1b basal 
promotors drown in blue. Constructs are not drawn to scale.  
To characterize, if the 5’ upstream region of the Tetraodon ngf coding sequence was erinacine 
C responsive and which region would mediate this response luciferase assays were performed. 
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First, the different reporter constructs were transfected into 1321N1 astrocytoma cells together 
with the reference vector expressing renilla luciferase. After transfection, cells were incubated 
with normal serum-reduced media, 0.5% ethanol, or erinacine C (5 µg/ml). After 24h of 
incubation the expression of the luciferase was quantified by analyzing the respective luciferase 
activity which is correlated to the induction of luciferase expression (Figure 35). The first graph 
shows the activity of the firefly luciferase divided by the reference of activated renilla luciferase 
to correct for different transfection efficiencies. Next, the obtained luciferase activity from an 
unrelated Gal4-dependent luciferase reporter were deducted to subtract background activity 
from the ngf reporter value. Finally, the values of the different ngf reporter constructs were 
compared. 
The 2.1 kb genomic fragment induced luciferase expression was activated in an erinacine C 
dependent manner by about 1.7 ±0.2 fold (serum-reduced media 0.71 ±0.05; 0.5% ethanol 0.75 
±0.04; erinacine C 1.31 ±0.2). Upon removal of the first 5’ 500bp, the genomic fragment (1.5-
0kb) lost its activity to levels of the control, which was drastically reduced (serum-reduced 
media 0.42 ±0.02; ethanol 0.37 ± 0.2; erinacine C 0.49 ±0.02). When another 500bp of genomic 
DNA was removed (1-0kb) activity raised again upon erinacine C treatment to 1.6 ±0.2 fold 
(serum-reduced media 1.1 ±0.2; ethanol 1 ±0.1; erinacine C 1.7 ±0.3). Further reducing the 
elements from the 5’ end down to 500bp no increase upon erinacine C stimulation was observed 
(serum-reduced media 0.7 ±0.05; ethanol 0.65 ±0.04; erinacine C 0.75 ±0.06).  
Next, the reporters were analyzed in which the ngfß genomic fragment was stepwise deleted 
from its 3’ ends. When 500bp were removed from the 3’ end, the region 2-0.5kb was activated 
by erinacine C yet to non-significant values (serum-reduced media 0.48 ±0.08; ethanol 0.5 
±0.09; erinacine C 0.63 ±0.1). Similar results were obtained when the 1000bp were removed 
(serum-reduced media 0.64 ±0.11; ethanol 0.68 ±0.12; erinacine C 1.1 ±0.15). When only the 
fragment 2-1.5kb was used in the reporter construct, the luciferase activity did not at all respond 
to erinacine C (serum-reduced media 0.2 ±0.001; ethanol 0.18 ±0.001; erinacine C 0.1 ±0.001). 
No response to erinacine C was obtained, suggesting that this genomic part does not contain an 
activator region. This hints of the 1.0kb-500bp fragment to contain an erinacine C responsive 
element. The second graph displays the respective luciferase activity as fold upregulation 
compared to the cells being incubated with 0.5% ethanol control (ethanol was set to 1). The 
highest and significant upregulation was visible for the 2.1-0kb (1.7 ±0.2 fold). Compared to 
the respective ethanol control the next upregulation was 1.5-0kb (1.6 ±0.2 fold), but as shown 
before, the activity was drastically lower. The next significant upregulation was 1-0kb (1.7 ±0.2 
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fold). This was followed by a lack of activation from the 0.5-0kb fragment (1.2 ±0.1 fold), 2-
0.5kb (1.5 ±0.4 fold) and 2-1kb (1.4 ±0.3 fold). The last tested fragment 2-1.5kb showed no 
upregulated activity at all (0.6 ±0.3). This suggest that the both regions 2.0-1.5kb and 1.0-0.5kb 
contained no elements responsive to erinacine C treatment, while the 1.5-1.0kb fragment 
harbors a repressive element. Alternatively, the 2.1-1.5kb region contains a repressive function 
of the 1.5-1.0kb repressor. Apart from that, the constructs containing not the endogenous ngfß 
promotor region, but instead the basal E1b promotor, seemed to be weaker than the constructs, 
which did not lack the endogenous promotor, suggesting that the endogenous promotor was 
stronger than the basal E1b promotor. This would lead to a drastically weaker induction of the 
firefly luciferase expression and activity. 
 
Figure 35: erinacine C induced luciferase activity of reporter constructs containing genomic DNA of different length 5’ 
to Tetraodon ngfß. The first graph shows the activity of the firefly luciferase divided by renilla luciferase activity and connected 
for to background expression constructs with Gal4 level. Seven different genomic DNA fragments of the 5’ region of the 
Tetraodon ngf gene driving firefly luciferase were transfected into 1321N1 astrocytoma cells and incubated with normal serum-
reduced media (control, white bars), supplemented with ethanol (EtOH, gray bars) or erinacine C (black bars). The two 
fragments 1.5 – 0kb and 2 – 1.5kb showed the lowest luciferase activity. Only the 2.1 – 0kb and the 1 – 0kb fragments were 
able to be significantly stimulated by erinacine C. The second graph shows the x fold upregulation compared to the ethanol 
control. Only two fragments were able to be significantly stimulated by erinacine C. These are the 2.1-0kb and 1.0-0kb 
fragments. The fragments 0.5 – 0kb and 2 – 1.5kb did not mediate an upregulation of the reporter activity when erinacine C is 
added compared to the ethanol control. (n = 4; ± SEM; One-way-Anova: * p ≤ 0.05; ** p ≤ 0.001; *** p ≤ 0.001; **** p ≤ 
0.0001) 
In order to determine whether ETS signaling has an influence on the activity of the Tetraodon 
sequence 2.1 kb large fragment of the Tetraodon ngf 5’ upstream region, the respective reporter 
construct was co-transfected with the different already introduced constructs for constitutive 
ETS activation (ETS1DBD-TA4 and ETS1DBD-TA2) as well as repression (ETS1DBD-KRAB) in 
1321N1 astrocytoma cells (Figure 36). After transfection, the media was exchanged for the 
2.1kb fragment transfection and for the co-transfection with the ETS repressor construct 




































































































































































































































For the ETS activator constructs (ETS1DBD-TA4 and ETS1DBD-TA2) the media was exchanged 
to serum-reduced media. After incubation for 24h the luciferase expression was measured by 
analyzing the luciferase activity. In this assay the ratio of firefly luciferase construct to the 
activator/repressor constructs was chosen as 1:1, because the activity for the putative ngf 
regulatory region was very low. In Figure 36A the results are shown as the quotient of firefly 
luciferase activity to the renilla luciferase and as reference level. The results were corrected for 
background level activity with the luciferase activity of Gal4 mediated luciferase activity 
(which was set as the background with transfecting the 4xUAS binding site). When the 2.1kb 
fragment alone was transfected and incubated afterwards with serum-reduced media 
supplemented with ethanol or erinacine C, a significant upregulation at the activity was visible, 
as shown before (serum-reduced media 1.1 ±0.1; ethanol 1.2 ±0.1; erinacine C 1.8 ±0.25). Once, 
the activators of ETS were transfected together with the 2.1kb fragment of the putative ngf 
regulatory element and treated with only serum-reduced media after that, the luciferase activity 
was also upregulated, but weakly and only significantly for the ETS1DBD-TA2 construct, which 
is the stronger transcriptional activator (TA4 1.5 ±0.4; TA2 1.6 ±0.3). Using instead the ETS 
repressor construct (ETS1DBD-KRAB), the activity of the putative 2.1kb ngf regulatory 
fragment was significantly decreased compared to the control, but an upregulation caused by 
erinacine C was still visible (serum-reduced media 0.5 ±0.1; ethanol 0.5 ±0.1; erinacine C 0.9 
±0.2). Figure 36B shows the representation of luciferase activities displays as x fold 
upregulation compared to the control, which was only transfected with the 2.1kb fragment and 
incubated with serum-reduced media. When incubated with erinacine C only a significant 
upregulation by 1.7 ±0.2 fold was visible. When the 2.1kb fragment was co-transfected with 
the activator TA4 the activity was also upregulated (1.4 ±0.2 fold), but not significantly, like it 
was seen for TA2 (1.6 ±0.2 fold). When the signaling activity of ETS was inhibited, the activity 
of the 2.1kb fragment was also downregulated (1 ±0.1 fold). This led to the suggestion that ETS 
activity is involved in the erinacine C dependent upregulation of the 2.1kb fragment, but it was 
seen that this was not alone involved in the upregulation, since there was an erinacine C 





Figure 36: Effect of the different ETS constructs on the predicted enhancer region. 1321N1 astrocytoma cells were 
transfected with the 2.1 kb NGF enhancer fragment together with the different ETS inducing constructs. When the fragment is 
transfected alone and afterwards incubated with serum-reduced media as control, ethanol and erinacine C, the activity of the 
luciferase is significantly increased with erinacine C. When the fragment is cotransfected with the different ETS inducing 
constructs TA4 and TA2 the signaling is induced but only significant with the stronger TA2 construct. When cotransfected 
with the methylation inducing KRAB construct and afterwards incubation with the different additives the signaling at all is 
significantly increased but compared to the control after KRAB transfection the erinacine C incubation cause also significantly 
increase in the activation.  
These results showed that the predicted ngf regulatory region was able to respond to erinacine 
C incubation. The last 500bp did not appear to contribute to this response, suggesting that these 
parts were not responsible for erinacine C dependent NGF regulation. The last experiment 
showed also that the NGF regulation seem to be ETS mediated, but not alone.  
3.4 Effect of erinacine C and other substances isolated from Hericium sp. in vivo 
 
So far, the effect of erinacine C was only shown in vitro, where the effect was characterized in 
cells within a single culture of cell line. But in an organism, cells are normally surrounded by 
several cell types. In addition, organs are often protected by barriers, like the blood-brain barrier 
(BBB), where the central nervous system is separated from the blood flow. Therefore, it remains 
questionable, whether pharmacological substances are able to reach a certain cell type of choice. 
Therefore, the possibility of erinacine C to reach the vertebrate brain should be investigated. 
3.4.1 Is erinacine C able to cross the blood-brain barrier? 
 
When thinking about using erinacine C as medication, the compound should be able to cross 
the blood-brain barrier (BBB). To analyze the ability of erinacine C to cross the BBB, an already 
established assay was used, were the BBB was mimic as a co-culture of the cell types involved 
in BBB formation. The BBB consists of three different cell types: the astrocytes, pericytes and 
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endothelial cells (Daneman and Prat, 2015). Such three cell types were isolated by Verena 
Ledwig, a member of the Institute of pharmaceutical technology (Technical University 
Braunschweig), from pig primary cell culture and cultivated to obtain purified single cell types. 
With specific markers, the purity of each cell type was validated (Figure 37). Endothelial cells 
were identified by the expression of the Van-Willebrand-factor that was detected by 
immunohistochemistry. The von Willebrand factor (vWF) is a glycoprotein, which is a useful 
marker for endothelial cells. This protein performs as both an antihemophilic factor carrier and 
a platelet-vessel wall mediator in the blood coagulation system (Ginsburg et al., 1985). In 
endothelial cells that produce vWF, the factor is stored in the so-called Weibel-Palade bodies 
(Berriman et al., 2009). Pericytes was identified using an antibody against alpha-smooth muscle 
Actin. Actins are a family of globular multi-functional proteins that form microfilaments. It was 
shown that smooth muscle alpha-actin mRNA and smooth muscle alpha-actin contractile 
protein elements were present within the renal medullary pericytes (Park et al., 1997). 
Astrocytes were identified by their expression of Glial Fibrillary Acidic Protein (GFAP). This 
protein represents the main component of the intermediate filaments in the cytoplasm of glial 
cells and especially in astrocytes in the central nervous system (Zhang et al., 2017). The three 
different cell types, endothelial cells, pericytes and astrocytes, were cocultivated in a specific 
chamber, schematic shown in the drawing (Figure 37). These culture conditions allowed the 




Figure 37: Structure of the Experiment performed by Verena Ledwig. The blood-brain barrier consists of three different 
cell types: astrocytes (A), endothelial cells (E), and pericytes (P). The cells were isolated from pig primary cell culture and 
purified to obtain individual cell types. The picture for a pure single cell type is shown in the upper row and their 
characterization by immunohistochemistry displays expression of different markers in the lower row. The nuclei war counter 
stained using DAPI. The first picture for the endothelial cells displays expression of the van-Willebrand-Factor specifically 
identify endothelial cells. The picture for pericytes reveals immunofluorescence staining of the alpha-smooth muscle actin 
antibody to specifically validate immunohistochemical pericytes. And the picture for astrocytes shows a staining against GFAP 
marking specifically glial fibrillary acidic protein in the astrocytes. The lower row depicts the cocultivation of these three cell 
types on a costumer-made chamber. By that, a strong barrier can be established by the cells shown in the diagram on the lower 
right site. The graph shows the TEER value in Ω per cm2. Only a cocultivation of E (endothelial cells), P (pericytes) and A 
(astrocytes) can establish a strong barrier of high TEER values, nearly comparable to the natural blood-brain barrier (normally 
around 1200 Ωxcm2. (Experiments, pictures, and graphs performed by Verena Ledwig) 
Using erinacine C in the brain barrier like co-cultivation method, established by Verena 
Ledwig, the penetration of erinacine C through this barrier was analyzed (Figure 38). The time 
course of permeabilization was characterized by an analysis of erinacine C (10 µg/ml) paasing 
through a mono-culture of endothelial cells (left graph, dark line Figure 38) compared to the 
passage through a triple-cell culture (left graph, bright line, Figure 38). There was no difference 
visible in the time course of metabolite penetration. When the time course of barrier penetration 
for erinacine C was compared between a mono-culture of endothelial cells (without strong 
barrier) only and the triple-culture of endothelial cells, astrocytic cells and pericytes building 
the strong barrier no differences was observed (Figure 38). This suggests that erinacine C was 
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able to pass through different cell barrier and by that should be able to also cross the blood-
brain barrier. 
 
Figure 38: Course of Permeabilization of erinacine C performed by Verena Ledwig and Dr. Kathrin Wittstein. To 
establish a strong blood-brain barrier like structure astrocytes, pericytes and endothelial cells isolated from pig primary cell 
culture are cocultivated and erinacine C is added to the donor site. The amount of erinacine C is measured using HPLC after a 
permeabilization time starting at 30 min of incubation until 270 min of incubation. The amount of erinacine C increases over 
time in the component across the endothelial cell monoculture (dark gray) or in the coculture (bright gray). There is no 
difference in the amount of erinacine C in the monoculture in comparison to the cocultivation visible. With the incubation time 
and the amount of erinacine C, the coefficient of the permeabilization can be quantified as shown in the second graph. Also 
here it is visible that there is no difference for the cocultivation compared to the monoculture. (Experiment was performed by 
Verena Ledwig, quantification with HPLC performed by Dr. Kathrin Wittstein, n = 2) 
In cells, the efflux transporter is important to transport ions and other molecules from the inside 
of a cell to the outer extracellularly space. For medications, it is important to clarify, if 
substances are recognized by these transporters. erinacine C was able to cross the blood-brain 
barrier. But in case it was recognized by an efflux transporter its amount would decline again. 
Therefore, the apical to the basolateral (A>B) transport through the in vitro BBB was analyzed 
as defined before and this was compared to the basolateral to apical (B>A) transport with and 
without an inhibitor for the P-gp efflux transporter (Figure 39). P-glycoprotein (P-gp) is a 
primarily active efflux transporter that transports its substrates from the cell membrane into the 
extracellular space. It is expressed in the intestine, liver, blood-brain barrier, placenta, and 
kidney, among others, and acts as a transport barrier against foreign substances. On the one 
hand, P-gp inhibits the absorption of these substances in the organism and sensitive organs and 
on the other hand it promotes their excretion. The substrates include numerous active 
pharmaceutical compounds, the pharmacokinetics of which are determined by P-glycoprotein. 
P-gp inhibitors can increase the bioavailability and the distribution of the active substances 
inside the target tissue. Conversely, inductors increase the barrier function of the transporter 
and promote the elimination of the medication. As explained before the permeabilization 
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coefficient for erinacine C was quantified. The graph showed that there was no difference in 
the directional transport coefficient when comparing the apical to basolateral to the basolateral 
to apical transport of erinacine C in the presence or absence of the P-gp inhibitor suggesting 
that erinacine C is not a target of the P-gp efflux transporter. This suggests that erinacine C 
once it has crossed the blood-brain barrier will not be returned to the blood vessels in the brain. 
 
Figure 39: Coefficient of Permeabilization with and without an inhibitor of the efflux transporter performed by Verena 
Ledwig. The efflux transporter is a transport protein which can transport chemicals from the inside of the brain to the outside 
and into the blood system. The first bar shows the coefficient when measured the erinacine C amount which passed from the 
apical to basolateral side of the epithelial barrier, as described before. The second bar is the amount of erinacine C that passed 
from the basolateral to the apical side of the epithelium in the absence of verapamil (which is an inhibitor for a P-gp efflux 
transporter). The third bar shows the coefficient for the amount of erinacine C which had passed from the basolateral to the 
apical side of the epithelium in the presence of verapamil. No difference between these conditions is visible indicating that 
erinacine C is not a target of the P-gp efflux transport system. (Experiment was performed by Verena Ledwig, quantification 
with HPLC was performed by Dr. Kathrin Wittstein, n = 1) 
With the in vitro model it can be seen that erinacine C should be able to cross the BBB. But these data 
still have to award their validation in vivo. Therefore, the zebrafish was used as a model system, being 
a small vertebrate model with a functional BBB and an endothelial cell-based vasculature (Eliceiri et 
al., 2011). The BBB is established in zebrafish larvae between 4dpf and 10dpf (Eliceiri et al., 2011). To 
characterize the ability of erinacine C to cross the BBB, 4dpf old larvae were incubated with 5µg/ml 
erinacine C for 48h in normal zebrafish media. After this incubation time, 50 heads and 50 brains were 
isolated. Using HPLC (performed by Dr. Kathrin Wittstein and Dr. Zeljka Rupcic) the amount of 
erinacine C was measured and quantified with the help of the erinacine C specific retention time. Figure 
40 shows the chromatogram of the suspensions obtained from isolated heads and brains. The yellow box 
marks the erinacine C specific peak. Erinacine C was clearly visible in the suspension obtained from the 
head after an incubation period for 48h, as well as in the isolated brains. Of note these suspensions also 





Figure 40: HPLC chromatogram of a suspension of an erinacine C treated zebrafish larvae brain. 4dpf old larvae were 
incubated with erinacine C (5µg/ml) for 48h. After the incubation time, 50 heads and 50 brains are isolated, suspended and 
measured for the content of erinacine C using HPLC. The peak of erinacine C is visible in both samples (yellow bar). 
Since the BBB is established between 4dpf and 10dpf in the zebrafish, different developmental 
stages during the formation of the BBB were chosen. To quantify the ability of erinacine C to 
pass the BBB, zebrafish larvae were incubated with erinacine C (5µg/ml) at different ages 
(Figure 41). The incubation with erinacine C was started at 4dpf, 7dpf, and 10dpf, for periods 
of 24h, 48h, and 72h. After this incubation, 50 brains of each time point and treatment were 
isolated. The selected brains were taken up in methanol and extracted in an ultrasonic bath. 
After evaporation of the supernatant, the residues were dissolved in methanol. The amount of 
erinacine C was measured by HPLC by Dr. Kathrin Wittstein (Helmholtz Centre for Infection 
Research). The peak area occurring at the retention time of erinacine C was quantified and 
correlated to a calibration line. With a progressing time of incubation of the zebrafish, the 
amount of erinacine C increased over time in the extracts (4dpf: 24h 11.9 ±4 area units, 48h 
30.4 ±9 area units, 72h 105.4 ±36.5 area units; 7dpf: 24h 39.1 ±21.3 area units, 48h 63.3 ±30.2 
area units, 72h 196.8 ±87.4 area units; 10dpf: 24h 8.6 ±4 area units, 48h 18.6 ±6 area units, 72h 
51.6 ±19.1 area units). These data revealed that initially from 4dpf to 7dpf the uptake of 
erinacine C in the brain increased. Yet, with a mature BBB at 10dpf the amount of erinacine C 
taken up by the brain was reduced again. Nevertheless, with increasing incubation time, the 
amount of erinacine C in the brain accumulated constantly at all ages. Of note, the values for 
this experiment vary, since during the experiment some of the larvae died and thus, a high 
standard derivation was visible. The amount of erinacine C was calculated to the amount per 
brain and here the increase over time and the differences for the different starting points were 
equivalent (4dpf: 24h 4.5 ±0.4 ng per brain, 48h 37.9 ±20.7 ng, 72h 229 ±146.1 ng; 7dpf: 24h 
15.3 ±6.1 ng, 48h 41.4 ±13.9 ng, 72h 284 ±134.9 ng; 10dpf: 24h 3.6 ±1 ng, 48h 42.3 ±25.5 ng, 
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72h 155.3 ±57.9 ng). With the increasing incubation time, the amount of erinacine C, deduced 
from the peak area and also the amount of erinacine C per brain in all three stages of 
development (4 dpf, 7 dpf, 10 dpf). The variance during the experiments was relatively high 
due to the variation in egg quality and their maintenance. Nevertheless, at all developmental 
time points erinacine C could be detected in the head and brain of the specimens, showing that 
erinacine C was able to enter into the brain of a zebrafish. 
 
Figure 41: Ability of erinacine C to enter the zebrafish brain. Zebrafish from different stages (4dpf, 7dpf, 10dpf) were 
incubated with erinacine C (5µg/ml) for 24h, 48h, and 72h. After the incubation time, the larvae were washed with 10% 
methanol in fish water and the brains were isolated. The washing supernatant was not free from erinacine C and contained a 
small amount of erinacine C yet smaller than the measured sample. The samples were measured by HPLC (performed by Dr. 
Kathrin Wittstein, Helmholtz Centre for Infection Research). The peak area or the amount of erinacine C per brain can be 
analyzed. This data revealed that with progressing time an increasing amount of erinacine C is taken up by the fish. At all 
stages, erinacine C can be detected. 
These findings show that erinacine C was detected in vitro after penetrating through the blood-brain 
barrier model or in vivo after diffusion into the zebrafish brain, suggesting that erinacine C is able to 
cross the blood-brain barrier. 
3.4.2 Effect of substances isolated from Hericium sp. in vivo 
 
Secondary metabolites were isolated from an edible mushroom. This leads to the suggestion, 
that all isolated substances should not have a toxic effect. But keeping high concentration can 
cause multiple side effects. Thinking about the effects in vitro, this leads to the conclusion, that 
starting at a specific concentration, these metabolites can cause toxic effects in cells. 
Since the zebrafish is a suitable model system, for analyzing side effects in vivo, the zebrafish 
was used to analyze these side effects. To highlight one metabolite, which was used regarding 






























































with forceps and incubated for 48h with corallocin A (15µg/ml). This incubation caused 
aggregation of blood in the head, especially in the hindbrain region. This leads to the suggestion, 
that corallocin A is able to destroy the blood vessels and leads to an aggregation of blood in the 
head. 
 
Figure 42: Effect of corallocin A in vivo. 24 hpf old zebrafish embryos are incubated with corallocin A (15µg/ml). After 48h 
of incubation, a red color in the brain is visible in the hindbrain. (n = 2) 
It was shown, that corallocin A is able to cause accumulation of blood in the head, especially in the hind 
brain region, since there is a ventricle, making space to accumulate blood.  
3.5 Establishment of different assays to analyze the effect of erinacine C and other 
substances isolated from Hericium spp. in vivo. 
 
Erinacine C has been identified as an NGF inducing secondary metabolite from the fungus Hericium 
erinaceus. Moreover, this substance was shown to be able to pass the blood-brain barrier and could thus 
likely induce NGF expression in the brain. To identify cell populations that may be affected by an 
increased presence of this neurotrophin, the expression of its high affinity receptor TrkA needs to be 
analyzed. Thus, mRNA in situ hybridization an adult brain section against the expression of the ligand 
ngf and its cognate receptor trkA was performed. 
3.5.1 Analysis of expression of NGF and its high-affinity receptor TrkA. 
 
To analyze the expression pattern for ngf and bdnf mRNA adult zebrafish brains were isolated 
and cut by a vibratome in 50µm thick sagittal sections. Using these sections fluorescent in situ 
hybridization for ngf and bdnf was performed and analyzed using a laser scanning microscope. 
Figure 43 shows the expression pattern of ngf mRNA costained with DAPI to mark the nucleus 
of individual cells. There was a widespread expression of ngf noticeable. Expression was 
observable in the forebrain, in the medial zone of the diencephalon (Dm) and the diencephalon 
(D) itself, as well as in the midbrain, in the optic tectum (TeO), the periventricular gray zone 
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(PGZ), the central and dorsal posterior thalamic nucleus (CP/DP), periventricular nucleus of 
posterior tuberculum (TPp) and intermediate reticular formation (IMRF), and also in the 
hindbrain, especially in the valvula of Cerebelli (Val), medial division of valvula cerebelli 







Figure 43: Expression pattern of ngf in the adult zebrafish brain. The pictures show the expression pattern of ngf mRNA. 
To mark specifically ngf mRNA in situ hybridization for ngf was performed (green fluorescence; picture A, B, C). In blue the 
nuclei are marked by flouresent DAPI staining (picture A, B, D). A schematic drawing of the adult zebrafish brain in sagittal 
view is shown in gray (taken from Wullimann et al., 1996). A higher magnification of the cerebellum is shown in picture B. 
Expression is visible in: medial zone of diencephalon (Dm), diencephalon (D), optic tectum (TeO), periventricular gray zone 
(PGZ), central and dorsal posterior thalamic nucleus (CP/DP), periventricular nucleus of posterior tuberculum (TPp), 
intermediate reticular formation (IMRF), valvula of Cerebelli (Val), medial division of valvula cerebelli (Vam), corpus cerebelli 
(CCe), crista cerebellaris (CC). 
The cerebellum is an important part of the central nervous system. The structure of the 
cerebellum is highly conserved through evolution, the mammalian and teleost cerebelli show 
the same cell types, containing three different layers: the molecular layer, the Purkinje cell 
layer, and the granular cell layer (Hibi and Shimizu, 2012). In the granular cell layer, mossy 
fiber afferents arrive and contact granule cells and Golgi cells. Below the granular layer is the 
white matter, formed by the input and output nerve-fiber systems of this cortex (Lackey et al., 
2018). The Purkinje cell layer is a simple cell layer, containing the Purkinje cell somata as well 
as Bergmann glia. This layer is positioned above the granule cell layer. The level peripheral to 
the Purkinje cell layer, containing the molecular layer interneurons (baskets and stellate cells), 
Purkinje cell dendritic arbors and parallel fibers and the axons of the granule cells (Bae et al., 
2009). The cerebellum performs important tasks in controlling motor skills: It is responsible for 
coordination, fine-tuning, unconscious planning and learning of movement sequences (Manto 
et al., 2012). It has also recently been assigned a role in numerous higher cognitive processes. 
If the cerebellum is damaged or dysfunctions, several characteristic symptoms can occur 
depending on the location and extent of the affected area. The common term for most cerebellar 
symptoms is ataxia (Walter et al., 2006). Ataxia is the failure of proper motor coordination. 
This is the most common symptom in case the function of the cerebellum is impaired. In this 
thesis, the cerebellum was the main brain compartment in focus, because of its high 
evolutionary conservation. To analyze the expression of ngf in the cerebellum, an adult 
zebrafish brain was cut in sagittal sections and these were costained in addition to the in situ 
hybridization against ngf with an antibody against ZebrinII (Aldolase C) to mark specifically 
Purkinje cells (Figure 44). Purkinje cells are the characteristic large multipolar nerve cells with 
a highly branched dendrite tree in the cerebellar cortex, the axons of which represent the efferent 
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of the cerebellar cortex. Green fluorescence of ngf mRNA was visible in the granular cell layer 
of the cerebellum, but also in Purkinje cells (Figure 44, white arrow). 
 
Figure 44: Expression pattern of ngf in the adult zebrafish cerebellum. The pictures show the expression pattern of ngf in 
the adult zebrafish cerebellum detected by fluorescent mRNA in situ hybridization (A, C, E) costained with an antibody against 
ZebrinII (red fluorescence; A, D, E) marking Aldolase C in Purkinje cells. To mark specifically ngf mRNA in situ hybridization 
against ngf was performed (green fluorescence; A, C, E). The pictures C, D and E show a higher magnification of the box in 
the left picture (A). The white arrow points out a double fluorescent Purkinje cell. The lower picture (B) shows a drawing of 
the adult zebrafish brain in sagittal view (taken from Wullimann et al., 1996). 
Since ngf mRNA was widely expressed in the brain as shown before, the expression of the high-
affinity receptor TrkA, to characterize the NGF responding cells, needed to be analyzed. 
Therefore, the in situ hybridization against trkA was performed in the adult zebrafish brain 
(Figure 45). The expression pattern of trkA was widespread like shown for ngf through the adult 
zebrafish brain. Expression was visible in the forebrain regions like the medial zone of the 
diencephalon (Dm) and the diencephalon (D), but also in midbrain regions, like in the optic 
tectum (TeO) and in the periventricular gray zone (PGZ) and in the caudal zone of 
periventricular hypothalamus (HC). The expression of trkA was also found in hindbrain regions, 
like the valvula of the cerebellum (Val) and the medial division of the valvula cerebelli (Vam), 
and the corpus cerebelli (Cce) and the crista cerebellaris (CC). Flourescence of the trkA in situ 






Figure 45:Expression pattern of trkA mRNA in the adult zebrafish brain. The pictures A, C, D and E show the expression 
pattern of trkA mRNA. To mark specifically trkA mRNA, in situ hybridization against trkA mRNA was performed (green 
fluorescence; A, C, D). In blue the nuclei were marked by DAPI staining (A, C, E). The lower picture (B) shows a drawing of 
the adult zebrafish brain in sagittal (taken from Wullimann et al., 1996). Expression of trkA mRNA is visible in: ventral nucleus 
of the ventral telencephalic area (Vv), medial zone of diencephalon (Dm), diencephalon (D), optic tectum (TeO), periventricular 
gray zone (PGZ), caudal zone of periventricular hypothalamus (HC), valvular of cerebellum (Val), medial division of valvula 
cerebelli (Vam), corpus cerebelli (Cce), crista cerebellaris (CC), rhombencephalus (Rh). 
The expression pattern in the cerebellum was characterized in more detail by using the anti-
ZebrinII antibody to detect Purkinje cells (Figure 46). Surprisingly, apart from the expression 
of trkA in the granular cell layer, trkA was expressed not in all Purkinje cells. It seemed that 
there are two different populations of Purkinje cells: one expressing trkA and one not expressing 
trkA.  
 
Figure 46: Expression pattern of trkA mRNA in the adult zebrafish cerebellum. The pictures A, C, D and E show the 
expression pattern of trkA mRNA (green flourscence; A, C, E) in the adult zebrafish cerebellum costained with an antibody 
against ZebrinII (red fluorescence; A, D, E) marking Aldolase C in Purkinje cells. To mark specifically trkA mRNA, in situ 
hybridization against trkA was performed (green fluorescence; A, C, E). The right pictures (C, D, E) show a higher 
magnification of the boxed area in the left picture. The white arrow marks a double fluorescent Purkinje cell whereas the blue 
arrow marks a Purkinje cell without trkA expression. The lower picture (B) shows a drawing of the adult zebrafish brain in 
sagittal view (taken from Wullimann et al., 1996). 
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Expression of ngf and trkA were 
widespread in the adult 
zebrafish brain. It can be 
suggested that expression of ngf 
and trkA were visible in 
neurogenic regions, like it was 
also shown by Kaslin et al. 
(2008; Figure 47). In this 
publication it was shown that neurogenic regions are found in the telencephalon, optic tectum, 
cerebellum and hypothalamus. In this thesis it can be suggested, when analyzing the whole 
brain using in situ hybridization, that ngf and trkA mRNA were also expressed in these regions. 
However, this should be investigated in the future using specific proliferation markers. 
3.5.2 Characterization of a transgenic trkA:mClover zebrafish line. 
 
The cells, which are able to respond to NGF secretion by expressing the high affinity receptor 
trkA were analyzed before. However, it would be suitable, to have a stable transgenic reporter 
fish line, to characterize trkA expressing cells over time and to also characterize their possible 
reaction on erinacine C treatment. Therefore, a stable line expressing a reporter gene in all trkA 
expressing cells should be established. Since the zebrafish is an organism suitable for screening 
approaches, because the zebrafish has a small size and develops completely outside of the 
mother, it is a water living organism, so substances, which need to be analyzed, can be diluted 
directly into the surrounding water. First of all, an enhancer fragment driving expression in 
trkA-expressing cells would be useful, and such a regulatory element has been described 
previously by Palanca et al. (2013).  
A transgenic zebrafish line was introduced by me previously, expressing the fluorescent protein 
mClover under control of this trkA regulatory element. This fish line was analyzed in this thesis 
in more detail (Figure 48). First expression of mClover was visible after 24h in sensory neurons, 
such as the lateral line nerve, the motoneurons (Figure 48 D) and the trigeminal neurons (Figure 
48 C). After 48 to 72h expression started in the central nervous system; in the optic tectum, the 
rhombencephalon, and in the cerebellum region (Figure 48 I). To characterize the expression 
in the cerebellum in more detail and to compare the results with the in situ hybridization data, 
the transgenic line was crossed with a specific Purkinje cell marking zebrafish line where a 
Purkinje cell specific enhancer was used, called ca8 – a Purkinje cell specific regulatory element 
derived from the carbonic anhydrase related protein 8 gene of zebrafish (Namikawa et al., 
Figure 47:  Neurogenic region in the adult zebrafish brain. Neurogenic regions 
are visible in the telencephalon, optic tectum, hypothalamus, cerebellum and 
hindbrain. In orange the neurogenic areas are marked and in red the adult stem 





2019a). In this fish strain the ca8 enhancer drives expression of the red fluorescence protein 
tagRFP-T specifically in cerebellar Purkinje cells. In the double transgenic embryos and larvae 
expression in the cerebellum of Purkinje cells was comparable to the expression pattern of the 
in situ hybridization of trkA. Some Purkinje cells revealed expression of mClover in tagRFP-T 
positive Purkinje cells, but not all red fluorescent Purine cells expressed mClover. In addition, 
other cells of the cerebellum located in the molecular layer above the Purkinje cell layer as well 
as some located below in the granular cell layer also expressed the green fluorescent mClover. 
The trkA-mClover strain therefore expresses the green fluorescent mClover protein in a subset 
of Purkinje cells as shown in the trkA fluorescent mRNA in situ hybridization results.  
 
Figure 48: Analysis of a transgenic zebrafish line showing mClover fluorescence under control of a trkA regulatory 
element. The picture A shows a schematic drawing of an adult zebrafish and of the construct used to establish a stable transgenic 
trkA-mClover reporter line. The construct consists of the promotor/enhancer region of trkA in front of the coding region of the 
fluorescence protein mClover. To target the expression only to neurons a NRSE (neuron specific silencer element) was cloned 
in between of the enhancer and mClover. The construct was cloned in between two Tol1 transposon sites to introduce the DNA 
easily into the genome by injecting the construct together with a Tol1 transposase. In pictures on the right (B, C, D, E, F, G, H, 
I and J) the development of the transgenic line is shown after 24 (B, C, D), 48 (E, F, G) and 72h (H, I, J) of development 
recorded by confocal laser scanning microscopy. The head is to the left. Expression is visible in sensory neurons, like the 
trigeminal neurons (tn), the lateral line nerve (lln) and the motoneurons (mn). The shown scale bar indicates 500 µm. The 
picture K shows an analysis of the cerebellum after crossing the transgenic line with another transgenic line ca8:RFP expressing 
the red fluorescent protein tagRFP-T specifically in Purkinje cells of the cerebellum. Expression of the green fluorescence of 
mClover is visible in Purkinje cells (white arrow) but also some other cells show mClover expression. However, there is a 
heterogeneity of Purkinje cells, since some Purkinje cells show no mClover expression. 
A stable transgenic zebrafish line was established, showing green fluorescence in dependence 
of a regulatory element derived from the Fugu rubripes trkA enhancer, especially in 
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motoneurons, lateral line nerve and the trigeminal neurons, but also in cells of the central 
nervous system, shown exemplary by analysis of the expression in Purkinje cells. The results, 
which were shown in this chapter support also the results, which were shown for the expression 
of trkA by in situ hybridization. 
3.5.3 Establishment of different screening assay for analysis of different neurotrophin 
stimulating metabolites 
 
The zebrafish is able to generate new neurons in all stages of life. Because of that, the zebrafish 
is a suitable model for analysis of regeneration in vivo. Neurotrophins are possible candidates 
to promote regeneration, since they have an influence on neurodegeneration as well as 
neuroregeneration. Secondary metabolites, like erinacine C, which are able to stimulate 
neurotrophin production, could be used in regeneration assays and the possible regeneration-
promoting activity can be characterized. 
Since the introduced transgenic line should mark trkA expressing cells and by that cells, which 
should be able to respond to NGF stimulating substances, this transgenic line was used as a 
model. As already explained, neurotrophins are involved in maintenance, differentiation and 
regeneration of neurons. The effect of regeneration inducing capacity of secondary metabolites 
being able to induce neurotrophin expression should be analyzed during the regeneration 
process. Therefore, a regeneration system needed to be established.  
The spinal cord is an optimal region to induce regeneration. The spinal cord region can be easily 
destroyed with a needle trying to only touch this region and not the blood vessel underneath of 
the spinal cord (Figure 49). At 3dpf the spinal cord is completely established in the zebrafish 
larvae (Lewis and Eisen, 2003). At this time point the lesion was performed in a trkA:mClover 
transgenic line, where it was shown, that the spinal cord including motoneurons are marked 
with the fluorescence protein mClover, using a needle in a region above and behind the end of 
the yolk. The regeneration curve was analyzed using the confocal laser scanning microscope. 
Directly after lesion the gap was visible (Figure 49). After 48h the gap was closed by axons 
passing through the wound region (shown in the last picture, Figure 49). All in all, it can be 





Figure 49: Overview of the spinal cord lesion in trkA:mClover transgene zebrafish and regeneration afterwards. 3dpf 
old larvae were lesioned in the spinal cord using a needle to destroy the spinal cord including motoneurons and axons in a 
region above and behind the end on the yolk. Important is to avoid inflammation or bleeding out by taking care to not destroy 
the blood vessel which is located underneath the spinal cord. The transection through the spinal cord is imaged afterwards with 
the confocal laser scanning microscope. After 48h the lesioned spinal cord region is completely regenerated by axons crossing 
the lesion side. 
The next step was to classify if trkA expression was involved in the regeneration of the spinal 
cord lesion. Therefore, an in situ hybridization against trkA was performed during spinal cord 
regeneration (Figure 50). After 6, 10, 24, 32 and 48h of transsectioned larvae were fixed and 
the in situ hybridization to detect trkA mRNA was conducted. As control the in situ 
hybridization against trkA was performed with unlesioned embryos. To characterize the 
specificity of the trkA signal in the lesion other probes were used as control. The first was the 
sense probe, which should not give any signal. The second control was a probe, which is not 
involved in regeneration, called parvalbumin (parv). Parvalbumin is related to Calmodulin and 
Troponin C and has 3 EF hand motifs that serve to bind calcium. It is found in the fast-
contracting muscles, in the brain and in endocrine-active tissue. It is known to mark in the 
zebrafish larvae muscle tissue in the head especially in the masticatory muscles and also in the 
cerebellum of the zebrafish especially in the Purkinje cells. This specific expression was also 
seen in this experiment. Expression of trkA mRNA in the lesioned region was visible starting 
at 10h post lesion and decreased until 48h post lesion. Unlesioned embryos that served as 
control did not show the expression of trkA in this region. Also, the lesioned embryos showed 
a specific pattern of trkA mRNA expression, where the sense probe and also another probe 
(used as negative control), were not expressed during the regeneration period (parv – 
parvalbumin) showed no pattern in the lesion area.  With that it can be suggested, that trkA 
expression is involved in the spinal cord region. 
 






Figure 50: Expression pattern of trkA mRNA during spinal cord regeneration. Transsection through the spinal cord was 
performed at 3dpf and larvae 6, 10, 24, 32 and 48h after lesion were fixed and in situ hybridization against trkA was performed 
afterwards. Expression of trkA mRNA in the lesion side was visible starting at 10h after the lesion, where the unlesioned larvae 
(first row, lesioned embryos) show no trkA expression. The expression pattern of trkA mRNA stayed there until 48h after the 
lesion. To proof the specificity of the trkA mRNA pattern the in situ hybridization was performed for the trkA mRNA sense 
probe as well as for a probe unrelated to regeneration (parv) marking parvalbumin. (n = 4) 
A quantification was performed after the in situ hybridization, since not all larvae showed trkA 
mRNA expression at the lesion side at the specific time points, the number  of larvae showing 
trkA mRNA expression in the lesion side was quantified and calculated against the larvae which 
showed no expression of trkA mRNA in the lesion (Figure 51). The expression pattern of trkA 
mRNA in the lesion side increased significantly at 10h after the lesion was performed and was 
maintained until 24h post lesion. At 48h after the lesion there was again a significant increase 
in the amount of embryos showing the trkA mRNA expression. This lead to the suggestion that 




Figure 51: Quantification of trkA mRNA expressing embryos which show a signal in the lesion side. The number of fishes 
showing the trkA mRNA expression in the lesion side was analyzed and calculated against the number showing no expression 
in the side. The expression in the lesion side becomes significantly increase at 10h post lesion and stay significant until 24h. 
At 32h the number of fishes decreased. At 48h after lesion the expression is significantly increased again. (n = 4) 
The lesion in the spinal cord was performed to study the regeneration in the central nervous 
system. To analyzed now the peripheral nervous system, which is more selected by NGF/TrkA 
signaling, since NGF/TrkA is more located in the peripheral nervous system (Manni et al., 
2011; Hudson et al., 2000; Cao et al., 2011), lesion in the lateral line nerve will be established. 
Therefore, the already introduced fish line marking sensory neurons by the trkA:mClover 
system was used (Figure 52). At 3dpf the lesion was performed. Therefore, a cut in the region 
of the lateral line nerve (as shown in Figure 52, upper picture) was conducted by using a needle. 
It is important to not destroy the blood vessel, which is located underneath the lateral line nerve. 
Directly after lesion a clear cut is visible (Figure 52, second picture) It can be seen that the 






































Figure 52: Overview of the lateral line nerve transsection in trkA:mCLover transgenic zebrafish and regeneration 
afterwards. The lesion was performed at 3dpf in larvae from trkA:mClover strain. The lesion was analyzed directly after the 
lesion was performed and after 24h with laser scanning microscope. After 24h the lesion site was closed again. (n = 4) 
These two different wounding assays were established to analyze the effect of the different 
Hericium secondary metabolites in possibly promoting regeneration. Since the introduced 
compounds isolated from Hericium spec. were able to stimulate neurotrophin production, like 
it was shown for NGF and BDNF, these substances are the best compounds to study the effect 
of cyathane diterpenoids in a model organism especially during regeneration. The both 
established regeneration models are efficient models, to perform compound screening for 
regeneration stimulating substances, since a larger number of animals can be challenged easily 
and with that a high number can be analyzed. But for high throughput assays, another way to 
challenge neurons should be found than microsurgery. 
  







Neurotrophins, like NGF and BDNF, have increasingly attracted attention for the treatment of 
neurodegenerative diseases. The common feature for all neurodegenerative diseases are 
characterized by a loss of neurons that leads to impairment of neural functions (Bredesen et al., 
2006). Neurotrophins can act as survival factors to support the maintenance and differentiation 
of neurons, as well as the proliferation of neuronal precursors (Reichardt, 2006). Neurotrophins 
cannot be used as external therapeutic factors, because they are unable to cross the blood-brain 
barrier, which is an important barrier that separates the blood flow from the neuronal system 
(Pardridge, 2002b). Therefore, smaller metabolites with lower molecular weights become 
increasingly important in research. Compounds that can cross the blood brain barrier to 
stimulate the neurotrophin production are in the focus of this thesis. 
4.1 Secondary metabolites of Hericium spp. are able to stimulate neurotrophin 
production 
 
Different metabolites isolated from Hericium spp. were characterized in this thesis. A new 
group of compounds called corallocins was identified that have an influence on neurotrophin 
production. Corallocins are related to hericenones, which can be isolated from the fruiting body 
of Hericium erinaceus. These substances are known to promote neurotrophin expression 
Kawagishi et al., 1992; Ma et al., 2010). In this thesis it was shown that corallocins have an 
influence not only on ngf expression, but also on bdnf transcription. There two of three 
corallocins were able to induce PC12 cell differentiation after the incubation with a supernatant 
that was conditioned by astrocytoma cells. In this thesis there was shown that corallocin A is 
able to induce PC12 cell differentiation by upregulation of the ngf mRNA level in astrocytoma 
cells, while a bdnf upregulation could not be observed. Corallocin B failed to induce PC12 cell 
differentiation, but it was able to induce the ngf mRNA expression, yet at a lower amount than 
corallocin A. This suggests a threshold for PC12 cell differentiation requiring higher levels of 
NGF in the media. Mori and coworkers showed that the amount of NGF protein, secreted by 
1321N1 cells after incubation with ethanol extracts of Hericium erinaceus, is too low to induce 
PC12 cell differentiation. The authors conclude that other neurotrophic factors were become 
activated by these extracts (Mori et al., 2008). An alternative explanation could be that extracts 
contains lower amounts of specific corallocins leading to lower amounts of neurotrophin 
expression below a threshold required for PC12 cell differentiation. Corallocin C can induce 
PC12 cell differentiation by treatment with the conditioned media of corallocin C treated 
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astrocytoma cells. It was shown that corallocin C is able to induce ngf mRNA and bdnf mRNA 
expression. Surprisingly, corallocin B and C, which share an isoindolinone backbone, have 
different biological properties. Corallocin B stimulates ngf expression weakly, whereas 
corallocin C can increase both, ngf and bdnf expression. Corallocin A, which possesses a 
benzofuranone structure, is only able to stimulate ngf production. These findings provide first 
hints for a structure-activity-relationship analysis. 
In addition, a group of already known derivates, called erinacines, was analyzed and two new 
structures were found. Erinacines are cyathans. To this subclass Striatoides also belong. These 
compounds are known to enhance NGF-mediated neurite outgrowth in PC12 cells (Bai et al., 
2015). All erinacines were able to stimulate ngf expression, even the new ones, but at weaker 
levels. It was shown for the first time that erinacine C stimulates bdnf transcription. 
Remarkably, erinacine B and C differ only by one residue: Erinacine B has an aldehyde group 
at the position where erinacine C has a hydroxyl group (Figure 53). Erinacine C is the 
corresponding allyl alcohol to the reactive vicinal unsaturated aldehyde erinacine B. The latter 
compound is a Michael acceptor and therefore exerts a much high toxicity than erinacine C. A 
Michael acceptor is a carbonyl group, by which the Michael donator, e.g. other carbonyl groups, 
can be added. 
 
Figure 53: Nearly identical structure of erinacine B and C. The structure of erinacine B and C is nearly identical, the only 
difference is the aldehyde group for erinacine B, where erinacine C has a hydroxyl group as residue (shown with the red boxes). 
The precise structure by which the stimulation of neurotrophin expression takes place is still 
unknown. Further analysis needs to be performed, starting with de-novo synthesis and changing 
of different residues, followed by analysis of the activity and ability to induce neurotrophin 
expression and secretion. 
We assume that more growth factors could become stimulated by these compounds than the 
two neurotrophins that were tested so far. For example, EGF and FGF can cause differentiation 
of PC12 cells (Tyson et al., 2003). Their differentiation is not exclusively induced by TrkA 
signaling, because other factors like FGF, EGF or PDGF was involved. This cannot be excluded 
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by our experiments with dnTrkA or inhibitor analysis. In case of the dnTrkA receptor 
experiments not all cells could become transfected and hence differentiation of PC12 cells 
induced by NGF and or by the conditioned media was never completely abolished. There was 
never a complete absence of differentiated cells after the incubation with the different inhibitors. 
Especially, the Erk1/2 and MAPK are downstream of the EGF signaling cascades or the FGF 
and PDGF mediated signaling. Further analysis should focus also on these growth factors. 
4.2 Different signaling cascades are activated by erinacine C 
 
Different transcription factor binding site activities in cells are increased upon erinacine C 
incubation. ETS was the binding site, which was analyzed in more detail in this thesis. The 
analysis included positive and negative controls (activating and inactivating ETS). ETS activity 
is not necessary for ngf transcription. Some results suggest that ETS mediated signaling could 
have a minor influence on the bdnf expression, because ets1 transcription had a high level after 
6h of erinacine C incubation whereas the bdnf expression took 48h to a reach a significant peak. 
With the ETS1 transcriptional activators, no upregulation of the bdnf levels was shown, 
suggesting that ETS1 activity is not sufficient to induce bdnf expression.  
There are more binding sites showing increased activities after erinacine C incubation, like 
ERE, NFkappaB, Gli1 or STAT3. It is known that the predicted ngf enhancer element isolated 
from Tetraodon contains also binding sites for NFkappaB, suggesting, that NFkappaB is 
probably involved in the erinacine C dependent upregulation of ngf.  
ERE is the downstream DNA binding site of the nuclear estrogen signaling. Estrogen signaling 
has a neuroprotective function in brain injury models (McCullough and Hurn, 2003) and 
increases the neurogenesis after stroke (Li et al., 2011). This factor was important, when 
searching for a treatment against neuronal death or for regeneration. It was shown that bdnf 
levels are increased after treatment with estrogen (Li et al., 2011; Sohrabji et al., 1995). 
NFkappaB was an interesting factor, too. NFkappaB plays an important role in inflammation, 
immunity, cancer and neuronal plasticity (Häcker and Karin, 2006; Perkins, 2007). 
Furthermore, NFkappaB is involved in embryonic and adult neurogenesis (Wang and Bordey, 
2008; Young et al., 2009). Gli proteins are essentially involved in development, homeostasis 
and disease, including neurogenesis and tumorigenesis. Gli1 is the binding site for the 
Hedgehog pathway. In embryonic development Hedgehog proteins control the patterning of 
neuronal precursors, and their neuronal and glial progenitors. It was also shown that Hedgehog 
is involved in the formation and plasticity of neuronal circuits (Yao et al., 2016). Among others, 
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Hedgehog is able to increase the bdnf expression levels in regenerating cavernous nerve (Bond 
et al., 2013). In addition, STAT3 would be a very interesting candidate, since it was shown that 
there is a connection between brain inflammation and STAT3 activation (Chen et al., 2013). 
STAT3 has an influence on cytokine- and growth factor induced signals and by that it has an 
influence on cell proliferation, differentiation and apoptosis (Ihle, 2001). 
These growth factors which are involved in PC12 cell differentiation, was affected by Erinacine 
C mediated by ETS signaling.  
4.3 The predicted ngf enhancer fragment is erinacine C responsive 
 
The 5’ regulatory region of the human ngf gene has a very complex structure, it is hard to predict 
the enhancer region of this gene. Luckily, the Tetraodon nigrovirdis genome is highly 
conserved. The ngf gene consists of only one exon, and the regulatory region could be in the 5’ 
upstream region. A 2.1 kb fragment upstream of the ngf exon, isolated from T. nigrovirdis, was 
cloned in front of a luciferase reporter. It was shown, that the predicted ngf enhancer fragment, 
responds to erinacine C incubation. This was analyzed in more detail on four subcloned 
fragments (500 bp fragments of the 2.1kb enhancer region; 1, 2, 3, 4). It seemed, when using 
the endogenous promotor, which is probably located in the 500bp nearest to the start codon 
(Figure 54; 4), is necessary for a strong activation of the luciferase expression. The construct, 
where a basal E1b promotor was used, are weaker in the activation of luciferase expression. For 
further analysis this has to be kept in mind, since no significant upregulation upon erinacine C 
treatment with the basal promotor was observed.   
Our results indicate that the first 500bp region of the enhancer fragment (Figure 54; 1) is 
required to activate the luciferase expression. Interestingly, also the third element (Figure 54; 
3) contains regions that are involved in the process of luciferase activation by erinacine C, while 
the second region (Figure 54; 2) that lies in between has no, or an inhibitory function. The 
fourth most distant part of the 2.1kb fragment containing the 5’ most 500bp region (Figure 54; 
4) shows no inducible luciferase activity by erinacine C. Hence, this element is very likely not 
involved in the erinacine C dependent upregulation, but this part probably contains the 





Figure 54: Assumption of effects of the regulatory elements in the putative ngf regulatory 5’ region of Tetraodon. There 
are two of the several possible variants of activating or inhibiting elements contained in the 2.1 kb 5’ fragment (A, B, green 
fragment). Elements of the first 500bp (1) seem to act as an activator: it could directly activate the expression of luciferase as 
shown in Figure A, or it could activate the second 500bp (2) laying elements (B, red) or the third 500bp (3) containing elements 
(B, blue). On the other side elements of the second 500bp (2) seem to work as repressor, for the third 500bp (A, B; blue; 3) 
or directly for the luciferase expression (A, B; red). The third 500bp (3) could act as activator, directly activate the luciferase 
expression (A, B). In the experiments, the last 500bp (4) seem to be not responsive to erinacine C incubation, but probably 
contain the basal promotor. 
Apart from that, our results lead to the suggestion that a 2.1kb ngf enhancer fragment is 
responding to ETS activation and repression. These binding sites should become identified in 
future experiments. Interestingly, the use of a KRAB construct to repress ETS signaling did not 
completely inhibit the luciferase activity after erinacine C treatment.  This suggests that 
additional factors are involved in the erinacine C dependent activation within the predicted ngf 
enhancer fragment. 
4.4 Erinacine C can cross the blood-brain barrier 
 
In this thesis it was shown that erinacine C is likely able to cross the blood brain barrier. This 
was proven in vitro and in vivo. For the in vitro approach, a triple culture of endothelial cells, 
pericytes and astrocytes was used to establish a strong barrier. Using this approach, it was also 
shown, that erinacine C is able to pass this barrier and is not a target of the P-gp efflux 
transporter. For the in vivo approach we used the zebrafish as a vertebrate model to test whether 
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erinacine C is able to cross the blood-brain barrier. In zebrafish larvae the blood-brain barrier 
is established between day 4 - 10 post fertilization (Leeuwen et al., 2018). We treated different 
larval stages with erinacine C. After 3 days of incubation, the brains of the larvae were dissected 
and the amount of erinacine C was measured using HPLC. Erinacine C was detected in varying 
amounts, but in all zebrafish brains at all developmental stages. But it is not clear yet, if 
erinacine C was isolated from the nervous system or from the blood vessels. 
Future experiments should clarify in which brain regions erinacine C is active. Different 
approaches were applied: erinacine C was coupled to a fluorescent marker to make it visible in 
the zebrafish larvae. Another approach could generate a split fluorescent protein, which can 
become active only, when the two components are co-localized in the same region. 
Neurotrophin is upregulated by erinacine C and NGF is widely expressed in the zebrafish brain. 
The suggestion is to express one part of the split fluorescent protein under control of an 
enhancer that activates expression specifically in one cell type. The second part can be 
expressed under the control of the binding sites that can become activated by erinacine C, as 
shown in this thesis. Then, fluorescence should indicate if a certain signaling cascade becomes 
activated in a specific cell type. 
In this thesis it has been shown that erinacine C is likely able to cross the blood-brain barrier. 
Based on this finding, further analysis was performed using the zebrafish model. The zebrafish 
is a very suitable organism and needs little space. Embryos, larvae and even adults can be kept 
temporarily in small volumes of conditioned media, which is beneficial for compound 
screenings. Because the zebrafish is able to regenerate neuronal cells, different regeneration 
models was used to screen the effect of erinacine C in vivo.  
4.5 Analysis of possible effects of erinacine C in vivo 
 
Some compounds of edible fungi could have side effects in vivo. Pure substances in higher 
concentrations can induce toxicity. The zebrafish is a perfect screening system, to analyze side 
effects of substances. 
Neurotrophin stimulating compounds could influence different signaling pathways: In this 
thesis it was shown that the zebrafish ngf gene as well as the high affinity receptor trkA, are 
seemed to be expressed in neurogenic niches of the brain (D’Angelo et al., 2014). In future 
experiments compounds was used that are able to induce neurotrophin expression like NGF, to 
test their regenerative potencies. Successful compound treatments were verified by an increase 
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of neurogenic marker expression in corresponding niches. However, a double fluorescent in 
situ hybridization for both mRNA together would be very interesting, since some regions, like 
the cerebellum show both expressions, ngf and trkA. Purkinje cells, for example, seemed to 
show expression of ngf as well as trkA, suggesting, that there are autocrine pathways being 
activated. 
In a previous master thesis (Monique Rascher), a transgenic zebrafish line was established to 
analyze the effect of neurotrophin inducing compounds. This line was used to induce 
neurodegeneration and regeneration and to quantify late effects of compounds in vivo. In this 
context, also other factors like FGF was analyzed regarding their upregulated activity upon 
erinacine C incubation. FGF is known to be involved in glial cell bridges during spinal cord 
regeneration (Goldsmit et al., 2012). FGF8 was upregulated after erinacine C treatment in 
astrocytoma cell in vitro (Figure 24). This activity could also be important for spinal cord 
regeneration. It is known that zebrafish are able to regenerate spinal cord injuries within 48h 
(Goldshmit et al., 2012; Becker et al., 2004; Mokalled et al., 2017; Becker et al., 1997). The 
connective tissue growth factor a (ctgfa) is another trophic factor involved in spinal cord 
regeneration (Mokalled et al., 2017) that was tested for activation by erinacine C. 
In this thesis another regeneration model was established. The lateral line nerve belongs to the 
peripheral nervous system and substances, which are diluted in the surrounding media, are 
immediately accessible for the lateral line. This neuronal region has an easier access to 
compounds than neuronal cells of the central nervous system that are protected by the BBB. It 
was shown in this thesis that a regeneration of the lateral line nerve occurs 24h after lesion. 
Several signaling pathways including Notch, Wnt (canonical and non-canonical), FGF, BMP 
and Hedgehog play a role during regeneration of the lateral line nerve (Kelley, 2006, Fritzsch 
et al., 2011, Wu and Kelley, 2012, Munnamalai and Fekete, 2013). FGF, BMP and Hedgehog 
binding sites were activated by erinacine C treatment in astroglial cells and it was shown that 
NGF/TrkA signaling is involved in spinal cord regeneration. 
The bdnf expression pattern, as well as the high affinity receptor of BDNF, TrkB, should be 
analyzed and quantified regarding their expression during the regenerative processes of cells. 
In addition, zebrafish models for cerebellar Purkinje cell degeneration have been established in 
the lab of Prof. Dr. Reinhard W. Köster, modelling genetically induced ataxia in the zebrafish 
(Namikawa et al., 2019b) or by pharmacological induction of Purkinje cell degeneration 
(Weber et al., 2016). These two models could also be useful in future experiments to study the 
effect of neurotrophin inducing compounds during degeneration and regeneration. 
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The results shown in this thesis provide the first insights of direct cell responses upon natural 
product incubation. Using this approach, the effects of erinacine C treatment can be analyzed 
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6.3 Maps of used plasmids 
 
6.3.1 pCS-rat dnTrkA-CitrineERex 
 
Figure 54: Plasmid Map of Plasmid #5435 pCS-rat dnTrkA-CitrineERex. Map was generated with SnapGene®. 
6.3.2 pBSII-Tol2-4xNFkb-EIb-Luc2 
 





Figure 56: Plasmid Map of Plasmid #5264 pBSII-Tol2-4xGli-EIb-Luc2. Map was generated with SnapGene®. 
6.3.4 pBSII-Tol2-4xNotch-E1b-Luc2 
 





Figure 58: Plasmid Map of Plasmid #5270 pBSII-Tol2-4xDyrk1A-EIb-Luc2. Map was generated with SnapGene®. 
6.3.6 pBSII-Tol2-4xPea3B-E1b-Luc2 
 





Figure 60: Plasmid Map of Plasmid #5273 pBSII-Tol2-4xCREB1-EIb-Luc2. Map was generated with SnapGene®. 
6.3.8 pBSII-Tol2-4xTCF/LEF-E1b-Luc2 
 





Figure 62: Plasmid Map of Plasmid #5275 pBSII-Tol2-4xLhx2-Sox2-EIb-Luc2. Map was generated with SnapGene®. 
6.3.10 pBSII-Tol2-4xSBE-E1b-Luc2 
 





Figure 64: Plasmid Map of Plasmid #5277 pBSII-Tol2-4xHRE-EIb-Luc2. Map was generated with SnapGene®. 
6.3.12 pBSII-Tol2-4xNBRE-E1b-Luc2 
 





Figure 66: Plasmid Map of Plasmid #5279 pBSII-Tol2-4xSF1-EIb-Luc2. Map was generated with SnapGene®. 
6.3.14 pBSII-Tol2-4xSRE-E1b-Luc2 
 





Figure 68: Plasmid Map of Plasmid #5281 pBSII-Tol2-4xHSE-EIb-Luc2. Map was generated with SnapGene®. 
6.3.16 pBSII-Tol2-4xUAS-E1b-Luc2 
 





Figure 70: Plasmid Map of Plasmid #5289 pBSII-Tol2-4xSTAT3-EIb-Luc2. Map was generated with SnapGene®. 
6.3.18 pBSII-Tol2-4xARE-E1b-Luc2 
 





Figure 72: Plasmid Map of Plasmid #5291 pBSII-Tol2-4xElk1-EIb-Luc2. Map was generated with SnapGene®. 
6.3.20 pBSII-Tol2-4xnfy-E1b-Luc2 
 





Figure 74: Plasmid Map of Plasmid #5293 pBSII-Tol2-4xSP1/KLF-EIb-Luc2. Map was generated with SnapGene®. 
6.3.22 pBSII-Tol2-4xNRF-E1b-Luc2 
 





Figure 76: Plasmid Map of Plasmid #5296 pBSII-Tol2-4xE2F-EIb-Luc2. Map was generated with SnapGene®. 
6.3.24 pBSII-Tol2-4xbHLH-E1b-Luc2 
 





Figure 78: Plasmid Map of Plasmid #5298 pBSII-Tol2-4xbZIP-EIb-Luc2. Map was generated with SnapGene®. 
6.3.26 pBSII-Tol2-4xSox/Pou-E1b-Luc2 
 





Figure 80: Plasmid Map of Plasmid #5300 pBSII-Tol2-4xKLF5-EIb-Luc2. Map was generated with SnapGene®. 
6.3.28 pBSII-Tol2-4xETS-E1b-Luc2 
 





Figure 82: Plasmid Map of Plasmid #5304 pBSII-Tol2-4xNGF1A-RE-EIb-Luc2. Map was generated with SnapGene®. 
6.3.30 pBSII-Tol2-4xNFAT/AP1-E1b-Luc2 
 





Figure 84: Plasmid Map of Plasmid #5306 pBSII-Tol2-4xERE-EIb-Luc2. Map was generated with SnapGene®. 
6.3.32 pBSII-Tol2-4xRunt-E1b-Luc2 
 





Figure 86: Plasmid Map of Plasmid #5308 pBSII-Tol2-4xFexf2-EIb-Luc2. Map was generated with SnapGene®. 
6.3.34 pBSII-Tol2-4xLexA-E1b-Luc2 
 





Figure 88: Plasmid Map of Plasmid #5343 pBSII-Tol2-4xNFAT-EIb-Luc2. Map was generated with SnapGene®. 
6.3.36 pBSII-Tol2-4xSim2-E1b-Luc2 
 





Figure 90: Plasmid Map of Plasmid #5345 pBSII-Tol2-4xTbox-EIb-Luc2. Map was generated with SnapGene®. 
6.3.38 pBSII-Tol2-4xFOXO-E1b-Luc2 
 





Figure 92: Plasmid Map of Plasmid #5347 pBSII-Tol2-4xBRE-EIb-Luc2. Map was generated with SnapGene®. 
6.3.40 pBSII-Tol2-4xTEAD-E1b-Luc2 
 





Figure 94: Plasmid Map of Plasmid #5453 pTol2-2xUAS-E1b-Luc2. Map was generated with SnapGene®. 
6.3.42 pTol2-6xUAS-E1b-Luc2 
 
























ATP  Adenosine triphosphate 
BDNF  brain-derived neurotrophic factor 
cDNA  complementary DNA 
CO2  carbon dioxide 
CREB  cAMP response element-binding protein 
DMEM Dulbecco's Modified Eagle's Medium 
DMSO Dimethylsulfoxid 
dn  dominant negative 
DNA  deoxyribonucleic acid 
DTT  Dithiothreitol 
Dyrk1A Dual specificity tyrosine-phosphorylation-regulated kinase 1A 
ER  Endoplasmic reticulum 
ERex  ER export signal 
Erk  Extracellular-signal Regulated Kinases 
EtOH  Ethanol 
ex  export 
FIJI  FIJI is just ImageJ 
GAP  Growth Associated Protein 
GAPDH Glycerinaldehyd-3-phosphat-Dehydrogenase 
Gli  glioma-associated oncogene 
HCl  hydrochloric acid 
LEF  Lymphoid enhancer-binding factor 
Lhx  LIM homeobox 
MAPK Mitogen-activated protein kinase 
MAPKK  Mitogen-activated protein kinase kinase 
mRNA messenger RNA 
MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid 
NFkB  nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
NGF  nerve growth factor 
SBE  Smad binding element 
Sox  SRY-related HMG-box genes 
PBS  Phosphate buffered saline 
PC12  pheochromocytoma cells 
PCR  polymerase chain reaction 
PLCγ  Phosphoinositid-Phospholipase C 
RNA  ribonucleic acid 
RPMI  Roswell Park Memorial Institute 
RT  room temperature 
RT-PCR reverse transcriptase PCR 
TCF  transcriptionfactor 
TrkA  Tropomyosin receptor kinase A 
UV  ultraviolet light 
